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Abstract 
 
Kinesins are molecular motors that use energy from ATP hydrolysis to transport 
cargoes along microtubule tracks. There are at least 14 families of kinesins with 
different structural organisations but all kinesins have a motor domain that is 
the catalytic core for ATP hydrolysis and the binding site for microtubules. Most 
kinesins have a stalk domain, which facilitates oligomerisation, and a tail domain 
that is implicated in cargo binding and regulation. Depending on their structural 
organisation, each kinesin is suited for different functions. Some are involved in 
transporting vesicles and organelles in cells, while others are essential for axonal 
transport in neurons. Still others are involved in intraflagellar transport in cilia. 
Lastly, a group of kinesins participate in different steps of mitosis.  
 
One such kinesin is the human mitotic kinesin Eg5. It is a homotetrameric kinesin 
that is made up of a dimer of anti-parallel dimers. By cross-linking anti-parallel 
microtubules and moving towards their plus ends, Eg5 slides them apart and 
establishes the bipolar spindle. When Eg5 is inhibited by antibodies or siRNA, 
cells arrest in mitosis with non-separated centrosomes and monoastral spindles. 
Prolonged mitotic arrest eventually leads to apoptotic cell death. For that 
reason, Eg5 is a potential target for drug development in cancer chemotherapy 
with seven inhibitors in Phase I and II clinical trials. The first inhibitor of Eg5 was 
discovered in a phenotype-based screen and is called monastrol. Since then, 
several classes of inhibitors, such as ispinesib (a clinical trial candidate) and S-
trityl-L-cysteine (STLC), have been discovered.  
 
To develop more potent inhibitors, we employed a structure-based drug design 
approach. By determining crystal structures of the Eg5 motor domain in complex 
with various inhibitors, we can understand the interactions between the 
inhibitor and Eg5; thus, analysis of the structure-activity relationship (SAR) can 
help us to improve their potency. Consequently, these inhibitors could 
complement or act as alternatives to taxanes and vinca alkaloids, which are 
successful cancer chemotherapeutics currently used in the clinic, but have the 
tendency to cause neurotoxicities and develop resistance in patients. 
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Here, I report the crystal structures of Eg5 in complex with three monastrol 
analogues, STLC, and four STLC analogues separately. Based on the crystal 
structures with monastrol analogues, I identified the preferential binding mode 
of each inhibitor and the main reasons for increased potency: namely the better 
fit of the ligand and the addition of two fluorine atoms. Next, the crystal 
structure of Eg5-STLC indicates that the three phenyl rings in STLC are buried in 
a mainly hydrophobic region, while the cysteine moiety of STLC is solvent-
exposed. In addition, structures of Eg5 in complex with STLC analogues, which 
have meta- or para-substituents on one or more of the phenyl rings, reveal the 
positions of the substituents and provide valuable information for the SAR study. 
In short, these structures reveal important interactions in the inhibitor-binding 
pocket that will aid development of more potent inhibitors.  
 
To understand the molecular mechanism of inhibition, I examined the structure 
of the Eg5-STLC complex, which revealed an unprecedented intermediate state, 
whereby local changes at the inhibitor-binding pocket have not propagated to 
structural changes at the switch II cluster and neck linker. This provides 
structural evidence for the sequence of drug-induced conformational changes. In 
addition, I performed isothermal titration calorimetry to determine the 
thermodynamic parameters of the interaction between Eg5 and its inhibitors. 
The structural information and the thermodynamic parameters obtained help us 
to gain a better understanding of the molecular mechanism of inhibition by an 
Eg5 inhibitor. 
 
While there is a large amount of information about the motor domain of Eg5, 
less is known about the stalk domain, which facilitates oligomerisation. A 
prediction program showed that the first ~100 residues of the stalk domain have 
a high probability of forming a coiled-coil structure, while the middle ~150 
residues have a low probability. Using analytical ultracentrifugation, I showed 
that the Eg5 stalk364-520 domain exists predominantly as a dimer with a 
sedimentation coefficient of 1.76 S. The purported coiled-coil quaternary 
structure is backed-up by circular dichroism data, which showed that Eg5 
stalk364-520 domain contains about 52 % helical content. Finally, the low resolution 
solution structure of Eg5 stalk364-520 domain was determined by small angle X-ray 
scattering, which revealed an elongated structure that is ~165 Å in length. 
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Together, these data give us a glimpse into the structural characteristics of the 
Eg5 stalk364-520 domain. 
 
Besides gaining a better understanding of Eg5, I decided to investigate the 
molecular mechanism of autoinhibition in conventional kinesin (later known as 
kinesin-1). As the founding member of kinesins, it was first discovered to be 
involved in axonal transport. When not transporting cargo, kinesin-1 is 
autoinhibited to prevent squandering of ATP. Although it is widely accepted that 
the tail binds to the motor domain to keep it in a folded autoinhibited state, the 
molecular mechanism remains unclear and several mechanisms have been 
proposed. Here, I report the crystal structures of the Drosophila melanogaster 
kinesin-1 motor domain dimer and the dimer-tail complex. The dimer, which 
exhibits ~180° rotational symmetry between the monomers, provides valuable 
structural information for modeling the motility of kinesins on microtubules. 
 
By comparing the free dimer with the dimer-tail complex, we observe that the 
motor domains have considerable freedom of movement in the absence of tail 
binding. However, in the dimer-tail complex, a ‘double lockdown’ at both the 
neck coil and the tail interface freezes out major movements. This could 
prevent conformational changes, such as neck linker undocking. Data from our 
collaborator (David Hackney) showed that a covalent cross-link, which mimics 
double lockdown of the dimer, prevents ADP release. Together, we propose a 
‘double lockdown’ mechanism, in which cross-linking at both the coiled-coil and 
tail interface prevents the movement of the motor domains that is needed to 
undock the neck linker and release ADP. In short, the structures shed light on 
the autoinhibition mechanism, reveal important residues at the dimer-tail 
interface, invalidate other proposed mechanisms, and open up the possibility 
that other kinesins may be regulated by the same mechanism. 
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1 Introduction 
1.1 Overview of kinesins 
Kinesins are a family of proteins that belong to a larger group of proteins called 
molecular motors (Figure 1-1). Like its motor protein cousins — myosins and 
dyneins — kinesins use the energy derived from ATP hydrolysis to produce the 
force required for it to perform essential functions in the cell. Despite the 
common source of ‘fuel’, these motor proteins differ in the type of cytoskeletal 
filament they associate with and the functions they perform in the cell. Myosins 
bind specifically to actin filaments, while dyneins and kinesins associate with 
microtubules. A well-known class of myosins (myosin II) is involved in muscle 
contraction, while a class of dyneins (axonemal dyneins) is responsible for 
driving the beating of cilia and flagella. Kinesins, on the other hand, are more 
commonly known for axonal transport among other functions. 
 
Kinesin was first discovered about 26 years ago by Vale et al. and Brady et al., 
while studying axonal transport in squid and chick brain respectively1,2. 
Subsequently named kinesin-1, it was found to be involved in the transport of 
organelles from the cell body to the axon of neurons. When immobilised on a 
glass slide, this force-generating molecule induced gliding of the added 
microtubules along the glass surface (Figure 1-2a). Similarly, when the 
microtubules were immobilised on the glass slide, kinesin was shown to carry 
cargo, in the form of latex beads or organelles, along the microtubule tracks3,4 
(Figure 1-2b). Although kinesin was discovered much later than myosin or 
dynein, its reputation as an important molecular motor was hence established. 
 
After the sequence of the Drosophila melanogaster kinesin heavy chain was 
deposited in 19895, numerous families of kinesins were identified in various 
species, including yeast Saccharomyces cerevisiae, nematode Caenorhabditis 
elegans, humans and even plants. Phylogenetic analysis6 and a standardised 
naming system7 for kinesins have led to the classification of at least 14 distinct 
families, with each member of a family sharing sequence homology, domain 
organisation, motility characteristics and similar functions (Figure 1-3). To date, 
about 45 kinesins have been identified in humans.  
Chapter 1  21 
 
 
Figure 1-1. Schematic of molecular motors.  
Kinesin has the smallest catalytic motor domain (yellow) among the molecular motors. The motor 
domain is usually associated with the stalk domain (blue). Associated polypeptides for the various 
molecular motors are depicted in purple. Adapted from Woehlke et al., 20008. 
 
 
 
 
Figure 1-2. Kinesin motility assay.  
(A) Kinesin molecules immobilised on a glass slide causes added microtubules to glide along the 
surface. (B) Kinesin molecule transports cargo along immobilised microtubule track. Figure 
adapted from http://www.fli-leibniz.de/www_elmi/Motility_assays.jpg. 
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Figure 1-3. Kinesin family tree.  
Phylogenetic analysis classifies kinesins into at least 14 distinct families, with each member of a 
family sharing sequence homology, domain organisation, motility characteristics and similar 
functions (Red: chromosome and spindle organisation; green: vesicular and organelle transport). 
The standardised nomenclature for each family of kinesins is shown in blue. Adapted from 
Dagenbach et al., 20049. 
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1.1.1 Structural organisation of kinesins 
Despite their different functions, all kinesins consist of a globular motor domain, 
which is usually attached to a coiled-coil stalk domain of varying lengths. At the 
other end of the stalk domain lies a tail domain (Figure 1-3). Depending on the 
position of the motor domain in the molecule, kinesins are divided into three 
categories: N-terminal, middle or C-terminal. Those with motor domains at the 
N-terminal (e.g. kinesin-1) move towards the plus end of microtubules, while 
those with C-terminal motor domains (kinesin-14) are minus-end directed. 
Kinesins with motor domains in the middle of the molecule (kinesin-13) do not 
move in similar ways, but diffuse to the plus or minus end of microtubules to 
perform their function10.  
 
The arrowhead-shaped motor domain (~350 residues) is highly conserved as 
shown by crystal structures of various kinesins. It is the catalytic site for ATP 
hydrolysis and binding site for microtubules. It has an eight-stranded β-sheet, 
surrounded by three α-helices on each side (Figure 1-4). L11-α4-L12-α5 form the 
microtubule-binding site and loop L8 is implicated in microtubule binding11-14. On 
the opposite side, the nucleotide occupies the active site through binding of the 
α- and β-phosphates to the P-loop (GxxxxGKS/T)15, which is conserved in G 
proteins, myosins and kinesins. Switch I (SSRSH) and switch II (DLAGSE) are two 
other highly conserved motifs that undergo conformational changes during the 
ATP hydrolysis cycle16,17. The former acts as a γ-phosphate sensor and translates 
local changes to a larger conformational change in the latter.  
 
Linking the motor domain to the stalk domain is a short polypeptide called the 
neck linker (Figure 1-4). When the switch II cluster (formed by α4-L12-α5) shifts 
upwards toward the N-terminal of helix α4, the neck linker is allowed to dock 
parallel to the motor domain. Conversely, when it shifts downwards toward the 
C-terminal of helix α4, the neck linker is undocked and perpendicular to helix 
α6. In the ADP-bound kinesin-1 monomer structure, the neck linker is observed 
to be disordered and undocked17, but becomes ordered and docked in the 
microtubule-bound kinesin-AMPPNP (slowly-hydrolysable ATP analogue) monomer 
structure18 (Figure 1-5). A conformational change in the neck linker is believed 
to be pivotal in producing movement for the molecular motor.  
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Figure 1-4. Structural organisation of the kinesin motor domain.  
(A) Arrowhead-shaped motor domain consisting of an eight-stranded β-sheet (blue), surrounded by 
three α-helices (pink) on each side. Mg2+ADP (orange) binds in the active site as shown. The neck 
linker (red) at the C-terminus of the motor domain links the motor to the stalk domain (yellow). 
(PDB ID: 2Y5W) (B) Simple topology of the major secondary structure elements of the motor 
domain. Conversed motifs, such as P-loop, switch I (S1) and switch II (S2), are shown.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1-5. Conformational changes in the neck linker.  
(A) Structure of kinesin-1 monomer showing disordered and undocked neck linker (red). (PDB ID: 
1BG217) (B) Structure of kinesin-1 monomer showing an ordered neck linker that is docked to the 
motor domain. (PDB ID: 1MKJ19) A partial helical stalk domain is shown in red.    
A 
B 
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While the neck linker is crucial for force generation, the stalk domain is 
essential for coordinating movement. For the majority of kinesins (e.g. kinesin-
1), the stalk domain mediates dimerisation and is implicated in coordinating the 
movement of the kinesin motor domains along the microtubule. For kinesin-5, 
further oligomerisation occurs as two anti-parallel dimers interact via the stalk 
to form a homotetramer (Figure 1-3), which is necessary for its function in 
sliding anti-parallel microtubules apart20. Still other kinesins (e.g. kinesin-221) 
rely on the stalk domain to associate with a different family of kinesin or with 
non-motor proteins. As there are no crystal structures available for the entire 
stalk domain of kinesin, the coiled-coil structure is generally inferred from the 
heptad repeats in the sequence. Using a prediction program called COILS22, 
kinesin-1 is predicted to consist of an interrupted coiled-coil stalk domain. The 
hinges or flexible regions in the stalk domain allow it to fold back onto itself to 
form a compact autoinhibited molecule23. 
 
The tail domain of kinesin is believed to play an important role in regulating the 
molecular motor. When kinesin is folded into a compact form, the tail domain 
interacts with the motor domain and inhibits activity24. This prevents the 
squandering of ATP when kinesin is not transporting cargo or performing its 
functions. Another significant role of the tail domain is the binding and selection 
of cargo, which gives rise to the specificity of each family of kinesin for its 
cargo. However, in the case of kinesin-14, the tail domain does not bind vesicles 
or organelles, instead it binds microtubules25,26. Thus, both the motor and tail 
domains cross-link microtubules and slide them apart during spindle assembly27. 
Finally, the tail domain has also been shown to interact with kinesin-associated 
proteins, such as UNC-76, which could further regulate the cargo binding and 
transport abilities of kinesin28. 
  
1.1.2 Functions of kinesins 
The basic function of kinesins is to transport cargo along microtubules. To this 
end, some kinesins are highly processive, for example kinesin-1, which takes 
about a hundred steps before dissociating from the microtubule track29-31. Each 8 
nm step32,33 requires the hydrolysis of a single ATP molecule34, which produces a 
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force of 6-8 pN35. Ncd (kinesin-14), on the other hand, is a non-processive 
kinesin that dissociates from the microtubule track after each step. To overcome 
this problem, it does not work alone but as an array of multiple motors that bind 
to the microtubules alternately36. Although the mechanism by which kinesins 
move along microtubules is poorly understood, it is widely accepted that the 
molecular motor walks by a ‘hand-over-hand’ mechanism (Figure 1-6), whereby 
the motor domains take turns to be the leading and lagging motor37-39.  
 
Spanning the 14 families of kinesins is a myriad of different cellular functions 
that are implicated in development40, higher brain function41 and tumour 
suppression42. In neurons, kinesins transport vesicles, protein complexes and 
membranous organelles, such as mitochondria43, either anterograde or 
retrograde for the development and normal functioning of neurons. Kinesins also 
transport vesicles and messenger ribonucleoprotein (mRNP) complexes44 in 
dendrites for synaptic transmission. In cells, the roles of kinesins are aplenty. 
They transport vesicles, such as endosomes and lysosomes, and organelles, such 
as the endoplasmic reticulum and Golgi apparatus to their respective 
destinations in the cell45. Finally, kinesins also transport components of the cilia 
in intraflagellar transport46. Thus, given their many cellular functions (Figure 1-
7), it is not surprising that a loss or mutation of a certain kinesin gene could 
result in embryonic lethality, developmental abnormalities, tumorigenesis, 
neuropathies, neurodegeneration47 and dysfunction.  
 
Apart from intracellular transport, kinesins have been discovered to be involved 
in cellular division48. Immunodepletion of kinesins in Xenopus eggs has shed light 
on the role of kinesins in the various steps of mitosis. At least 12 out of 45 
human kinesins belong to this special class called mitotic kinesins that facilitate 
spindle assembly, chromosome segregation and cytokinesis (Figure 1-8). To start 
with, Eg5 (kinesin-5) is largely responsible for the separation of centrosomes and 
formation of the bipolar spindle49. CENP-E (kinesin-7)50 and MCAK (kinesin-13)51, 
among others, help to align chromosomes in metaphase. Finally, members of the 
kinesin-6 family are involved in cytokinesis. Although some of the mitotic 
kinesins are redundant and have counterparts that perform similar functions, the 
importance of kinesins in the regulation of cell division is undisputed.   
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Figure 1-6. Diagram depicting the ‘hand-over-hand’ model of kinesin motility.  
In this model, the motor domains alternate between being the leading and lagging motor. This 
model also predicts that for every ATP hydrolysis cycle, a dye placed on one motor will move 0 and 
16.8 nm alternately. Figure adapted from Yildiz et al., 200439.  
 
 
 
 
 
Figure 1-7. The roles of kinesin in intracellular transport.  
(A) Axonal and dendritic transport of cargoes in neurons by different families of kinesins. (B) 
Kinesins transport vesicles, protein complexes and organelles to their respective locations in the 
cell. (C) An example of intraflagellar transport of vesicles by kinesins in cilia. Figure adapted from 
Hirokawa et al., 200952.  
 
16.8 nm 
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Figure 1-8. Mitotic kinesins involved in different steps of cell division.  
Mitotic kinesins facilitate spindle assembly, chromosome alignment and cytokinesis. Figure 
adapted from Jackson et al., 200753. 
 
 
1.2 Homo sapiens mitotic kinesin Eg5 
A decade before kinesin-1 was first discovered in giant squid axons, a gene was 
found to be crucial in nuclear division of Aspergillus nidulans54. The 
temperature-sensitive mutant of this gene caused mitotic arrest soon after the 
cell had entered mitosis. It was given the name bim. A few years after the 
discovery of kinesin, a homologue of bim was discovered during a differential 
screening of Xenopus egg cDNA for genes that are necessary for nuclear division 
and cell proliferation55. This gene and bim were later classified as members of 
the kinesin-5 family. The human homologue (henceforth called Eg5) was then 
isolated and characterised by Blangy et al.56. The results showed that Eg5 indeed 
has a role to play in the formation of the bipolar spindle and is regulated by a 
protein kinase, p34cdc2.   
 
1.2.1 Structural organisation of Eg5 
Eg5, like many other kinesins, consists of a globular motor domain of ~350 
residues at the N-terminus, an interrupted α-helical coiled-coil stalk domain of 
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~460 residues in the middle of the protein, and a non-helical C-terminal tail 
domain of ~220 residues (Figure 1-9). However, unlike many kinesins that form 
dimers, electron micrographs of rotary-shadowed Eg5 provide evidence that it 
exists as a homotetramer57 (Figure 1-10a). By forming a dimer of anti-parallel 
dimers, Eg5 assembles into a dumbbell-shaped bipolar kinesin with two motor 
domains at each end, which allows it to bind microtubules at both ends (Figure 
1-10b). This quaternary structure is consistent with and can help to explain its 
function of cross-linking and sliding anti-parallel microtubules apart.  
 
The structure of ADP-bound Eg5 motor domain monomer, solved by Turner et 
al.58, has provided insights into the catalytic domain. Although it does not share 
a high sequence homology with other kinesins, the basic eight-stranded β-sheet 
and six α-helices structure is still observed. The nucleotide-binding pocket, P-
loop and switch I are also conserved. The neck linker that follows after the 
switch II cluster is undocked, akin to kinesin-1. Recently, a crystal structure of 
AMPPNP-bound Eg5 that mimics the ATP-bound state was solved59 and it revealed 
a docked neck linker, which is in agreement with that of kinesin-1. However, 
due to the static nature of crystal structures and the fact that many kinesins do 
not work alone as a monomer, it would be difficult to correlate these structures 
with the different stages of the ATPase cycle60,61 with great certainty. 
 
A significant difference between the motor domain of Eg5 and other kinesins is 
the length of L5, which is a loop that interrupts helix α2. Consisting of ~18 
residues (Glu116 to Ile133), Eg5 has the longest loop L5 of all kinesins. While its 
function remains unclear, biochemical and biophysical studies have shown that 
this loop, along with other conserved motifs like switch I, is likely to be involved 
in the regulation of nucleotide and microtubule binding62,63. During the ATPase 
cycle, loop L5 moves between an ‘open’ conformation, when ADP is bound58, and 
a ‘closed’ conformation in the ATP state59,64. This in turn influences the neck 
linker conformation and affects force generation and movement of Eg562,63.  
 
Although many crystal structures of the motor domain are available, little is 
known about the stalk and tail domains. As previously mentioned, the stalk 
domain helps facilitate the formation of an oligomer, and in this case a 
tetramer. It is also necessary for coordinating the ‘hand-over-hand’ movement 
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of the motor domains. Using the COILS program22, the stalk is predicted to be an 
interrupted coiled-coil domain, with the first ~100 residues having a very high 
score and probability of forming a coiled-coil, while the middle ~150 residues 
have a very low score and probability of forming a coiled-coil (Figure 1-11). 
Unfortunately, without a high resolution crystal structure, the true structure and 
conformation of the stalk domain remains elusive.  
 
Although there are no crystal structures of the C-terminal tail domain of Eg5, 
studies have revealed a number of important roles for this domain. Firstly, the 
association of human Eg5 with centrosomes during early prophase is regulated by 
the phosphorylation of Thr927 by protein kinase p34cdc2, more commonly known 
as cyclin-dependent kinase 1 (Cdk1)56. This temporal regulation localises the 
protein on centrosomes and a single point mutation at this tail domain residue is 
sufficient to abolish interaction of the protein with the spindle apparatus. In 
addition, it was discovered through a yeast two-hybrid screen that the tail 
interacts with p150Glued, a subunit of the dynactin complex, which could mediate 
the association of Eg5 with microtubules or the spindle apparatus65. Recently, 
the tail, in addition to the motor domain, was shown to bind microtubules20,66. 
The results suggest that the low processivity of Eg567 could be compensated by 
the tail domain, which continues to bind and cross-link microtubules.   
 
 
 
Figure 1-9. Structural domains of Eg5.  
(A) Schematic diagram of full length Eg5 showing the motor, stalk and tail domains. (Not drawn to 
scale) (B) Cartoon of how Eg5 monomers may interact to form a homotetramer via interactions of 
the stalk domains. Figure adapted from http://www.proweb.org/kinesin/BE5a_BimC.html.  
A 
B 
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Figure 1-10. Electron micrographs of rotary-shadowed Eg5.  
(A) Multiple images of dumbbell-shaped Eg5, which indicate that Eg5 exists as a homotetrameric 
bipolar kinesin. (B) Images of Eg5 binding to a single microtubule (left) and cross-linking two 
microtubules (right). Figure adapted from Kashina et al., 199657. 
 
 
 
 
Figure 1-11. Prediction of quaternary structure of the Eg5 stalk domain.  
Output from the COILS prediction program22 shows that the first ~100 residues have a high score 
and probability of forming a coiled-coil structure, while the middle ~150 residues have a low 
probability. 
A 
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1.2.2 Functions of Eg5 
The main and often talked about function of Eg5 is the formation of the bipolar 
spindle. Many studies have used various techniques and different cell lines to 
probe the function of this bipolar kinesin. In the earliest study on human Eg5, 
Blangy et al.56 showed that the inhibition of Eg5 by antibodies caused HeLa cells 
to arrest in mitosis with a very characteristic phenotype: cells form a monoastral 
spindle with an array of microtubules emanating from a pair of non-separated 
centrosomes (Figure 1-12). Another study using siRNA to knockdown Eg5 in PtK 
cells also resulted in the monopolar spindle phenotype and mitotic arrest68. 
Thus, the current model suggests that Eg5 separates the duplicated centrosomes 
by cross-linking antiparallel microtubules and sliding them apart, as it moves 
towards the plus end of microtubules (Figure 1-13).  
 
Further investigations are in place to find out whether Eg5 works alone, 
synergistically or antagonistically with other molecular motors to maintain the 
bipolarity of the spindle. Two studies have suggested that kinesin-14 and dynein, 
both minus-end directed motors, could oppose the activity of Eg569,70. On the 
other hand, kinesin-12 has been found to cooperate with or even take over the 
function of Eg5 in bipolar spindle formation under particular conditions71. While 
the primary function of kinesin-12 is to maintain the spindle bipolarity, it can 
also drive centrosome separation when Eg5 is inhibited. With the help of a 
microtubule-associated protein, TPX2, it appears that kinesin-12 may be able to 
completely replace the function of Eg5.  
 
The other function of Eg5 is its role in developing neurons. Although Eg5 is a 
mitotic kinesin that is expressed in dividing neuroblasts, Ferhat et al.72 showed 
that Eg5 continues to be expressed in postmitotic neurons. Using 
immunofluorescence staining with an antibody against Eg5, the molecular motor 
was found to be localised in the cell body, along the length of and at the distal 
tips of developing processes, namely the axon or dendrites (Figure 1-14). The 
study also suggests that unlike kinesin-1, Eg5 does not transport organelles from 
the cell body to the tips of neurons. Instead, Eg5 may be involved in regulating 
microtubule organisation and behaviour within the distal tips of developing 
processes, although the exact mechanism remains unclear.  
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Figure 1-12. Role of Eg5 in establishing the bipolar spindle.  
(A) Normal cell in a control setup showing chromosomes aligned at the metaphase plate of a 
bipolar spindle. (B) Cell arrests in mitosis with a monoastral spindle upon knockdown of Eg5 using 
siRNA. Figure adapted from Stout et al., 200668. 
 
 
 
 
Figure 1-13. Bipolar Eg5 homotetramer cross-links and slides microtubules apart.  
(A) By forming a homotetramer, Eg5 has two motor domains binding to one microtubule and the 
other two motor domains binding to an adjacent but anti-parallel microtubule. (B) As Eg5 is a plus-
end directed motor, it moves towards the plus end of microtubules and in doing so, it pushes the 
anti-parallel microtubules apart, separates the duplicated centrosomes, and establishes the bipolar 
spindle. Figure adapted from Sarli et al., 200873. 
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Figure 1-14. Immunofluorescence staining of Eg5 in cultured rat hippocampal neurons.  
(A) At stage 2 of early development, Eg5 is localised within the cell body and at the tips of minor 
processes. (B, C, D) At stage 3, the localisation of Eg5 does not change, although in some cases, 
it is not observed at the distal tip of the axon (B, arrow).  
 
 
More recently, Bartoli et al.74 reported a new and unexpected role of Eg5 in 
polypeptide synthesis. In the study, Eg5 was shown to be essential for the 
production of normal levels of protein in the cell. When Eg5 was inhibited, an 
approximately 40 % decrease in proteins levels was observed after ruling out 
factors such as mitotic arrest and cell death. In addition, the ribosome transit 
time (the time during which the growing polypeptide chain remains attached to 
the ribosome) was also decreased. Through in vitro binding assays, Eg5 was 
shown to associate with ribosomes and act as a link between ribosomes and 
microtubules. This link could promote ribosome transit. Hence, Eg5 is postulated 
to play an important role in translation and elongation of the polypeptide chain 
by facilitating association of the ribosomes to the cytoskeleton and hence 
increasing the efficiency of the ribosomes.   
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1.2.3 Validated drug target for cancer chemotherapy 
Over the past twenty years, taxanes and vinca alkaloids, which target tubulin 
and interfere with microtubule dynamics, have been used successfully in the 
clinics as anti-cancer drugs75. Although these drugs possess anti-tumour 
properties by impeding cell proliferation, patients treated with these drugs also 
suffer from microtubule-dependent side effects, such as peripheral neuropathy 
76. Given the risk of neurotoxicity caused by these drugs and the development of 
drug resistance by tumour cells77-79, an alternative to microtubule-based drugs is 
greatly desired. Currently, several novel targets for drug development in cancer 
therapy, such as kinases and mitotic kinesins, have been identified. Given that 
the inhibition of Eg5 by antibodies and siRNA causes cells to arrest in mitosis and 
prolonged mitotic arrest then leads to apoptotic cell death, Eg5 has become an 
interesting candidate for drug development in cancer chemotherapy.  
 
The first inhibitor of Eg5 was discovered by Mayer et al.80 while conducting a 
phenotype-based screen for small molecules that inhibit the formation of the 
bipolar spindle (Figure 1-15). Out of more than 16000 compounds, they narrowed 
down their search to 139 compounds that caused mitotic arrest in cells. Next, 
using an in vitro tubulin polymerisation assay, they found 86 compounds that do 
not affect microtubule dynamics. Finally, they managed to obtain 5 hits that 
affected only proliferating cells undergoing mitosis. One such compound, which 
was found to be a specific inhibitor of Eg5, was named monastrol, because of 
the characteristic monoastral spindle phenotype it causes in dividing cells. 
Despite its relatively weak potency in cancer cells (IC50 = 34 µM)81, it is the 
prototype small molecule inhibitor that is widely used in biochemical assays to 
study the functions and mechanisms of Eg5. 
 
While efforts are underway to improve the potency of monastrol analogues82, 
many other classes of Eg5-specific inhibitors are currently being investigated. 
Cell-based and in vitro assays have led to the discovery of a series of inhibitors 
that target Eg5. S-trityl-L-cysteine (STLC), from the National Cancer Institute 
library, was previously identified as a new Eg5 inhibitor that is 36 times more 
potent than monastrol83. STLC not only inhibits basal and microtubule-activated 
Eg5 ATPase activity by preventing ADP release, it also inhibits microtubule 
Chapter 1  36 
gliding in motility assays84. Tumour cells treated with STLC were shown to 
undergo mitotic arrest through the activation of the spindle assembly 
checkpoint, evident by the phosphorylation of BubR185. Prolonged mitotic arrest 
consequently led to the activation of caspase-9, cleavage of caspase-8 and 
accumulation of caspase-3, which is indicative of apoptosis by the intrinsic 
apoptotic pathway86.  
 
Tetrahydroisoquinolines87 and pyrrolotriazine-4-one based inhibitors88 are other 
examples of compounds that bind to the same pocket as, but exhibit greater 
potency than monastrol. More recently, benzimidazole inhibitors have been 
shown to bind to a different site and are uncompetitive with ATP89. This new 
class of inhibitors provides a strategy against resistance that may develop from 
mutations in the monastrol-binding pocket90. The specificity of new inhibitors is 
also a major concern in the effort to reduce side effects and improve efficacy of 
potential new cancer therapy. Thus, screening the potential inhibitor against a 
variety of kinesins would weed out those that have cross-reactivity with other 
families of kinesins81. Finally, in order to develop more potent and specific 
inhibitors against Eg5, a structure-based drug design approach may be pursued.  
 
 
 
Figure 1-15. Phenotype-based screen for inhibitors of the mitotic spindle.  
This diagram depicts the process that led to the discovery of monastrol, a specific inhibitor of Eg5, 
which causes cells to arrest in mitosis but does not have an effect on microtubule dynamics. Figure 
adapted from Mayer et al., 199980. 
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The crystal structure of Eg5 in complex with monastrol was solved by Yan et 
al.91. At a resolution of 1.9 Å, the ternary structure of Eg5 in complex with S-
monastrol and Mg2+ADP provides a great deal of insight into the inhibitor-binding 
pocket (Figure 1-16a). By comparing this structure with that of native Eg5-ADP58, 
one is also able to observe several conformational changes that occur upon 
inhibitor binding. Firstly, to accommodate the inhibitor, Arg119 (on helix α2) 
and Tyr211 (on helix α3) move outward, while Trp127 of loop L5 swings 
downwards, by about 7 Å, from a solvent-exposed region to form an aromatic 
edge-to-edge π-interaction with the phenol ring of Tyr211 (Figure 1-16b). These 
conformational changes close the entrance of the induced-fit pocket and form a 
snug inhibitor-binding pocket.  
 
Secondly, switch I, which is the γ-phosphate sensor, swings outward towards the 
solvent by about 6 Å (Figure 1-17) in the inhibitor-bound structure. It also 
transforms from a loop in the native Eg5-ADP structure to a short helix in the 
inhibitor-bound complex. Conformational changes in and around the inhibitor-
binding pocket also translate to changes at helix α4, α5 and the neck linker. 
Helix α4 and α5, which form the switch II cluster, shift upwards towards the N-
terminal of helix α4; thus, opening space for the neck linker to assume a docked 
conformation parallel to the motor domain (Figure 1-17). These conformational 
changes observed in the crystal structure were further confirmed by Maliga et 
al., in a study using spectroscopic probes to dissect the structural changes 
caused by monastrol binding92. 
 
A closer look at the inhibitor-binding pocket reveals that it is bordered by helix 
α3, loop L5 and helix α2. A total of about 20 residues surround the inhibitor. This 
pocket is about 12 Å away from the nucleotide pocket, thus monastrol is 
considered an allosteric or ATP-noncompetitive inhibitor. By studying the 
interactions between the inhibitor and the motor domain, one can think of ways 
to improve the potency of the small molecule. The 3-hydroxy group on the 
phenyl ring forms hydrogen bonds with several residues (Glu118, Ala133 and 
Arg119) of the motor domain. The phenyl ring also forms a C—H---π interaction 
with Pro137 and π-π interactions with Trp127 and Tyr211. Lastly, the oxygen in 
the carbonyl group of the ketone forms a hydrogen bond with Arg119 (Figure 1-
18).  
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Figure 1-16. Structure of Eg5-ADP-monastrol complex.  
(A) Overall structure of the ternary complex (PDB ID: 1X88). The inhibitor and nucleotide are 
represented by ball-and-stick models (C = orange, N = blue, S = yellow, O = red). (B) Stereoplot 
showing the conformational changes (before = red, after = green) that take place upon inhibitor 
binding. Loop L5 swings downwards to close the pocket. Figure adapted from Yan et al., 200491. 
 
 
 
Figure 1-17. Conformational changes in switch I, switch II cluster and neck linker upon 
inhibitor binding.  
Switch I swings towards the solvent, while the neck linker docks onto the motor domain. (before = 
red, after = green). Figure adapted from Yan et al., 200491. 
 
 
 
Figure 1-18. Stereoplot of Eg5-monastrol inhibitor-binding pocket.  
Monastrol (ball-and-stick model) forms hydrogen bonds, π-π interactions and C—H---π interaction 
with the motor domain residues (light blue). Figure adapted from Yan et al., 200491. 
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As more potent inhibitors are being developed through structure-based drug 
design, rigorous testing in tumour cell lines and mouse xenographs are required 
to determine the efficacy of the compounds in vivo. Various classes of inhibitors 
have been tested on paediatric cancers, pancreatic cancer and glioblastoma cell 
lines and xenografts. The results proved to be very encouraging, as complete 
responses, tumour regression and total eradication of tumours have been 
observed in the respective mouse xenograft models93-95. In addition, taxane-
resistant prostate and ovarian cancer cell lines were shown to be sensitive and 
responsive to Eg5 inhibitors96,97. The treated cells arrested in mitosis and 
consequently died by apoptosis. As Eg5 inhibitors work via a different mode of 
action compared to microtubule-targeting drugs, multidrug resistance that arise 
from the mutation of tubulin subunits will not pose a problem for the former. 
 
Besides being able to overcome drug resistance that may develop due to long 
term usage of taxanes and vinca alkaloids, Eg5 inhibitors are also relatively more 
specific against cancer cells. While microtubule-targeting drugs would affect all 
cells containing microtubules, Eg5 inhibitors would only kill cells that are rapidly 
proliferating, in particular various cancers, such as pancreatic cancer and 
leukaemias, that have been shown to possess an elevated expression profile of 
Eg598,99. Although the overexpression of Eg5 may be a consequence of cancer 
cells naturally having a higher mitotic index, Castillo et al.100 showed that 
overexpressing Eg5 in mice resulted in chromosome instability, which is a newly 
identified hallmark of cancer101, and predisposed the mice to the development 
of tumours. Ultimately, whether the high expression levels of Eg5 is a result of 
rapidly proliferating cancer cells or the overexpression of Eg5 results in the 
development of cancers, one cannot deny that Eg5 inhibitors are relatively more 
specific than microtubule-binding drugs.  
 
In conclusion, seven specific inhibitors are currently in Phase I and II clinical 
trials. The best studied compound, ispinesib, was developed by Cytokinetics and 
GlaxoSmithKline, and was the first to enter into human trials102. Other 
compounds include MK-0731 by Merck and ARRY-520 by Array BioPharma. All 
these compounds have been shown to be highly potent against tumour cell 
proliferation and have IC50 in the low nanomolar range (<10 nM). The Phase I 
study of ispinesib showed that it is well-tolerated, safe and did not cause 
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neurotoxicity in patients with solid tumours103-105. The results underscore the use 
of drugs that do not affect microtubule dynamics, as they do not cause serious 
and often irreversible peripheral neuropathy in patients. Nevertheless, side 
effects such as fatigue, nausea and neutropenia are unavoidable.  
 
Phase II study of ispinesib in a large range of adult solid tumours revealed 
greatest activity of the drug in breast, ovarian and non-small cell lung 
carcinoma. The most promising results were shown in advanced and metastatic 
breast cancer patients treated with ispinesib, as half of the number of patients 
enrolled experienced stable disease for up to half a year106. Unfortunately, the 
use of ispinesib in the treatment of other solid tumours did not yield any 
significant response. Thus, the future direction would be to test ispinesib and 
more potent analogues, such as SB 743921, in combination with other 
chemotherapeutics, in hope of achieving a synergistic effect.  
     
1.3 Drosophila melanogaster kinesin-1 
The founding member of kinesins, discovered about 26 years ago, used to be 
called conventional kinesin, as it was believed to be the archetypal kinesin. 
After the discovery of other families of kinesins that possess different 
characteristics and structural organisation, and with the implementation of a 
standardised nomenclature, it became known as kinesin-1. While it was first 
discovered in squid and chick, homologues of this ubiquitous kinesin have now 
been found in many other organisms, such as human, fruit fly and fungus. Here, 
we focus on the D. melanogaster homologue of kinesin-1, whose sequence was 
the first to be deposited5, and describe its structure, function, motility and 
regulation.  
 
1.3.1 Structural organisation of kinesin-1 
The first insight into the structure of kinesin-1 came from electron micrographs 
of rotary-shadowed bovine kinesin-1. Images revealed a ~80 nm rod-shaped 
molecule that contains a pair of globular domains at one end and a fan-shaped 
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structure at the other end107. Addition of monoclonal antibodies against the 
kinesin heavy chain labeled the globular domains, while antibodies against the 
kinesin light chain decorated the fan-shaped structure (Figure 1-19). From these 
results, it was inferred that kinesin-1 is a heterotetramer consisting of two heavy 
chains and two light chains (Figure 1-20a).  
 
The heavy chain of D. melanogaster kinesin-1 (henceforth called kinesin-1) is 
made up of an N-terminal globular motor domain (~360 residues) that is linked 
to the stalk domain via a neck linker5 (Figure 1-20b). Similar to other kinesins, 
the motor domain is the catalytic site for ATP hydrolysis and the binding site for 
microtubules. The neck linker is believed to not only provide the ‘power stroke’, 
but also to determine directionality108-110. The coiled-coil stalk domain (~500 
residues), which facilitates dimerisation, is interrupted in at least two positions 
by kinks or hinges that confer flexibility to the molecule. This allows the 
molecule to fold back onto itself, such that the N-terminal motor domain comes 
into contact and interacts with the C-terminal tail domain (~40 residues). This 
folded conformation is believed to be the inhibited form of the molecular 
motor111. About 150 residues preceeding the tail domain is a predicted coiled-
coil region that is involved in cargo binding and association with the kinesin light 
chain112. At 508 residues long, the kinesin light chain determines the specificity 
of cargo being transported by kinesin-1.  
 
The motor domain has been intensively studied and three crystal structures of 
the motor domain monomer are available: human, rat and fungal kinesin-
117,113,114. They provide insight into the overall structure, nucleotide-binding site 
and conserved motifs within the catalytic core. The motor domain has the same 
fold as that of other kinesins: eight major β-strands in the core, surrounded by 
three major α-helices on each side. The nucleotide-binding site and motifs, such 
as the P-loop, switch I and II are also conserved. However, as the kinesin-1 heavy 
chain exists as a dimer, it is also important to study the structure of a dimer to 
understand how the molecular motor works. The first kinesin-1 dimer structure 
was solved by Kozielski et al. and it revealed a 120° rotational symmetry 
between the Rattus Norvegicus kinesin-1 monomers115 (Figure 1-21). Although 
the structure revealed a small portion of the stalk domain being intertwined as a 
coiled-coil, there were no interactions between the catalytic core and the stalk.  
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Figure 1-19. Electron micrographs of rotary-shadowed bovine kinesin-1.  
(A) Heterotetrameric kinesin-1 consisting of a pair of globular domains on one end and a fan-
shaped structure on the other end. (B) Kinesin-1 molecule folded at a hinge in the stalk domain. (C) 
Antibodies against the heavy chain label the globular domains. (D) Antibodies against the light 
chain label the fan-shaped structure. Figure adapted from Hirokawa et al., 1989107. 
 
 
      
Figure 1-20. Structural domains of kinesin-1.  
(A) Cartoon of kinesin-1 heterotetramer formed by two kinesin heavy chains (KHC, consisting of 
the motor, stalk and tail domains) and two kinesin light chains (KLC). Figure adapted from Verhey 
et al., 2009116. (B) Schematic diagram of the full length kinesin-1 heavy chain (not drawn to scale). 
 
 
 
Figure 1-21. Crystal structure of R. norvegicus kinesin-1 dimer.  
Monomers exhibit a rotational symmetry of ~120° about an axis close to the coiled-coil domain 
(PDB ID: 3KIN115). 
A 
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1.3.2 Functions of kinesin-1 
When kinesin-1 was first discovered in squid axon, it was found to be involved in 
anterograde axonal transport of vesicles and organelles from the cell body to the 
tips of neurons. While there is no doubt about its role in axonal transport, the 
specific functions of kinesin-1 are not well understood. Thus, in order to probe 
the exact functions of kinesin-1, genetic studies were carried out in both larva 
and adult D. melanogaster117. The results from the studies indicate that the 
kinesin-1 heavy chain is essential for the viability of the larva, as mutations in 
both alleles proved to be lethal, but a cloned copy of wild-type heavy chain 
rescued lethality. The mutant hemizygotes were not spared either as they 
suffered growth abnormalities, such as slower growth and reduction in size, 
especially in the posterior regions. This is evident in the skinny and tapered tails 
of hemizygous mutants, compared with the broad and blunt-end tails of wild-
type larva. 
 
Besides growth abnormalities, hemizygote larvae also experienced behavioural 
changes and neuromuscular malfunction. By measuring their rate of crawling and 
feeding, it was found that they were more sluggish than their wild-type 
counterparts. This could be linked to loss of neuromuscular function in the 
posterior region, as the mutant larvae were observed to use only their anterior 
half in their crawling motion, while dragging their paralysed tail along. In 
addition, their posterior region also lacked tactile sensitivity, as they did not 
respond when touched with a needle. Having ruled out necrosis of the tissues in 
the posterior region, it became apparent that an impaired kinesin-1 function 
results in growth abnormalities, motor and sensory impairment of the posterior 
end.  
 
A temperature-sensitive mutant of the kinesin-1 heavy chain tested in adult flies 
revealed similar results: sluggish movements characterised the homozygous 
mutant flies. Furthermore, behavioural depression, in the form of reduced 
courtship, mating and minimal response to stimuli, was observed when the flies 
were cultured in restrictive temperature. On the other hand, the temperature-
sensitive mutant tested in embryos saw no effect on proliferation and 
embryogenesis. In short, all these data come together to show that kinesin-1 
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heavy chain is essential for proper development and neuronal function, in 
particular motility, tactile sensation and behaviour. Loss of function of this 
molecular motor causes lethality but does not impede cellular division in 
embryogenesis.  
 
However, the question remains as to how the role of kinesin-1 in axonal 
transport affects normal physiological function in neurons. To answer this, Gho 
et al.118 dissected the molecular mechanism and showed that the kinesin-1 heavy 
chain is required for action potential propagation in axons and the release of 
neurotransmitters at the nerve ends. However, it was shown that the kinesin-1 
mutant does not impair neurotransmitter release by reducing transportation of 
synaptic vesicle components. Instead, the authors postulate that kinesin-1 may 
be essential for the anterograde transport of vesicles that carry ion channels, 
presynaptic membrane or protein components to their respective locations, 
where they will be inserted or incorporated.  
 
In light of the role of kinesin-1 in axonal transport, the molecular motor has 
been linked to several diseases in human. Firstly, it is implicated in Alzheimer’s 
disease after it was found that amyloid precursor protein (APP) binds to kinesin-
1 light chain119. Recently, Kif5B (one of the three isoforms of kinesin-1 in 
humans) was identified to form a complex with two neurofibromatosis tumour 
suppressors120; thus linking the molecular motor to cancer. Finally, kinesin-1 is 
linked to certain viral infections, as it was found to be necessary for the 
transport of vaccinia virus and herpes viruses121,122. With a better understanding 
of how kinesin-1 works in each of these diseases, strategies that target the 
molecular motor could be employed to combat these diseases.  
 
1.3.3 Motility of kinesin-1 
In order for kinesin-1 to perform its functions, it must possess two important 
characteristics: directional motility and processivity. As mentioned earlier, the 
plus-end directed kinesin-1 is highly processive, as it takes about a hundred 
steps before dissociating from the microtubule29-31. Each step spans 8 nm and is 
coupled to the hydrolysis of a single ATP molecule32,34. Initially, an ‘inchworm’ 
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model, whereby one motor domain will always be leading, was proposed for 
kinesin-1 motility123 (Figure 1-22). The study involved immobilising the tails of a 
kinesin dimer to a surface, adding microtubules to the motor domains and 
observing their movement. If the kinesin dimer moves by a symmetric ‘hand-
over-hand’ model, one would expect the microtubule to rotate by 180°. 
However, the microtubules did not show any rotation relative to the immobilised 
kinesin dimers; thus, a symmetric ‘hand-over-hand’ model was ruled out.  
 
Subsequently, three separate experiments were carried out and the results were 
shown to be inconsistent with the ‘inchworm’ model. Firstly, Kaseda et al.38 
produced and observed the movement of a heterodimeric kinesin, consisting of a 
wild-type motor and a mutant motor domain that hydrolyses ATP at a slower 
rate. It was found that the kinesin moved at an alternating fast and slow speed, 
consistent with the ‘hand-over-hand’ model, whereby the two motors step 
alternately (Figure 1-22). The same result was also observed by Asbury et al.124, 
who used homodimeric kinesin containing different truncated lengths of the 
stalk domain. The limping movement (alternate fast and slow motion) of the 
homodimer was strong evidence for the ‘hand-over-hand’ model.  
 
Finally, using the direct method of labelling and visualising a single motor 
domain as it moves, Yildiz et al.39 showed that the probe moved a distance of 
about 16.6 nm for every other ATP hydrolysis cycle. This experiment dealt the 
final blow to the ‘inchworm’ model. Nevertheless, the finer details of the ‘hand-
over-hand’ model are still unclear. Therefore, several groups have produced 
electron cryomicroscopy (cryo-EM) maps of microtubules decorated with kinesin-
1 monomers or dimers, with different nucleotides bound, to create images of 
kinesins in each step of the processive motion13,125-128. By docking the kinesin-1 
monomer or dimer crystal structure onto microtubules, one can observe the 
binding pattern and position of each motor domain and attempt to model 
motility on microtubules.  
 
In general, all the maps agree on the position of the bound motor domain 
monomer: at the crest between the α- and β- tubulin heterodimer. In the case 
of a dimer, the second unattached motor domain was observed to point towards 
the direction of movement, which is the plus end for kinesin-1 (Figure 1-23). 
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However, the position of the second motor domain is a point of contention, with 
two propositions: it is free125 or tethered to the first motor domain126. 
Consequently, Hoenger et al.129 advised caution when interpreting these 
helically averaged three-dimensional maps, as they may represent an average of 
several conformational states. Also, the concentration of kinesin dimers used to 
decorate the microtubules could affect the position of the unattached motor.  
 
Nonetheless, with the available biophysical data, crystal structure of kinesin-1 
dimer and cryo-EM maps, Hoenger et al.129 attempted to model the ‘hand-over-
hand’ mechanism. In doing so, they realised that unlike human feet that have 
handedness, kinesin-1 dimer consists of two identical motor domains that would 
overwind and produce torsional stress on the stalk if it moves in a symmetric 
mode. Therefore, an asymmetric mode is proposed whereby each motor domain 
undergoes a different conformational change as it takes a step forward (Figure 
1-24). This would mean that the final conformation after taking a step is 
different from that at the beginning, allowing the neck linker to wrap and 
unwrap itself. In short, to dissect the details of motility, more biophysical data, 
crystal structures and cryo-EM maps of different states of motility are needed.  
 
 
 
 
Figure 1-22. Models of motility of kinesin-1.  
(A) Inchworm model where one motor domain is always the leading motor. (B) Symmetric hand-
over-hand model with the lagging motor always passing the front motor to the left or to the right. 
This model is symmetric because the conformation of each motor is the same at the beginning and 
end of each step. (C) Symmetric hand-over-hand model with the lagging motor passing the front 
motor alternately from the left and right side. Figure adapted from Yildiz et al., 2005130.  
 
A B C Inchworm Symmetric             hand-over-hand I 
Symmetric            
hand-over-hand II 
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Figure 1-23. Cryo-EM maps of microtubule decorated with kinesins.  
Tubulin protofilaments are in green, attached motor in cream and unattached motor domain in 
orange. (A) Kinesin-1 dimer, (B) kinesin-1 monomer and (C) kinesin-14 Ncd dimer. The unattached 
motor domain points towards the direction of motility. Figure adapted from Hirose et al., 1996120. 
 
 
 
Figure 1-24. Cartoon depiction of asymmetric hand-over-hand motility of kinesin-1.  
Each motor domain undergoes a different conformational change as it takes a step forward. This 
would mean that the conformation of each motor at the end of a step is different from the 
conformation at the beginning of the step. In this model, the neck linker is able to wrap and unwrap 
itself to relieve over winding and torsional stress build up. Figure adapted from Hoenger et al., 
2000121. 
A 
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1.3.4  Autoinhibition of kinesin-1 
When kinesin-1 is not transporting cargo along the microtubule track, it has to 
be regulated to prevent squandering of ATP and overcrowding of the 
microtubule highway. To this end, the molecular motor adopts a compact and 
folded conformation, through an autoinhibitory mechanism, that keeps it 
inactive in the absence of cargo23,131,132 (Figure 1-25). This folded and compact 
structure has been shown to be the default conformation of the molecule at 
physiological ionic concentration111. By folding into a compact structure, the tail 
comes into close proximity with the motor domain and interacts with it with 
tight affinity (Kd ≈ 20-40 nM)133,134. Although the tail domain can bind to 
microtubules, the interaction of the tail and motor domains has been shown to 
reduce the affinity of kinesin-1 to microtubules. This in turn inhibits 
microtubule-stimulated ADP release24. However, it was later discovered that the 
tail can inhibit ADP release from the motor domains even in the absence of 
microtubules135.  
 
While it is generally accepted that the folded structure inactivates the 
molecular motor, the exact mechanism as to how the tail autoinhibits the motor 
domain is not well understood. An idea put forward is that kinesin-1 may go by 
the same autoinhibition mechanism that keeps myosin II in a compact inactive 
conformation, whereby the tail loops around and binds to the motor domain.  
Using mutational studies and truncated constructs, several studies have 
narrowed down the site of interaction between the tail and motor domains to 
the IAK region of the tail23,126. This region is highly conserved among metazoan 
and fungal kinesin-124,136; thus, further supporting its role in the regulation of 
kinesin-1 (Figure 1-26).  
 
The sequence immediately before the IAK region, called the auxiliary binding 
site (ABS) region, is positively-charged and conserved among metazoan but not 
fungal kinesin-1 (Figure 1-26). While it helps to increase the affinity of the tail 
to motor domains, the ABS region alone is not sufficient to cause autoinhibition 
in metazoan kinesin-1, let alone fungal kinesin-1 that lacks this region. 
Therefore, the ABS region is not implicated in the binding to motor domains, but 
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may play a secondary role as a binding site for the kinesin light chain, which 
coincidentally is lacking in fungal kinesin-1134.  
 
Figure 1-25. Cartoon of how kinesin-1 may be inhibited.  
Kinesin-1 is activated when it in an extended conformation. It becomes inhibited when the tail binds 
to the motor domains in a compact folded structure. Figure adapted from Coy et al., 1999132. 
 
 
 
 
Figure 1-26. Sequence alignment of selected metazoan and fungal kinesin-1s.  
Conserved residues and motifs as shown by multiple seqence alightment using ClusterW. 
Conserved residues in the motor domains are highlighted by red boxes. The IAK region is 
highlighted by a green box, while the positively-charged ABS region is shown by a blue box. Dm: 
Drosophila melanogaster (GI:125414); Hs-A,B,C: Homo sapiens isoforms (GI:143811412, 
GI:417216, GI:3043586); Sp: Strongylocentrotus purpuratus, sea urchin (GI:10270); Lp: Loligo 
pealii, squid (GI:125415); and Nc: Neurospora crassa (GI:6016437).  
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Recent studies have shown that the monomeric tail domain is sufficient for tight 
binding to and half-site inhibition of the dimeric motor domain133. This 
unexpected finding raises questions as to what the role of the second tail 
domain might be. Using a yeast two-hybrid screen, Gindhart et al.28 showed that 
the tail domain binds to UNC-76. A loss of UNC-76 function resulted in impaired 
axonal transport; thus, it could probably help to regulate the cargo binding and 
transport ability of kinesin-1. Besides binding to kinesin-associated proteins, the 
tail domain is also involved in cargo binding and it has been shown that the 
addition of cargo, in the form of beads, activates a previously inhibited kinesin-
1132.   
 
Several models have been proposed to explain the role of the tail domain in 
inhibiting the motor: 1) the tail domain could block the microtubule binding site 
of the motor domain and cause steric inhibition, 2) the tail domain could bind to 
and induce a conformational change in the motor domain, resulting in allosteric 
inhibition, and 3) the tail domain could bind to the neck linker and adjacent 
coiled-coil region of the motor domain, which is implicated in the ‘power 
stroke’, thus inhibit movement23. However, Coy et al.132 has shown that the tail 
domain is not a competitive inhibitor by measuring enzymes kinetics. Since the 
tail domain does not compete with microtubules for the binding to the motor 
domain, the steric inhibition model is unlikely. The model in which the tail 
domain binds to the neck coiled-coil region is also not highly plausible. This is 
because Friedman et al.131 showed that a mutation in the neck coiled-coil region 
greatly, but not completely, relieved the tail-mediated inhibition of movement.  
 
Finally, only the allosteric model of inhibition has been supported by structural 
information in the form of an 8 Å cryo-EM map of a photochemically cross-linked 
motor-tail complex on microtubules. It revealed simultaneous interaction of the 
tail domain with the motor domain switch I region and the microtubule137. The 
authors propose an allosteric model, whereby the binding of the tail to the 
motor domain induces a conformational change and the release of ADP is 
prevented; hence, the motor domain is halted in an ADP state on the 
microtubule track. Nevertheless, further confirmation of this allosteric model 
would be necessary before it is set in stone.  
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1.4 Objectives of the thesis 
Since its discovery 26 years ago, a great amount of work has been done to 
characterise the structures and functions of various families of kinesins. The 
knowledge gained has allowed us to better understand the molecular mechanism 
of each of its functions. However, where there are gaps in our knowledge of 
kinesins and where there are contradictions in proposed hypotheses, further 
investigations need to be carried out. To this end, the objectives of this thesis 
are: 
 
1) To determine the crystal structures of mitotic kinesin Eg5 in complex with 
various inhibitors for structure-activity relationship (SAR) studies. The 
structural information obtained will facilitate structure-based drug design 
of more potent and specific inhibitors of Eg5, by revealing important 
interactions in the inhibitor-binding pocket. Consequently, these 
inhibitors may be developed as potential drugs for cancer chemotherapy. 
 
2) To dissect the pathway of conformational changes that occurs when an 
inhibitor binds to Eg5. Such structural information will allow us to better 
understand the molecular mechanism of inhibition of Eg5 by potential 
cancer chemotherapeutics. 
 
3) To determine the thermodynamic parameters, such as binding affinity, 
enthalphy changes, entropy changes and stoichiometry of interaction 
between Eg5 and its inhibitors, using Isothermal Titration Calorimetry 
(ITC).  
 
4) To determine the oligomerisation state and sedimentation coefficient of a 
portion of the Eg5 stalk domain using Analytical Ultracentrifugation 
(AUC).  
 
5) To investigate the secondary structure of a portion of the Eg5 stalk 
domain using Circular Dichroism (CD). This will give us a clue to the actual 
structure of the stalk domain.  
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6) To determine the structure of a portion of the Eg5 stalk domain in 
solution using Small Angle X-ray Scattering (SAXS). The structural 
information will give us a glimpse of the overall shape of the polypeptide.  
 
7) To determine the crystal structure of the kinesin-1 motor domain dimer, 
in order to make available additional structural information for the 
docking of the kinesin dimer to microtubules in cryo-EM maps and the 
modeling of kinesin motility. 
 
8) To determine the crystal structure of the kinesin-1 motor domain dimer in 
complex with the tail domain. Comparison of this structure with the 
motor domain dimer structure will elucidate the molecular mechanism of 
kinesin-1 autoinhibition. This structural information will also serve to 
validate or invalidate current proposed models of autoinhibition. 
 
9) To verify the essential residues involved in the binding of the tail to the 
motor domains during autoinhibition, through a peptide array.   
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2 Material and methods 
All reagents used are purchased from Sigma Aldrich, unless otherwise stated. 
Reagents that are used for molecular biology techniques and protein purification 
are of molecular biology grade. Reagents used in crystallisation are of the 
highest purity available.  
 
2.1 Mitotic kinesin Eg5 motor domain 
2.1.1 Molecular cloning of recombinant plasmid 
The motor domain of human Eg5 (residues 1-368) was initially cloned into the 
pET28a vector138. It was then cut with restriction enzymes NcoI and XhoI (New 
England Biolabs, NEB) and cloned into a modified pProExHT expression vector 
(Invitrogen), yielding a PreScission protease-cleavable N-terminal hexahistidine-
tagged protein.  
 
2.1.2 Expression and purification of protein 
The plasmid was transformed into BL21 Star (DE3) pLysS competent Escherichia 
coli (Invitrogen). Six liters of bacterial culture were grown at 37°C in Terrific 
Broth (TB) supplemented with 100 mg/l ampicillin to an A600 of approximately 
0.7 and induced overnight with 0.5 mM isopropyl ß-D-thiogalactopyranoside 
(IPTG, Melford) at 18°C. Harvested cells were resuspended in buffer A (50 mM 
PIPES pH 6.8, 2 mM MgCl2, 250 mM NaCl and 20 mM imidazole) supplemented 
with 1 mM PMSF, 1 mM MgATP, and 2.5 mg lysozyme, and subjected to one cycle 
of freeze-thaw and sonication, before 1 mM DNaseI and 10 mM MgCl2 were 
added. Sonication was carried out using the Vibra-Cell VCX 750 sonicator (Sonics 
& Materials, Inc.) with a 13 mm probe, at 70 % amplitude and 8 x 8 secs pulses 
with an 8-secs pause in between each pulse. 
 
Clear lysate was loaded onto a 5 ml HisTrapFF column (GE Healthcare) 
equilibrated in buffer A. The resin was washed with buffer A containing 50 mM 
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imidazole and the proteins were eluted on a gradient of buffer A from 50 mM to 
500 mM imidazole. Fractions containing protein of interest were pooled and the 
buffer was exchanged for protease buffer (50 mM PIPES pH 6.8 and 250 mM 
NaCl). 0.5 mg of PreScission protease, 1 mM MgATP, and 2 mM MgCl2 were added 
to the protein sample (~40 mg of Eg5) and the reaction was incubated overnight 
at 4°C. Uncleaved protein and protease were removed by NiNTA affinity 
chromatography. The cleaved protein was subjected to size exclusion 
chromatography on a Superdex75 column (GE Healthcare) equilibrated in gel 
filtration buffer (50 mM PIPES pH 6.8, 50 mM KCl, 1 mM DTT, 1 mM EGTA and 1 
mM MgCl2). Fractions containing the protein of interest were pooled and 
concentrated on an Amicon Ultra filtration device (Millipore), with size exclusion 
limit of 30 kDa, to a final concentration of approximately 20 mg/ml, frozen in 
liquid nitrogen, and stored at -80°C.  
 
2.1.3 Crystallisation of Eg5-inhibitor complexes 
2.1.3.1 Eg5 in complex with enastron, dimethylenastron or fluorastrol 
Purified Eg5 (10 mg/ml) was incubated with 2 mM of inhibitor in DMSO for 1 hr 
on ice and centrifuged at 13000 rpm for 5 mins at 4°C to pellet undissolved 
inhibitor before setting up of crystal trays. Crystals of Eg5 with enastron 
appeared 2 days after micro-seeding crystals of Eg5 with monastrol into hanging-
drops of 1 µl of Eg5-enastron complex mixed with 1 µl of reservoir solution 
containing 25 % PEG-3350, 0.2 M K2HPO4 and 0.1 M HEPES pH 8.0 in VDX plates 
(Hampton Research) at 4°C. A hexagonal-shaped crystal with dimensions of 
approximately 0.1 x 0.1 x 0.1 mm was immersed in cryoprotectant solution (30 % 
PEG-3350, 0.24 M K2HPO4, 0.12 M HEPES pH 8.0, 60 mM KCl and 20 % erythritol) 
and flash frozen in liquid nitrogen.  
 
Crystals of Eg5 with dimethylenastron crystallised 4 days after micro-seeding 
crystals of Eg5 with monastrol into hanging-drops of 1 µl of Eg5-dimethylenastron 
complex mixed with 1 µl of reservoir solution containing 28 % PEG-3350, 0.2 M 
K2HPO4 and 0.1 M HEPES pH 6.5 in VDX plates at 4°C. Hexagonal-shaped crystals 
with dimensions of approximately 0.1 x 0.1 x 0.1 mm were immersed in 
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cryoprotectant solution (33.6 % PEG-3350, 0.24 M K2HPO4, 0.12 M HEPES pH 6.5, 
60 mM KCl and 20 % erythritol) and flash frozen in liquid nitrogen. 
 
Crystals of Eg5 with racemic fluorastrol appeared after 1 day in hanging drops by 
mixing 1 µl of protein-inhibitor complex with 1 µl of reservoir solution containing 
30 % PEG-3350, 0.2 M K2HPO4 and 0.1 M HEPES pH 8.0 in VDX plates at 4°C. A 
block-shaped crystal with dimensions of approximately 0.1 x 0.1 x 0.1 mm was 
immersed in cryoprotectant solution (30 % PEG-3350, 0.24 M K2HPO4, 0.12 M 
HEPES pH 8.0, 0.3 M NaCl and 20 % erythritol) and flash frozen in liquid nitrogen. 
 
2.1.3.2 Eg5 in complex with S-trityl-L-cysteine (STLC) or 6 
Purified Eg5 (10 mg/ml) was incubated with excess STLC powder (Novabiochem) 
overnight at 4°C.  Purified Eg5 (20 mg/ml) was incubated with 2 mM 6 (in DMSO) 
for 2 hrs on ice. Before setting up of crystal trays, the sample was centrifuged at 
13000 rpm for 5 mins at 4°C to pellet undissolved inhibitor. Crystals of Eg5 with 
STLC appeared after 1 month in hanging drops by mixing 2.5 µl of protein-
inhibitor complex with 2.5 µl of reservoir solution containing 22 % PEG-3350, 
0.15 M sodium tartrate dibasic dihydrate and 0.1 M MES pH 6.5 in VDX plates at 
4°C. A block-shaped crystal with dimensions of approximately 0.1 x 0.1 x 0.3 mm 
was immersed in cryoprotectant solution (24 % PEG-3350, 0.18 M sodium tartrate 
dibasic dihydrate, 0.12 M MES pH 6.5, 0.06 M KCl and 20 % erythritol) and flash 
frozen in liquid nitrogen. 
 
Crystals of Eg5 with 6 appeared after 1 month in hanging drops by mixing 2.5 µl 
of protein-inhibitor complex with 2.5 µl of reservoir solution containing 25 % 
PEG-3350, 0.15 M sodium tartrate dibasic dihydrate and 0.1 M MES pH 6.0 in VDX 
plates at 4°C. A block-shaped crystal with dimensions of approximately 0.1 x 0.1 
x 0.2 mm was immersed in cryoprotectant solution (24 % PEG-3350, 0.24 M 
sodium sulphate decahydrate, 0.12 M MES pH 6.5, 0.06 M KCl, and 20 % 
erythritol) and flash frozen in liquid nitrogen. 
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2.1.3.3 Eg5 in complex with compound 7, 8 or 9 
Purified Eg5 (20 mg/ml) was incubated with 2 mM rac-7, 8 or 9 (in DMSO) for 2 
hrs on ice. Crystals of Eg5 with rac-7 appeared after 1 week in hanging drops by 
mixing 1 µl of protein-inhibitor complex with 0.2 µl of 1 M potassium sodium 
tartrate tetrahydrate and 1 µl of reservoir solution containing 23 % PEG-3350, 
0.25 M ammonium sulphate and 0.1 M MES pH 5.5 in VDX plates at 4°C. 
Dehydrating solution (33 % PEG-3350, 0.25 M ammonium sulphate, 0.1 M 
potassium sodium tartrate tetrahydrate, 0.1 M MES pH 5.5 and 10 % glycerol) was 
added slowly to the crystal droplet until the total volume of the drop was eight 
times the original. The drop was then equilibrated against air in 4°C for 30 mins. 
A cubic crystal with dimensions of approximately 0.1 mm on each side was then 
flash frozen in liquid nitrogen.  
 
Crystals of Eg5 with 8 appeared after 4 days in hanging drops by mixing 1 µl of 
protein-inhibitor complex with 1 µl of reservoir solution containing 22 % PEG-
3350, 0.25 M ammonium sulphate, 0.1 M potassium sodium tartrate tetrahydrate 
and 0.1 M MES pH 5.8 in VDX plates at 4°C. A thick needle-shaped crystal with 
dimensions approximately 0.1 x 0.01 x 0.01 mm was immersed in cryoprotectant 
solution (27.6 % PEG-3350, 0.36 M of ammonium sulphate, 0.12 M MES pH 5.5, 
0.06 M KCl and 20 % erythritol) and flash frozen in liquid nitrogen.  
 
Crystals of Eg5 with 9 appeared after 1 week in hanging drops by mixing 1 µl of 
protein-inhibitor complex with 1 µl of reservoir solution containing 22 % PEG-
3350, 0.3 M ammonium sulphate, 0.1 M MES pH 5.5 and 0.01 M trimethylamine 
hydrochloride in VDX plates at 4°C. Dehydrating solution (32 % PEG-3350, 0.36 M 
of ammonium sulphate, 0.12 M MES pH 5.5, 0.012 M trimethylamine 
hydrochloride and 10 % glycerol) was added as described above. A cubic crystal 
with dimensions of approximately 0.1 mm on each side was then flash frozen in 
liquid nitrogen.  
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2.1.4 Data collection and processing 
2.1.4.1 Eg5 in complex with enastron, dimethylenastron or fluorastrol 
The diffraction data for the Eg5-enastron and Eg5-dimethylenastron crystals 
were measured at the European Synchrotron Radiation Facility (ESRF) on ID23-1. 
The diffraction data for the Eg5-fluorastrol crystal was measured at beamline 
ID14-1. Assistance for data collection was provided by local contact Dr. Sandor 
Bruckhauser. The data for Eg5-fluorastrol was processed using 
HKL2000/Scalepack139; the data for Eg5-enastron and Eg5-dimethylenastron were 
processed using iMOSFLM140 and scaled using Scala141 from the CCP4 suite of 
programs142. The calculation of Rfree used 5 % of data. 
 
2.1.4.2 Eg5 in complex with STLC or compound 6 
Diffraction data for Eg5-STLC and Eg5-6 were recorded at the ESRF on station 
ID23-1 and ID29 respectively, with the assistance of local contact Dr. David Flot. 
The crystals belonged to space group P32. Data were processed using iMosflm140 
and Scala141 from the CCP4 suite of programs142 . The calculation of Rfree used 5 % 
of data. As the space group P32 is prone to crystal twinning, we carefully 
examined the cumulative distribution function in ctruncate and found no 
indication of twinning143. In addition, we submitted the data to the Merohedral 
Crystal Twinning Server144, which also confirmed the absence of any significant 
twinning. 
 
2.1.4.3 Eg5 in complex with compound 7, 8 or 9 
Diffraction data for the Eg5-inhibitor complexes Eg5-7 and Eg5-9 were recorded 
at the ESRF ID23-2 with the assistance of Dr. Gordon Leonard, while Eg5-8 was 
recorded at ID23-1 with the assistance of Dr. Alexander Popov. Data were 
processed using iMosflm140 and scaled using Scala141 from the CCP4 suite of 
programs142. The calculation of Rfree used 5 % of data. 
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2.1.5 Structure determination and refinement 
2.1.5.1 Eg5 in complex with enastron, dimethylenastron or fluorastrol 
The structures of all the complexes were solved by molecular replacement with 
MolRep145 from the CCP4 suite of programs142 using the Eg5 molecule in the Eg5-
monastrol structure as a search model (PDB Code: 1X88)146. The two molecules in 
the asymmetric unit were positioned and refined with Refmac5 using rigid body 
refinement followed by restrained refinement147.  Electron density and 
difference density maps were all σA-weighted, inspected and the models were 
rebuilt and improved using Coot148. The ligand coordinates and the cif 
dictionaries for the refinement were obtained using the Dundee PRODRG 
server149. Model geometry was analyzed using Procheck150 and the figures were 
prepared using PyMOL151.   
 
2.1.5.2 Eg5 in complex with STLC or compound 6 
The structures were solved by molecular replacement (MolRep145) using one 
molecule of Eg5 in the Eg5-monastrol structure (PDB code: 1X88)146 as a search 
model. Three subunits were positioned and refined with Refmac5147 for STLC and 
with simulated annealing using Phenix152 for compound 6. Electron-density and 
difference density maps all σA-weighted, were inspected and the model was 
improved using Coot148. The coordinates and the cif dictionary for the inhibitor 
molecule were calculated using the Dundee PRODRG server149. Model geometry 
was analysed using Procheck150. 96.49 % (880) of the residues are in the 
preferred regions, 2.30 % (21) are in the allowed regions, and 1.21 % (11) are 
outliers as shown by the Ramachandran Plot. Figures are prepared using 
PyMOL151.  
 
Since 3rd generation radiation was used for data collection, the crystal suffered 
slight radiation damage. The refined difference fourier map showed some 
negative density around the sulphur atom of STLC in all three molecules and also 
around the sulphur atoms of other residues at the surface. We also observed 
negative density around the sulphur atom of 6 in molecules B and C, but not in 
molecule A of the Eg5-6 structure. As sulphur atoms absorb more photons, at 
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wavelength of about 1 Å, compared to other atoms (C, O & N) present in the 
protein, the radiation damage on sulphur is greater compared to that of the 
other atoms. Moreover, sulphur atoms that are more exposed (present at the 
surface) or are in close proximity to solvent water molecules experience more 
profound effect due to secondary radiation damage from the water 
molecules153,154. These negative densities could therefore be a result of radiation 
damage during data collection.  
 
2.1.5.3 Eg5 in complex with compound 7, 8 or 9 
The structures Eg5-7, Eg5-8 and Eg5-9 were solved by molecular replacement 
(Phaser155) using one molecule of Eg5 motor domain from structures with PDB 
code 3KEN156, 1X88146 and 3KEN156 respectively. Refinement was carried out with 
Phenix152. Electron-density and difference density maps all σA-weighted, were 
inspected and the model was improved using Coot148. Model geometry was 
analysed using Molprobity157. For the Eg5-7 complex, 95.2 % (316) of the residues 
are in the preferred regions, 3.61 % (12) are in the allowed regions, and 1.20 % 
(4) are outliers. For the Eg5-8 structure, 95.7 % (2106) of the residues are in the 
preferred regions, 3.54 % (78) are in the allowed regions, and 0.77 % (17) are 
outliers as shown by the Ramachandran Plot. For the Eg5-9 complex, 97.0 % 
(322) of the residues are in the preferred regions, 2.7 % (9) are in the allowed 
regions, and 0.3 % (1) are outliers. Figures are prepared using PyMOL151. 
 
 
2.1.6 Isothermal Titration Calorimetry (ITC)  
ITC experiments were performed using a VP-ITC Isothermal Titration Calorimeter 
(MicroCal), with the assistance of Dr. Nahoum Anthony at the University of 
Strathclyde. Prior to performing the experiments, the motor domain of human 
Eg5 (residues 1-368) was cloned, expressed and purified as previously described 
(sections 1.1.1 and 1.1.2), apart from the following changes: the protein was 
incubated with 5 mM EGTA and 5 mM EDTA for 30 mins at 4°C before size 
exclusion chromatography was carried out to remove all nucleotides64, and the 
gel filtration buffer contained no MgCl2. The concentration of the protein was 
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measured in 6.7 M guanidine hydrochloride (buffered with 20 mM potassium 
dihydrogen phosphate at pH 7.0) using UV spectrophotometry at 280 nm and an 
extinction coefficient of 21200 M-1 cm-1. The protein, diluted to about 1 mg/ml, 
was then dialysed in 20 mM PIPES pH 6.8, 300 mM NaCl, 2 mM β-
mercaptoethanol, 5 mM MgCl2 and 500 µM ADP overnight at 4°C. 1 % DMSO was 
added to the dialysed protein before freezing the protein aliquots in liquid 
nitrogen and storing at -80°C. 
 
The inhibitors, ispinesib and STLC, were prepared in the dialysis buffer 
mentioned above to concentrations of 250 µM and 200 µM respectively and the 
final concentration of DMSO in each inhibitor sample is 1 %. Protein samples 
were centrifuged at 13000 rpm for 5 mins at room temperature (rtp) prior to the 
experiment. Protein and inhibitors were degassed immediately before use. All 
titrations were carried out at 25°C with a stirring speed of 351 rpm. 10 µl of 
inhibitor was injected 26 times, with spacings of 240 secs, into the cell 
containing 24 µM Eg5 motor domain with 1 % DMSO.  
 
For control experiments, the inhibitors were injected into dialysis buffer 
supplemented with 1 % DMSO. The heats of dilution were then subtracted from 
the respective inhibitor titrations before proceeding with data analysis using the 
Origin 5.0TM program (MicroCal). Two titrations were performed for each Eg5-
inhibitor interaction and analysed separately. Thermodynamic parameters 
obtained, such as N (stoichiometry), Ka (association constant), ΔH (enthalpy 
change) and ΔS (entropy change), were then averaged from the two titrations. 
Kd (dissociation constant) was calculated using equation 1. 
 
 
 
    Kd = 1 / Ka      Equation 1 
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2.2 Mitotic kinesin Eg5 stalk364-520 domain 
2.2.1 Molecular cloning of recombinant plasmid 
Polymerase chain reaction (PCR) was carried out to amplify residues 364-520 
from human Eg5 cDNA and to include restriction sites BamHI and XhoI. HotStar 
HiFidelity DNA Polymerase was used according to the manufacturer’s protocol 
(Qiagen). The forward and reverse primers used were 5’-CGT ATG GGA TCC GAA 
GTG AAT CAG AAA CTC ACC-3’ and  5’-CGT AGA CTC GAG TTA CTT ACG ATC CAG 
TTT GGA ATG G-3’ (Sigma). The PCR product was then digested with restriction 
enzymes BamHI and XhoI (NEB), gel purified (Qiagen), and ligated (Roche) into a 
modified pET28a expression vector (gift from Prof. Sondermann), yielding a Ulp-
1 protease-cleavable N-terminal SUMO fusion and hexahistidine-tagged protein. 
 
2.2.2 Expression and purification of protein 
The plasmid was transformed into BL21-CodonPlus competent E. coli 
(Stratagene). 12 liters of bacterial culture were grown at 37 °C in TB 
supplemented with 50 mg/l kanamycin to an A600 of approximately 0.7 and 
induced overnight with 0.5 mM IPTG (Melford) at 18°C. Harvested cells were 
resuspended in buffer A (50 mM PIPES pH 6.8, 2 mM MgCl2, 250 mM NaCl, 20 mM 
imidazole, 1 mM EGTA) supplemented with 1 mM PMSF and 2.5 mg lysozyme, and 
subjected to one cycle of freeze-thaw and sonication, before 1 mM DNaseI and 
10 mM MgCl2 were added. Sonication was carried out using the Vibra-Cell VCX 
750 sonicator (Sonics & Materials, Inc.) with a 13 mm probe, at 70 % amplitude 
and 8 x 8 secs pulses with an 8-secs pause in between each pulse. 
 
Clear lysate was loaded onto a 1 ml HisTrapFF column (GE Healthcare) 
equilibrated in buffer A. The resin was washed with buffer A containing 50 mM 
imidazole and the proteins were eluted on a gradient of buffer A from 50 mM to 
500 mM imidazole. Fractions containing protein of interest were pooled and the 
buffer was exchanged for protease buffer (50 mM PIPES pH 6.8 and 250 mM 
NaCl). 0.25 mg of Ulp-1 protease was added to the protein sample (~20 mg) and 
the reaction was incubated overnight at 4°C. Uncleaved protein and protease 
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were removed by NiNTA affinity chromatography. The cleaved protein was 
subjected to size exclusion chromatography on a Superdex200 column (GE 
Healthcare) equilibrated in gel filtration buffer (50 mM Tris pH 6.8, 50 mM KCl, 1 
mM DTT, 1 mM EGTA, and 2 mM MgCl2). Fractions containing the protein of 
interest were pooled and concentrated on an Amicon Ultra filtration device 
(Millipore), with size exclusion limit of 10 kDa, to a final concentration of 
approximately 20 mg/ml, frozen in liquid nitrogen, and stored at -80°C.  
 
2.2.3 Analytical Ultracentrifugation (AUC) 
AUC experiments and data analysis were carried out with the assistance of Dr. 
Olwyn Byron at the University of Glasgow. Prior to the experiments, the protein 
was dialysed in 50 mM PIPES pH 6.8, 150 mM NaCl and 1 mM tris(2-
carboxyethyl)phosphine (TCEP) at 4°C overnight. Sedimentation velocity (SV) 
experiments were used to determine the sedimentation coefficient, while 
sedimentation equilibrium (SE) experiments were used to determine the 
oligomeric state. Both experiments were performed using a Beckman Coulter 
Optima XL-I ultracentrifuge, an 8-place An-50 Ti rotor and two-sector cells. 
Seven samples of different concentrations were used for the experiments: 20, 
10, 2, 1, 0.5, 0.3 and 0.2 mg/ml.  
 
For the SV experiments, 60 µl each of the 20 and 10 mg/ml samples were loaded 
into 3 mm centrepieces, while 360 µl each of the rest of the samples were 
loaded into 12 mm centrepieces. The dialysis buffer was loaded into the second-
sector of each cell to be used as a reference. The experiment was carried out at 
49000 rpm and 4°C, using both interference and absorbance optics, and scans 
were recorded every 5 mins with a step size of 0.001 cm. SEDNTERP158 was used 
to calculate the partial specific volume (v-bar) of the protein. The buffer density 
(ρ) and viscosity (η) were calculated and provided by Christine Ebel from Institut 
de Biologie Structurale, France.  
 
SEDFIT159 was used to analyse the sedimentation profile and the data was fitted 
to a continuous c(s) distribution model. Subtraction of all systematic noise from 
the raw data was carried out only for data obtained from the interference 
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optics. The apparent sedimentation coefficient (s4,b), obtained from the fitting 
of the data to the non-interacting discrete species model, was converted to the 
true sedimentation coefficient (s20,w) using equation 2. s20,w was then plotted 
against protein concentration to obtain the sedimentation coefficient at zero 
concentration (s°20,w) for a given protein species.  
       
                    
  Equation 2 
 
where 20,w = at 20°C in water; and 4,b = at 4°C in buffer. 
 
 
For the SE experiments, 15 µl each of the 20 and 10 mg/ml samples were loaded 
into 3 mm centrepieces, while 80 µl each of the rest of the samples were loaded 
into 12 mm centrepieces. The second-sector of each cell contained the 
reference, which is the dialysis buffer. The SE experiments were carried out at 
20000 and 30000 rpm at 4°C, using the interference optics. Scans were recorded 
every 3 hrs until equilibrium was reached. SEDPHAT160 was used to analyse the 
data obtained at equilibrium. The apparent weight average molecular weight 
was obtained by fitting the data to the species analysis model individually and 
globally.  
 
2.2.4 Circular Dichroism (CD) 
Prior to the experiments, the protein was dialysed in 20 mM potassium 
dihydrogen phosphate (buffered at pH 7.0) and diluted to 1 mg/ml, as the 
original buffer absorbed strongly below 205 nm. Subsequent CD experiments and 
data analysis were carried out by Dr. Sharon Kelly at the Protein 
Characterisation Facility of the University of Glasgow. The CD spectra was 
recorded on a JASCO J-810 spectropolarimeter, at 25°C, in the near UV range 
(320 – 250 nm) using a 0.5 cm pathlength cell containing 1 mg/ml of protein. For 
the far UV range (260 – 180 nm), the CD spectra was recorded using a 0.02 cm 
pathlength cell containing 0.33 mg/ml of protein. The data obtained was 
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submitted to DichroWeb161, an online server, for secondary structure analysis 
using the CONTINLL algorithm162.   
 
2.2.5 Small Angle X-ray Scattering (SAXS) 
Prior to the experiments, the protein was dialysed in 50 mM PIPES pH 6.8, 150 
mM NaCl and 1 mM TCEP. Six samples of different concentrations were used for 
the experiments: 19.97, 9.86, 2.14, 0.98, 0.49, 0.29 mg/ml. The accurate 
concentrations were determined using UV spectrophotometry at 280 nm. Data 
was collected by Dr. Olwyn Byron on the beamline X33 at Deutsches Elektronen-
Synchrotron (DESY), European Molecular Biology Laboratory (EMBL). Background 
scattering was collected from the dialysis buffer and subtracted from the 
scattering profiles of the protein samples. All data were integrated, scaled and 
corrected for beam decay using PRIMUS163. 
 
With the given data, I then proceeded with data analysis. The radius of gyration 
(Rg) and the extrapolated intensity at zero scattering angle (I(0)) were 
determined by Guinier approximation164. Next, GNOM165 was used to obtain the 
p(r) or pair-distance distribution function plot and to determine the maximum 
dimension (Dmax) of the protein. More accurate values of Rg and I(0) were also 
obtained from the p(r) function. Then, using the p(r) plot as the fitting target, 
ab initio modelling of the molecular envelope was performed using GASBOR22166 
in reciprocal space. As the protein was found to exist as a dimer from AUC, the 
P2 symmetry was used during modelling. 20 independent simulations, consisting 
of 100 cycles of simulated annealing each, were carried out in batch mode for 
each of the six data sets. The solutions for each data set were then 
superimposed, averaged and filtered using DAMAVER167 to obtain a consensus 
structure. Figures were prepared using PyMOL151. 
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2.3 Drosophila melanogaster conventional kinesin 
2.3.1 Molecular cloning of recombinant plasmid 
The motor domain of D. melanogaster kinesin (residues 1-381) was initially 
cloned into the vector pET21168. PCR was carried out to amplify residues 1-365 
and residues 1-375, and to include restriction sites BamHI and XhoI. HotStar 
HiFidelity DNA Polymerase was used according to the manufacturer’s protocol 
(Qiagen). The forward primer used was 5’ CAT ATG GGA TCC GCG GAA CGA GAG 
ATT CC-3’ for both reactions, while the reverse primer used was 5’-CGT AGA 
CTC GAG TTA CTT ACC CTT TAG TCG GGC GTT CTT TTC C-3’ for residues 1-365 
and 5’ CGT AGA CTC GAG TTA GCG CGC AAG CTC GAT CTC for residues 1-375 
(Sigma). The PCR products were then digested with restriction enzymes BamHI 
and XhoI (NEB), gel purified (Qiagen), and ligated (Roche) into modified pET28a 
expression vector (Invitrogen) separately, yielding Ulp-1 protease-cleavable N-
terminal SUMO fusion and hexahistidine-tagged proteins. 
 
2.3.2 Expression and purification of protein 
The plasmid containing residues 1-365 was transformed into BL21-CodonPlus 
competent E. coli (Stratagene). 12 liters of bacterial culture were grown at 37°C 
in TB supplemented with 50 mg/l kanamycin to an A600 of approximately 0.7 and 
induced overnight with 0.5 mM IPTG at 18°C. Harvested cells were resuspended 
in buffer A (20 mM Tris pH 8.8, 1 mM MgCl2, 200 mM NaCl, 20 mM imidazole, 1 
mM EGTA) supplemented with 1 mM PMSF, 1 mM MgATP, and 2.5 mg lysozyme, 
and subjected to one cycle of freeze-thaw and sonication, before 1 mM DNaseI 
and 10 mM MgCl2 were added. Sonication was carried out using the Vibra-Cell 
VCX 750 sonicator (Sonics & Materials, Inc.) with a 13 mm probe, at 70 % 
amplitude and 8 x 8 secs pulses with an 8-secs pause in between each pulse. 
 
Clear lysate was loaded onto a 1 ml HisTrapFF column (GE Healthcare) 
equilibrated in buffer A. The resin was washed with buffer A containing 50 mM 
Imidazole and the proteins were eluted on a gradient of buffer A from 50 mM to 
500 mM Imidazole. Fractions containing protein of interest were pooled and the 
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buffer was exchanged for protease buffer (20 mM Tris pH 8.8 and 250 mM NaCl). 
0.25 mg of Ulp-1 protease, 1 mM MgATP, and 2 mM MgCl2 were added to the 
protein sample (~20 mg) and the reaction was incubated overnight at 4°C. 
Uncleaved protein and protease were removed by NiNTA affinity 
chromatography. The cleaved protein was subjected to size exclusion 
chromatography on a Superdex200 column (GE Healthcare) equilibrated in gel 
filtration buffer (20 mM Tris pH 8.8, 300 mM NaCl, 1 mM DTT, 1 mM EGTA, and 2 
mM MgCl2). Fractions containing the protein of interest were pooled and 
concentrated on an Amicon Ultra filtration device (Millipore), with size exclusion 
limit of 30 kDa, to a final concentration of approximately 20 mg/ml, frozen in 
liquid nitrogen, and stored at -80°C.  
 
2.3.3 Crystallisation of dimer and dimer-tail complex 
Crystals of the motor domain dimer (residues 1-365) appeared after 2 days in 
hanging drops by mixing 1 µl of protein with 1 µl of reservoir solution containing 
24 % PEG-3350, 0.15 M ammonium sulphate, and 0.1 M HEPES sodium pH 7.8 in 
VDX plates at 19°C. Micro streak seeding was carried out to produce single and 
larger crystals. A block-shaped crystal with dimensions of approximately 0.1 x 
0.1 x 0.1 mm was immersed in cryoprotectant solution (28.8 % PEG-3350, 0.18 M 
ammonium sulphate, 0.12 M HEPES sodium pH 7.8, 0.36 M NaCl, and 20 % 
erythritol) and flash frozen in liquid nitrogen. 
 
Initially, I crystallised the motor domain dimer (residues 1-365) in complex with 
tail910-952 peptide. However, the crystals diffracted no better than 2.7 Å. I was 
able to solve the structure and saw electron density for only ten residues of the 
peptide. Hence, we decided to use a shorter tail peptide for crystallisation. 
Purified motor domain (10 mg/ml) was incubated with tail937-952 peptide (6.1 
mg/ml) in a ratio of (1 monomeric motor : 2 tails) for 2 hrs on ice before setting 
up the crystal trays. The tail peptides were expressed and purified by our 
collaborator Prof. David Hackney (Carnegie Mellon University). Crystals of the 
motor domain dimer-tail complex appeared after 2 days in hanging drops by 
mixing 1 µl of protein complex with 1 µl of reservoir solution containing 18 % 
PEG-3350, 0.2 M KCl, and 0.1 M HEPES sodium pH 7.4 in VDX plates at 19°C. 
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Micro streak seeding was carried out to produce single larger crystals. A block-
shaped crystal with dimensions of approximately 0.3 x 0.1 x 0.1 mm was 
immersed in cryoprotectant solution (21.6 % PEG-3350, 0.24 M KCl, 0.12 M HEPES 
sodium pH 7.4, 0.36 M NaCl, and 20 % PEG-200) and flash frozen in liquid 
nitrogen. 
 
2.3.4 Data collection and processing 
Diffraction data for the dimer and dimer-tail complex were recorded at the ESRF 
ID23-2 and Swiss Light Source PXI, with the assistance of Dr. David Flot and Dr. 
Marcus Muller respectively. Data were processed using iMosflm140 and scaled 
using Scala141 from the CCP4 suite of programs142. The calculation of Rfree used 5 
% of data. 
 
2.3.5 Structure determination and refinement 
The dimer and dimer-tail structures were solved by molecular replacement 
(Phaser155) using one molecule of human kinesin-1 motor domain (PDB code: 
1BG2)17 and one molecule of the refined dimer structure as search models 
respectively. Refinement was carried out with Refmac5147. Electron-density and 
difference density maps all σA-weighted, were inspected and the model was 
improved using Coot148. Model geometry was analysed using Molprobity157. For 
the dimer structure, 90.31 % (587) of the residues are in the preferred regions, 
6.77 % (44) are in the allowed regions, and 2.92 % (19) are outliers as shown by 
the Ramachandran Plot. For the dimer-tail complex, 94.14 % (1270) of the 
residues are in the preferred regions, 4.97 % (67) are in the allowed regions, and 
0.89 % (12) are outliers. Protein domain interfaces were analyzed using 
PDBePISA169. Figures were prepared using PyMOL151. 
 
2.3.6 Alanine scan peptide array 
16-residue tail peptides, corresponding to a single, double, or triple alanine-
scan, were synthesised and bound to the membrane by the Peptide Synthesis 
Chapter 2  68 
Laboratory at the London Research Institute. Each residue was mutated to an 
alanine in turn, while an alanine was mutated to a glycine. Two identical 
membranes were synthesised and the experiment was repeated twice, once on 
each membrane, to validate the results. The membranes were soaked in 100 % 
ethanol for 15 secs, washed with TBS-T for 3 x 5 mins and blocked with 5 % milk 
in TBS-T for 1 hr at rtp. As a control for non-specific binding of the antibody, the 
membrane was incubated with 1:8000 dilution of HRP-conjugated anti-His6 
antibody (Clontech) for 1 hour (rtp) and developed like a western blot. Next, the 
membrane was washed with TBS-T as above, before incubating with 8 µg/ml of 
His6-tagged motor domain dimer (residues 1-375) overnight at 4°C. The protein 
was expressed and purified as above (section 1.3.2), but the His6 tag was not 
cleaved and the protein sample was not passed through a second Ni-NTA column. 
The membrane was then probed with antibody and developed as above.   
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3 Developing inhibitors of human mitotic kinesin 
Eg5  
The results in this chapter have been published in peer-reviewed journals: 
 
Kaan, H.Y., Ulaganathan, V., Hackney, D.D. & Kozielski, F. An allosteric 
transition trapped in an intermediate state of a new kinesin-inhibitor complex. 
Biochem J 425, 55-60 (2010). (Appendix 1) 
 
Kaan, H.Y., Ulaganathanm, V., Rath, O., Prokopcová, H., Dallinger, D., Kappe, 
C.O. & Kozielski, F. Structural basis for inhibition of Eg5 by dihydropyrimidines: 
stereoselectivity of antimitotic inhibitors enastron, dimethylenastron and 
fluorastrol. J Med Chem 53, 5676-83 (2010). (Appendix 2) 
 
Kaan, H.Y., Weiss, J., Menger, D., Ulaganathan, V., Tkocz, K., Laggner, C., 
Popowycz, F., Joseph, B. & Kozielski, F. Structure-activity relationship and 
multidrug resistance study of new S-trityl-L-cysteine derivatives as inhibitors of 
Eg5. J Med Chem 54, 1576-86 (2011). (Appendix 3) 
 
3.1 Aims and objectives 
Human mitotic kinesin Eg5 is an interesting target for drug development in 
cancer chemotherapy, because its inhibition causes cells to arrest in mitosis and 
eventually die by apoptosis. Monastrol was the first specific inhibitor of Eg5 to 
be discovered. Our lab later identified S-trityl-L-cysteine (STLC) as a potent and 
specific inhibitor against Eg5. Employing a structure-based drug design method, 
we hope to develop more potent and efficient inhibitors that may be used as 
alternatives or in complement with taxanes and vinca alkaloids. These drugs are 
used successfully in clinics against cancers, but they have the tendency to cause 
neurotoxicities and develop resistance in patients. As Eg5 inhibitors do not 
target microtubules but act via a different mode of action, we believe that they 
are potential alternatives that are worth pursuing. 
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In this chapter, I will report the crystal structures of Eg5 in complex with three 
monastrol analogues (enastron, dimethylenastron and fluorastrol), STLC, and 
four STLC analogues (compounds 6-9) separately (Figure 3-1). Based on the 
structures, I will discuss the structure-activity relationship (SAR) of each class of 
inhibitors. In addition, I will analyse the intermediate state of the Eg5-STLC 
structure to discuss the pathway of structural changes that occur upon inhibitor 
binding. Lastly, thermodynamic parameters of interaction between Eg5 and its 
inhibitors, determined by isothermal titration calorimetry (ITC), will be 
presented to help us gain a better understanding of the molecular mechanism of 
inhibition by an Eg5 inhibitor. 
 
 
 
 
Figure 3-1. Chemical structures of Eg5 inhibitors.  
Differences between monastrol and its analogues, and STLC and its analogues are shown in red. 
Asterisks mark chiral centers.  
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3.2 Results 
3.2.1 Structures of Eg5 in complex with enastron, 
dimethylenastron and fluorastrol 
We solved the crystal structures of human Eg5 in complex with enastron, 
dimethylenastron and fluorastrol. Each Eg5-inhibitor structure was solved in 
space group P212121. Statistics for data collection and refinement are 
summarised in Table 3-1.  All structures contain two molecules per asymmetric 
unit and are missing the first 15 residues at the N-terminus. Loop L11 is also 
absent as in most other kinesin structures, as it is flexible. All three structures 
have one molecule of Mg2+ADP bound in the nucleotide-binding pocket with the 
magnesium coordinated octahedrically with the β-phosphate, the oxygen (OG1) 
of the hydroxyl side chain of Thr112 and four water molecules. The three 
inhibitors bind to Eg5 at the well-characterised inhibitor-binding pocket, 
bordered by helix α2, loop L5 and helix α3. Based on the chemical structure, the 
three distinct inhibitors share a common 3-hydroxyphenyl group, which occupies 
the same position in all the crystal structures and makes virtually identical 
interactions with the residues in the inhibitor-binding pocket. 
 
Eg5 was crystallised in the presence of racemic enastron; yet, the structure 
revealed full occupancy of the inhibitor in the S-configuration and there is no 
evidence for binding in the R-configuration (Figure 3-2). The 3-hydroxyl group on 
the phenyl ring makes hydrogen bonds with the main chain carbonyl group of 
Glu118, the main chain amino group of Ala133 and the side chain nitrogen (NE) 
of Arg119. Moreover, the phenyl ring forms C—H---π interaction with the 
pyrrolidine ring of Pro137 and edge-to-face (T-shape) interactions with the 
phenyl rings of Trp127 and Tyr211. Next to the phenol group is the 
dihydropyrimidine ring. Here, the 2-thioxo group points towards the core of the 
protein and interacts with one water molecule. In addition, the nitrogen at 
position 1 (NAK) acts as a hydrogen donor and forms hydrogen bonds with two 
water molecules. Adjacent to the dihyropyrimidine ring is the oxo-cyclohexene 
ring system. The oxygen acts as a hydrogen bond acceptor and forms a hydrogen 
bond with the main chain amino group of Arg119 and with a structural water 
molecule. 
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Figure 3-2. Stereoplot of enastron in the inhibitor-binding pocket.  
Hydrogen bonds between inhibitor (green) and Eg5 residues (beige) or structural water molecules 
(red spheres) are depicted by black broken lines.   
 
 
The racemic mixture of dimethylenastron was used for crystallisation with Eg5. 
However, the structure indicates a preference of Eg5 for the S-enantiomer, 
instead of the R-enantiomer. The overall conformation of dimethylenastron in 
the inhibitor-binding pocket (Figure 3-3) and the interactions with the residues 
of the allosteric binding site is virtually identical to that observed with enastron. 
The only difference between the Eg5-enastron and Eg5-dimethylenastron 
complexes is the additional dimethyl group on the oxo-cyclohexene ring system, 
which points towards the solvent region, but maintains hydrophobic interactions 
(≤ 3.9 Å) with the hydrophobic main chain of Ala218 that constitutes part of 
helix α3. In addition, one of the methyl groups (CAA) forms a C—H---π 
interaction with Tyr211.  
 
 
Figure 3-3. Stereoplot of dimethylenastron in the inhibitor-binding pocket.  
Hydrogen bonds between inhibitor (green) and Eg5 residues (beige) or structural water molecules 
(red spheres) are depicted by black broken lines. 
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Eg5 was crystallised with the racemic mixture of fluorastrol and the structure 
revealed preferential binding of Eg5 to the R configuration, unlike enastron, and 
dimethylenastron, which bind in the S configuration. Consequently, the 
interactions in the inhibitor-binding pocket, apart from that of the 3-
hydroxyphenyl group which is common in all three inhibitors, are strikingly 
different from that of enastron and dimethylenastron. In the R configuration, 
the 2-thioxo group points to the solvent-exposed region of the protein and 
interacts with two water molecules (Figure 3-4). The N1-H on the 
dihydropyrimidine ring interacts with a water molecule and the N3-H group 
interacts via a hydrogen bond with the main chain carbonyl group of Gly117. The 
3’,4’-difluorophenyl group, on the other hand, points towards the core of the 
protein. One of the fluorines (FAF) forms multipolar interactions170 with the 
guanidinium side chain of Arg221, the main chain amide of Ala218 and the main 
chain carbonyl group of Gly217. In this configuration, the other fluorine (FAG), 
which points towards the edge of the phenyl ring of Phe239 and the carbonyl 
group (OAC) of the inhibitor do not form any hydrogen bonds with the rest of the 
protein.  
 
 
 
 
Figure 3-4. Stereoplot of fluorastrol in the inhibitor-binding pocket.  
Hydrogen bonds between inhibitor (green) and Eg5 residues (beige) or structural water molecules 
(red spheres) are depicted by black broken lines. Multipolar interactions between the inhibitor and 
Eg5 residues are depicted by pink broken lines. 
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Table 3-1. Data collection and refinement statistics of Eg5 in complex with monastrol 
analogues. 
 
 Enastron a Dimethylenastron a Fluorastrol a 
 
Unit cell dimensions 
a, b, c, β (Å, °) 
 
69.6, 79.8, 159.3, 
90.0 
69.5, 79.7, 159.3, 
90.0 
69.6, 79.8, 160.0, 
90.0 
Space group 
 
P212121 P212121 P212121 
Beamline / 
Detector 
 
ID23-1 / Q315R ID23-1 / Q315R ID14-1 / Q210 
Molecules per 
asymmetric unit 
 
2 2 2 
Resolution range (Å) 
 
30 - 1.9 30 - 2.30 30 - 2.40 
No. of reflections 
 
347186 314811 257554 
No. of unique 
reflections 
 
69235 40030 35497 
Completeness (%)  
 
98.2 (94.6) b 99.9 (99.4) 95.5 (93.4) 
Multiplicity  
 
5.0 7.9 7.3 
Rsym (%) 
 
11.8 (34.4) 10.3 (38.6) 9.6  (33.2) 
I/σ(I) 
 
10.0 (4.9) 16.0 (5.5) 10.8 (5.0) 
Wilson B (Å2) 
 
14.57 28.48 33.70 
Refinement statistics 
 
Rwork / Rfree (%) 
 
16.31 / 23.16 17.59 / 24.05 19.58 / 27.32 
Average B Factors    
     Overall  
 
19.49 21.42 23.41 
     Main chain /      
     Side chain 
 
16.58 / 21.72 19.58 / 22.93 21.97 / 24.67 
No. of Mg2+ADP / 
Inhibitor / Water 
 
2 / 2 / 822 2 / 2 / 541 2 / 2 / 433 
r.m.s.d. c in bond 
length (Å) 
 
0.0126 0.0135 0.0133 
r.m.s.d. in bond  
angle (°) 
1.502 1.649 1.819 
a The racemic mixture was used for crystallisation of the protein-inhibitor complex. 
b Values in parentheses pertain to the highest resolution shell. 
c r.m.s.d. is the root-mean-square deviation from ideal geometry. 
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3.2.2 Structures of Eg5 in complex with STLC and compound 6 
The crystal structures of the Eg5-STLC and Eg5-6 complexes were solved at a 
resolution of 2.0 and 2.2 Å respectively. Data collection and refinement 
statistics are shown in Table 3-2. Both complexes crystallised in the space group 
P32 with three molecules in the asymmetric unit. Loop L11 is flexible and missing 
as in most other kinesin structures. Mg2+ADP is bound in all the nucleotide-
binding pockets with the magnesium octahedrically coordinated. STLC and 
compound 6, which have well-defined electron density, occupy the inhibitor-
binding pocket similar to that of monastrol and its analogues. Although we used 
the diastereoisomeric mixture of 6 for crystallisation of the Eg5-inhibitor 
complex, we fitted only one of the diastereoisomers, S-(2-methyl-1,1-
diphenylbutyl)-L-cysteine, into the structure. 
 
The conformation of STLC and the interactions between STLC and Eg5 are 
virtually identical in all three molecules. The three phenyl rings in STLC, which 
represent the hydrophobic part of the inhibitor, are buried in the allosteric site 
and display several hydrophobic interactions with the alkyl side chains of 
Glu215, Glu116 and Arg119 (Figure 3-5). We also observed edge-to-face (T-
shape) interaction between the first phenyl group of STLC and the phenyl ring of 
Trp127; C—H---π interaction between the first phenyl group of STLC and the 
pyrrolidine ring of Pro137; offset stacked π-π interaction between the second 
phenyl group and Tyr211; and C—H---π interaction between the third phenyl 
group and the side chain of Leu214171.  
 
On the other hand, the hydrophilic part of the inhibitor, namely the cysteine 
moiety, is exposed to the solvent and we observe several hydrogen bond 
interactions: the amino group of the cysteine moiety with the main chain 
carbonyl oxygen of Gly117, the side chain oxygen (OE1) of Glu116, and a 
structural water molecule; an oxygen (OXT) of the carboxyl group of the 
cysteine moiety with one of the side chain amino groups (NH1) of Arg221 and 
four structural water molecules; and the other oxygen of the carboxyl group 
with one structural water molecule. All structural water molecules mentioned 
are conserved in all three molecules of the asymmetric unit. 
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Figure 3-5. Stereoplot of STLC in the inhibitor-binding pocket.  
Hydrogen bonds between inhibitor (green) and Eg5 residues (beige) or structural water molecules 
(red spheres) are depicted by black broken lines. 
 
 
Upon analysing the inhibitor-binding pocket, we observe identical hydrogen bond 
interactions between Eg5 and the cysteine moieties of STLC and 6 (Figure 3-6). 
In addition, 6 appears to form one more hydrogen bond with water, as compared 
to STLC. This hydrogen bond — formed between an oxygen (OXT) of the carboxyl 
group of the cysteine moiety and a structural water molecule — is only observed 
in molecule A and B of the Eg5-6 structure. With a high resolution structure and 
well-defined electron density map, we were able to determine undoubtedly the 
location of the alkyl chain substituent of 6. The alkyl chain points toward the 
solvent-exposed region of the protein and the methyl group (CAA) forms a C—H--
-π interaction with the phenyl ring of Tyr211. 
 
 
 
Figure 3-6. Stereoplot of compound 6 in the inhibitor-binding pocket.  
Hydrogen bonds between inhibitor (grey) and Eg5 residues (beige) or structural water molecules 
(red spheres) are depicted by black broken lines. 
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Table 3-2. Data collection and refinement statistics of Eg5 in complex with STLC and 
compound 6. 
 
 STLC a Compound 6 a 
 
Unit cell dimensions 
a, b, c, β (Å, °) 
 
 
96.5, 96.5, 124.4, 
120.0 
 
96.4, 96.4, 
124.4, 120.0 
Space group 
 
P32 P32 
Beamline / Detector 
 
ID23-1 / Q315R ID29 / Q315R 
Molecules per 
asymmetric unit 
 
3 3 
Resolution range (Å) 
 
30 - 2.0 30.0 - 2.2 
No. of unique reflections 
 
87598 65550 
Completeness (%) 
 
99.9 (100.0) b 99.9 (100.0) 
Multiplicity 
 
5.8 6.3 
Rsym (%) 
 
8.9 (40.0) 8.6 (28.7) 
I/σ(I) 
 
12.8 (4.0) 14.3 (6.0) 
Wilson B (Å2) 
 
27.2 33.4 
Refinement statistics 
 
  
Rwork / Rfree (%) 
 
15.9 / 21.8 17.4 / 22.4 
Average B Factors   
     Overall 
 
35.9 34.9 
     Main chain / 
     Side chain 
 
33.6 / 37.7 33.1 / 36.3 
No. of Mg2+ADP / 
Inhibitor / Water 
 
3 / 3 / 1192 3 / 3 / 783 
r.m.s.d. c in bond length 
(Å) 
 
0.0127 0.0130 
r.m.s.d. in bond 
angle (°) 
1.61 1.678 
a The racemic mixture was used for crystallisation of the protein-inhibitor complex. 
b Values in parentheses pertain to the highest resolution shell. 
c r.m.s.d. is the root-mean-square deviation from ideal geometry. 
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3.2.3 Structures of Eg5 in complex with compounds 7, 8 and 9 
The crystal structures of Eg5 in complex with 7, 8 and 9 were solved to 
resolutions of 2.75, 2.75 and 2.65 Å respectively. Data collection and refinement 
statistics are presented in Table 3-3. Eg5-7 and Eg5-9 complexes crystallised in 
space group I213 with 1 molecule per asymmetric unit, while Eg5-8 complex 
crystallised in space group P212121 with 7 molecules per asymmetric unit. A 
closer look at the inhibitor binding pocket reveals that the three phenyl rings of 
7, 8 and 9 are buried in the same pockets as that of STLC. Consequently, the 
same hydrophobic and aromatic interactions between the three phenyl rings and 
the residues in the inhibitor-binding pocket were observed. 
 
As the racemic mixture of 7 was used to crystallise the Eg5-inhibitor complex, 
electron density for both enantiomers were observed in the structure. Several 
hydrogen bond interactions between Eg5 and the cysteine moiety of (S)-7 were 
apparent: the amino group with the main chain carbonyl oxygen of Gly117 and 
the side chain oxygen (OE1) of Glu116; and an oxygen (OXT) of the carboxylic 
group of the cysteine moiety with one of the side chain amino groups (NH1) of 
Arg221 (Figure 3-7). However, these interactions were not observed for the R-
enantiomer. Instead, the amino group of the cysteine moiety forms a hydrogen 
bond with a structural water molecule.  
 
Although the sulphur in STLC has been substituted by a carbon in 7, the 
interactions between Eg5 and both inhibitors are virtually identical. The only 
difference lies in the length of the shorter C-C-C bonds (3.9 Å), as compared to 
the length of the longer C-S-C bonds (4.5 Å). With a well-defined electron 
density map, the position of the phenyl ring with the meta-substituted methyl 
group was determined unambiguously. It sits in the mainly hydrophobic pocket, 
formed by Ile136, Pro137, Leu160, Leu214 and Phe239. Consequently, the small 
lipophilic methyl substituent on the phenyl ring forms hydrophobic interactions 
with these Eg5 residues. 
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Figure 3-7. Stereoplot of compound 7 in the inhibitor-binding pocket.  
Hydrogen bonds between inhibitor (magenta: S-enatiomer; yellow: R-enantiomer) and Eg5 
residues (beige) or structural water molecules (red spheres) are depicted by black broken lines. 
 
 
In the structure of Eg5 in complex with 8, where the carboxylic acid in the 
amine tail is absent, hydrogen bond interactions were observed only between 
the amino group and the main chain carbonyl oxygen of Gly117 and the side 
chain oxygen (OE1) of Glu116 (Figure 3-8). The loss of the carboxylate group not 
only removes a hydrogen bond interaction, but also reduces restraints on the 
amine tail and increases its conformational freedom, as evident from one 
molecule (chain D) where the amino group points away from the side chain of 
Glu116 and towards the amino group of Arg221 instead. Based on the electron 
density map, the phenyl ring carrying the meta-substituted acetate group is 
positioned in the same pocket as the meta-substituted phenyl ring of 7. The 
methyl of the acetate group forms hydrophobic interactions with Phe239, 
Leu160, Ile136 and Leu214, similar to the methyl substituent of 7. The carbonyl 
oxygen of the acetate group of 8 forms a hydrogen bond with one of the side 
chain amino groups (NH1) of Arg221. 
 
 
Figure 3-8. Stereoplot of compound 8 in the inhibitor-binding pocket.  
Hydrogen bonds between inhibitor (blue) and Eg5 residues (beige) or structural water molecules 
(red spheres) are depicted by black broken lines. 
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Compound 9 is similar to 8 in that it lacks the carboxylic acid in the amine tail. 
Correspondingly, the amine tail of compound 9 adopts the same conformation as 
that of 8. In the crystal structure, the amino group of 9 points towards the side 
chain oxygen of Glu 116 and forms similar hydrogen bond interactions as 8 
(Figure 3-9). As there is only one molecule in the asymmetric unit, flexibility of 
the amine tail lacking the carboxylic acid was not observed. Despite the similar 
amine tail, compound 9 consists of a chiral carbon while 8 does not. Although 
the racemic mixture of compound 9 was used for crystallisation, only the R-
enantiomer was found to bind in the inhibitor-binding pocket.  
 
According to the well-defined electron density map, the phenyl ring carrying the 
meta-substituted ethyl group sits in the same pocket as the meta-substituted 
phenyl rings of 7 and 8. Hence, similar hydrophobic interactions form between 
the ethyl group and the residues of the hydrophobic pocket, such as Ile136, 
Leu160 and Leu214. Compound 9 also consists of a second phenyl ring that has a 
meta-substituted hydroxyl group. It is shown to fit in a pocket formed by Ala133, 
Leu132, Asp130, Trp127, Arg119, Glu118 and Pro137. In this position, the 
hydroxyl substituent points towards the core of the protein instead of outwards 
towards the solvent. The hydroxyl group also forms a hydrogen bond with the 
main chain nitrogen of Ala133.  
 
 
 
Figure 3-9. Stereoplot of compound 9 in the inhibitor-binding pocket.  
Hydrogen bonds between inhibitor (blue) and Eg5 residues (beige) or structural water molecules 
(red spheres) are depicted by black broken lines. 
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Table 3-3. Data collection and refinement statistics of Eg5 in complex with compounds 7, 8 
and 9. 
 
 Compound 7 a Compound 8 Compound 9 a 
 
Unit cell dimensions 
a, b, c, γ (Å, o) 
 
158.6, 158.6, 
158.6, 90.0 
145.7, 156.2, 
170.0, 90.0 
158.3, 158.3, 
158.3, 90.0 
Space group 
 
I213 P212121 I213 
Beamline / Detector 
 
I23-2 / MAR 225 ID23-1 / Q315R I23-2 / MAR 225 
Molecules per 
asymmetric unit 
 
1 7 1 
Resolution range (Å) 
 
30 - 2.75 30.0 - 2.75 30 – 2.65 
No. of unique 
reflections 
 
17322 (2496) b 98930 (14132) 19305 (2826) 
Completeness (%)  
 
99.8 (99.8) 97.7 (96.6) 99.9 (100.0) 
Multiplicity  
 
5.8 (5.4) 5.4 (5.5) 7.5 (7.6) 
Rsym (%) 
 
8.3 (60.9) 9.4 (57.7) 8.7 (58.5) 
I/σ(I) 
 
12.2 (3.2) 13.0 (2.7) 15.4 (3.9) 
Wilson B (Å2) 
 
77.98 70.75 66.89 
Refinement statistics 
 
   
Rwork / Rfree (%) 
 
19.76 / 24.30 22.06 / 28.04 18.53 / 22.76 
Average B Factors    
    Overall  
 
66.54 64.67 60.50 
    Main Chain /  
    Side Chain 
 
65.34 / 67.72 63.94 / 65.39 58.93 / 61.95 
No. of Mg2+ADP / 
Inhibitor / Water 
 
1 / 1 / 41 7 / 7 / 302 1 /1 / 110 
r.m.s.d. c in bond 
length (Å) 
 
0.012 0.013 0.012 
r.m.s.d. in bond  
angle (Å) 
1.75 1.70 1.68 
a The racemic mixture was used for crystallisation of the protein-inhibitor complex. 
b Values in parentheses pertain to the highest resolution shell. 
c r.m.s.d. is the root-mean-square deviation from ideal geometry. 
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3.2.4 Structure of the intermediate state of inhibitor-bound Eg5 
To study the intermediate state of inhibitor-bound Eg5, we examine the 
structure of the Eg5-STLC complex, which crystallises with 3 molecules per 
asymmetric unit. The three molecules reveal a variety of conformational 
changes throughout the molecule, when compared with the native structure of 
the Eg5 motor domain58 in the absence of an inhibitor. The most obvious changes 
occur in the inhibitor-binding pocket. In all three molecules, Arg119 and Tyr211 
move outwards, while Trp127 of the Loop L5 region (Gly117 to Ala133) swings 
downwards, by about 7 Å, from a solvent-exposed region in the native structure 
to form an aromatic edge-to-edge π-interaction with the phenol ring of Tyr211 in 
the inhibitor-bound structure (Figure 3-10). 
 
In the native and STLC-bound structures, Mg2+ADP occupies the active site 
through binding of the α- and β-phosphates to the P-loop. The overlay of 
molecules A, B and C with the native structure showed no differences in 
conformation of the P-loop. We then investigated helix α3. In all three 
molecules, the apex of the helix α3 is shifted towards the solvent by a maximum 
of about 2 Å at Glu209, when compared to the native structure (Figure 3-11). 
Following helix α3 is switch I, which adopts the same conformation in all three 
molecules, but differ from that of the native structure. Loop L9 is shifted 
towards the solvent by about 6 Å and displays an additional one-turn of a helix. 
The hydroxyl group of Tyr231, which is originally solvent-exposed in the native 
structure, moves by about 12 Å into the hydrophobic environment of the protein.  
 
 
Figure 3-10. Stereoplot showing overlay of the inhibitor-binding pocket of native Eg5 and 
Eg5-STLC complex.  
Yellow: native Eg5 (PDB ID: 1II6)58; blue: Eg5-STLC molecule B; and green: STLC. 
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Figure 3-11. Stereoplot showing overlay of helix α3 of native Eg5 and Eg5-STLC complex.  
Yellow: native Eg5 (PDB ID: 1II6)58; blue: Eg5-STLC molecule B; and green: STLC. 
 
 
Upon overlaying molecules A, B and C, using the main chain Cα atoms from 
residues 19 to 363, molecules A and B were found to be almost identical with a 
root mean square deviation of 0.33 Å. However, a larger deviation of 1.32 Å was 
observed when molecules A and B were overlaid with C. While the conformation 
of the inhibitor-binding pocket and structural motifs, such as the P-loop, helix 
α3 and switch I are virtually identical in all three molecules, the conformation of 
the switch II cluster (helix α4, loop L12 and helix α5) and neck linker differs 
greatly in molecule C.  
 
Comparing molecule C with molecule B and the native structure, I observe a 
clear progression of the switch II cluster as it rotates about 15° from the native 
structure to the intermediate state of molecule C and eventually to the final 
state in molecule B (Figure 3-12). In fact, this progression can be seen as two 
distinct movements: first an anti-clockwise rotation of approximately 10° about 
the origin around residue Leu293, then a similar rotation of approximately 5° 
about an origin beyond the apex of helix α4. On the other hand, the neck linker 
appears to be in the same conformation in native Eg5 and in the intermediate 
state (molecule C). It is in an undocked position, perpendicular to the helix α6. 
The neck-linker eventually moves by about 32 Å to adopt a docked position, 
parallel to helix α6 in the final state in molecule B (Figure 3-12).   
 
The occurrence of this intermediate state in molecule C, in particular the 
structural differences at the switch II cluster and the neck linker, is not caused 
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by crystal contacts with the symmetry-related molecule and is not a 
crystallographic artifact (Figure 3-13). The B-factors for the switch II cluster and 
neck linker region, though higher than the average B-factor of the entire 
molecule, are consistent throughout molecules A, B and C.  
 
 
Figure 3-12. Overlay of native, intermediate and final states of the switch II cluster and neck 
linker region.  
The switch II cluster (helix α4, loop L12 and helix α5) and the neck linker region, enlarged and 
shown as stereoplot insets, undergo conformational changes from native to intermediate (molecule 
C) to final inhibitor-bound state (molecule B). Helix α4 opens up space for the neck linker to dock. 
 
 
Figure 3-13. Closest crystal contacts to the neck linker of the intermediate state.  
The neck linker of the intermediate state (molecule C) is extended perpendicular to helix α6. This 
figure shows all the residues within a 20 Å radius of Pro363 of the neck-linker. Ala31 of the 
symmetry-related molecule is the closest residue to Pro363, with a distance of 12 Å between them. 
There are no residues close enough to form crystal contacts with the neck linker. 
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3.2.5 Isothermal Titration Calorimetry 
To obtain a thermodynamic analysis of STLC binding to Eg5, ITC binding studies 
were performed. The titration of Eg5 with ispinesib, a specific inhibitor 
currently in clinical trials, was used as a control and the values obtained were 
compared to those found in a similar study by Sheth et al.172. Representative 
calorimetric titrations of Eg5 with ispinesib and STLC, fitted to a standard single-
binding site model, are shown in Figures 3-14a and b respectively. The averaged 
and calculated thermodynamic parameters of Eg5-ligand binding are shown in 
Table 3-4.  
 
 
 
 
Figure 3-14. Representative calorimetric titrations of Eg5 with ispinesib and STLC.  
Upper panel shows the raw ITC data (exothermic heat exchange) of inhibitor binding to Eg5, while 
the bottom panel shows the normalised ITC data (after subtracting the heats of dilution) plotted 
against the molar ratio of ligand to protein, and fitted to a standard single-binding site model. 
Titration of (A) ispinesib and (B) STLC with Eg5.  
 
 
 
A B 
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Table 3-4. Thermodynamic parameters of ligand binding to Eg5. 
 
 Eg5-ispinesib Eg5-STLC 
 
Stoichiometry  
(no. of sites per mole of protein) 
 
1.05 ± 0.002 1.08 ± 0.002 
Ka (108 M-1) a 
 
5.58 ± 2.68 0.104 ± 0.006 
Kd (µM) 
 
0.002  0.096 
ΔH (kcal/mol) a 
 
-9.98 ± 0.05 -11.17 ± 0.04 
TΔS (kcal/mol) a 1.79 ± 0.70 
 
-1.59 ± 0.42 
a Values determined at 298.15 K, T = temperature in Kelvin.  
 
 
The binding stoichiometries of ispinesib and STLC to Eg5 were calculated to be 
1:1, which means that there is one ligand binding site per protein. From the 
binding curves (Figure 3-14), it can be seen that the data fits well to the 
standard single-binding site model. The association constant for the Eg5-
ispinesib complex is higher than that of the Eg5-STLC complex. Thus, the 
dissociation constant, which is inversely proportional to the association 
constant, is smaller for the Eg5-ispinesib complex than the Eg5-STLC complex. 
Both binding events of Eg5-ispinesib and Eg5-STLC are enthalpically favourable, 
as shown by the negative enthalpy change. On the other hand, the binding event 
of Eg5-ispinesib is entropically favourable, as shown by the positive entropy 
change, while that of Eg5-STLC is entropically unfavourable. 
 
3.3 Discussion 
3.3.1 Structure-activity relationship study of monastrol analogues 
Based on the in vitro microtubule-stimulated ATPase assays done by Gartner et 
al.82, enastron (IC50 = 2 µM) and dimethylenastron (IC50 = 200 nM) have been 
shown to be 15 and 150 times more potent than monastrol (IC50 = 30 µM ). By 
comparing the crystal structures of Eg5 in complex with each of the three 
inhibitors, we hope to understand how the structural differences of the three 
inhibitors could contribute to the varying levels of potency. Upon overlaying the 
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Eg5-enastron and Eg5-dimethylenastron structures with Eg5-monastrol91, no 
differences in the positions of the three inhibitors in the allosteric binding site 
were observed. The interactions between the inhibitors and the residues in the 
inhibitor-binding pocket are also virtually identical. The only striking difference 
is that enastron and dimethylenastron have the oxo-cyclohexene system, while 
monastrol has a C5-ester group.  
 
The crystal structure of the Eg5-monastrol complex91 shows that the ester group 
of monastrol extends out of the allosteric binding site into the solvent-exposed 
region, but does not completely fill the space in the solvent-exposed sub-pocket 
(Figure 3-15). In contrast, the oxo-cyclohexene group of enastron results in a 
better fit of the inhibitor in the solvent-exposed sub-pocket formed by Glu215, 
Tyr211 and Arg119. Therefore, we concur with Gartner et al.82 that the 
cyclisation of the side chain, resulting in a cyclic ketone, confers rigidity to the 
conformation of the inhibitor. The rigid conformation and the better fit of the 
inhibitor are the likely reasons for the 10 times increase in potency of enastron 
as compared to monastrol. In view of the small structural difference — namely 
the two methyl groups — between enastron and dimethylenastron, it seems 
surprising that the latter is about 10 times more active than enastron in vitro. 
The increase in potency would most likely be due to the C—H---π interaction 
that one of the methyl groups forms with Tyr211. In addition, the dimethyl group 
of dimethylenastron occupies the space of the solvent-exposed sub-pocket with 
a better fit to the allosteric binding site than enastron.  
 
 
 
Figure 3-15. Crystal structures reveal better fit of inhibitor as reason for increased potency.  
Crystal structures of (A) Eg5-monastrol (PDB ID: 1X88)91, (B) Eg5-enastron and (C) Eg5-
dimethylenastron. 
 
A B C 
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By comparing the crystal structure of Eg5-fluorastrol to that of a structurally 
similar inhibitor mon97138 (Figure 3-16), we can try to understand the reason 
behind the approximate five-fold increase in potency of fluorastrol as compared 
to mon97 in cell-based assays (Table 3-5). Upon overlaying the two structures, 
no differences in the positions of the main scaffold or interactions of the two 
inhibitors with the rest of the protein were observed. The only difference 
between the two inhibitors is the two fluorines that are attached to the phenyl 
ring in the meta- and para-positions. One of these fluorines plays an important 
role in forming multipolar interactions with the residues at the allosteric binding 
site, while the other fluorine points towards Phe239.  
 
Additionally, the aromatic ring stacks with the salt bridge formed by the side 
chain residues of Glu116 and Arg221. The two fluorine atoms and the carbonyl 
group withdraw electron density from the phenyl ring by inductive and 
mesomeric effects respectively. Thus, the fluorine atoms, bearing higher 
electron density, are closer to the positively-charged side chain of Arg221 and 
the electron-poor edge of Phe239, while the phenyl ring that has lower electron 
density is closer to the negatively-charged side chain of Glu116. This explains 
the overall improved affinity of this compound. In fact, there have been previous 
examples where the addition of fluorines to lead compounds has beneficial 
effects on the physico-chemical properties of the drug, and has strengthened the 
protein-ligand interactions. These major fluorinated drugs include Prozac, an 
antidepressant, and Lipitor, a cholesterol-lowering drug170.  
 
 
 
Figure 3-16. Crystal structures reveal addition of fluorine atoms as reason for increased 
potency.  
Crystal structures of (A) Eg5-mon97 (PDB ID: 2IEH)138 and (B) Eg5-fluorastrol. 
 
A B 
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Table 3-5. Growth inhibition assays of monastrol-like compounds conducted in different cell 
lines.  
 
EC50 [nM]
 a 
Compound HCT116 hTERT-HME1 BxPC3 K562 
rac-monastrol 24155 ± 2848 45082 ± 21354 > 100 µM > 100 µM 
rac-enastron 1811 ± 175 2443 ± 245 2072 ± 483 4775 ± 337 
rac-
dimethylenastron 330 ± 17 603 ± 44 743 ± 104 769 ± 71 
rac-fluorastrol 387 ± 22 247 ± 42 601 ± 105 1149 ± 46 
fluorastrol-E1 15171 ± 1582 > 100 µM 33651 ± 10182 26607 ± 1465 
fluorastrol-E2 327 ± 54 223 ± 48 736 ± 91 820 ± 20 
rac-mon97 1832 ± 182 1778 ± 140 5000 ± 671 5688 ± 648 
mon97-E1 6502 ± 487 > 50000 14421 ± 1753 11405 ± 671 
mon97-E2 1740 ± 111 1187 ± 87 3597 ± 193 3695 ± 507 
a Growth inhibition assays were carried out by Oliver Rath and published in Kaan et al., 2010, J. 
Med. Chem.173, using human colon (HCT116), lung (NCI-H1299), pancreas (BxPC3) and leukemia 
(K562) tumour cell lines. rac = racemic, E1 = enantiomer 1 and E2 = enantiomer 2. 
 
 
Besides providing structural evidence for the increased potency of inhibitors, the 
crystal structures also reveal the preferential binding modes of the inhibitors. 
For the improvement of small molecule inhibitors, it is essential to understand 
the stereoselectivity of the compound. By crystallising the racemic mixture of 
enastron and dimethylenastron with Eg5, it was found that the S-enantiomer of 
both inhibitors binds preferentially to Eg5 in the respective crystal structures. 
Therefore, we predict that the S-enantiomer of enastron and dimethylenastron, 
rather than the R-enantiomer, is the active agent. Consequently, they belong to 
class I of dihydropyrimidine (DHPM)-derived inhibitors that bind in the S 
configuration, similar to monastrol. 
 
Though all three small molecules, enastron, dimethylenastron, and fluorastrol, 
are DHPM inhibitors, they exhibit different stereoselectivity. While enastron and 
dimethylenastron bind preferentially to Eg5 in the S configuration, fluorastrol 
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binds preferentially in the R configuration as shown by the crystal structure. This 
unexpected configuration is backed by results of in vitro assays174 (Table 3-6), 
which show that the preferred binding mode (R-enantiomer) is the more active 
agent. Likewise, based on the structure of the Eg5-mon97 complex solved by 
Garcia-Saez et al.138,  the inhibitor mon97 was found to bind preferentially in 
the R configuration and hence belong to class II of DHPM inhibitors. Accordingly, 
fluorastrol is also a class II DHPM inhibitor.  
Table 3-6. Inhibition of basal ATPase activity of Eg5 by fluorastrol and mon97. 
 
Compound IC50 [nM]
 a 
rac-fluorastrol 393.8 ± 59.6 
S-fluorastrol 3457.4 ± 118.6 
R-fluorastrol 279.1 ± 59.7 
rac-mon97 466.5 ± 41.4 
S-mon97 952.6 ± 70.0 
R-mon97 334.8 ± 12.8 
a Values taken from Prokopcova et al., 2010, Chem. Med. Chem.174  
 
3.3.2 Structure-activity relationship study of STLC and its 
analogues 
Determination of the Eg5-STLC structure has revealed several important 
interactions between the cysteine moiety and Eg5 residues that contribute to 
the potency of STLC. The three phenyl rings of the inhibitor are buried in the 
mostly hydrophobic part of the inhibitor-binding pocket and form aromatic 
interactions with several Eg5 residues. To further improve the potency of STLC, 
our lab decided to synthesise STLC analogues bearing a para-substitution on one 
of its phenyl rings. As free rotation is possible around the C-S bond, the phenyl 
rings can interchange positions in the three sub-pockets of the inhibitor-binding 
site. Hence, it is difficult to determine where the para-substituted phenyl ring 
will be placed. Nevertheless, the new crystal structures of Eg5 in complex with 
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these STLC analogues will shed light on the position of the para-substituted 
phenyl ring. 
 
Ms. Katarzyna Tkocz, a six-month internship student under my supervision, 
solved the crystal structure of Eg5 in complex with an STLC analogue carrying a 
para-substituted chlorine on one of its phenyl rings (compound 10). The 
structure is published in Kaan et al., 2011, J. Med. Chem.175. The well-defined 
electron density map revealed that the substituted phenyl ring is buried in the 
mainly hydrophobic pocket formed by Ile136, Pro137, Leu160, Leu214, Phe239 
and the salt bridge between Glu116 and Arg221 (Figure 3-17). Taken together 
with the structures of Eg5-STLC and Eg5-6, and the in vitro ATPase assay results 
(Table 3-7), one can begin to understand the factors affecting the potency of 
these small molecule inhibitors.  
 
 
Figure 3-17. Stereoplot of compound 10 in the inhibitor-binding pocket.  
Hydrogen bonds between inhibitor (pink) and Eg5 residues (beige) or structural water molecules 
(red spheres) are depicted by black broken lines. 
 
 
Table 3-7. Inhibition of microtubule-stimulated ATPase activity of Eg5 by STLC, compound 6 
and 10. 
 
Compound IC50 [nM]
 a 
STLC 284.9 ± 13.7 
Compound 6 548.9 ± 130.0 
Compound 10 53.3 ± 1.5 
a Values taken from Kaan et al., 2011, J. Med. Chem.175. 
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Compound 6, which has a phenyl ring replaced by a —CH(Me)Et alkyl chain, has a 
slight decrease in potency compared to STLC. The substitution of the phenyl ring 
by the alkyl chain results in the loss of an offset stacked π-π interaction 
between the phenyl group and Tyr211. This could be the main reason for the 
slight decrease in potency; thus, substitution of an entire phenyl ring by an alkyl 
chain is unlikely to improve the potency of an inhibitor. Hence, para-substitution 
on the phenyl ring was considered. From the data above, it can seen that a small 
lipophilic para-substitution on one of the phenyl rings can increase the potency 
of STLC by approximately five times. This is further substantiated by the SAR 
study described in Kaan et al.175, which showed that when one phenyl ring 
carries a small lipophilic para-substituent, such as iodine, bromine, methyl or 
ethyl, the potency of the small molecule is greatly improved. The crystal 
structure also reveals that the small lipophilic group sits in the complementary 
hydrophobic environment (P3 sub-pocket, Figure 3-18), which could be a factor 
resulting in improved potency. 
 
With the knowledge gained from this SAR study, the next step was to synthesise 
STLC analogues with meta-substituents on one or more of its phenyl rings to 
confirm the trend that a small lipophilic substituent on a phenyl ring can 
improve the potency of the inhibitor. In addition, we decided to probe the 
importance of the sulphur atom and the carboxylic group in relation to the 
potency of the small molecule. Thus, in this second SAR study, we discuss the 
crystal structures together with the in vitro ATPase assay results and the 
multidrug resistance (MDR) ratio (Table 3-8) for compounds 7 to 9.  
 
 
 
Figure 3-18. Surface diagram showing the three sub-pockets in the inhibitor-binding pocket.  
Compound 10 is shown in the pocket with the para-substituted phenyl ring in the P3 sub-pocket.  
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Table 3-8. Compounds tested in basal ATPase assay and growth inhibition assay. 
 
Compound Kiapp [nM]
 a EC50 [nM]
 b MDR ratio c 
STLC 185.9 ± 20.5 1452 ± 76 42 
Compound 7 12.2 ± 3.8 73 ± 3 83 
Compound 8 185.8 ± 30.4 706 ± 47 nt 
Compound 9 16.0 ± 3.5 260 ± 19 9.1 
Ispinesib nt nt 9.6 
a Unpublished Kiapp values for the inhibition of basal Eg5 ATPase activity.  
b Unpublished EC50 values for the growth inhibition of K562 human leukemia tumour cell line.  
c Unpublished MDR ratios (EC50 value obtained with KB-V1 cells overexpressing P-glycoprotein 
divided by EC50 obtained with isogenic parental KB-3-1 cell line). nt = not tested. 
 
 
Compound 7, which is approximately 15 times more potent than STLC, has a 
meta-substituted methyl group on one of its phenyl rings and its sulphur atom 
has been replaced by a carbon. The crystal structure reveals that the methyl 
group sits in the same pocket as the chlorine substituent of compound 10. This is 
in agreement with the trend that a small lipophilic substituent would fit into the 
complementary hydrophobic sub-pocket (P3) and improve the potency of the 
inhibitor. As the sulphur atom has not been shown to make any important 
interactions with the residues of the inhibitor-binding pocket, the substitution of 
sulphur with carbon does not appear to decrease its potency. In fact, the carbon 
analogue could be a better alternative as the sulphur has been shown to be a 
site for metabolism by the enzyme phenylalanine monoxygenase found in the 
human body176. Hence, the carbon analogue, which is less susceptible to acid 
hydrolysis and S-oxidation, may prove to be a more stable chemotherapeutic 
agent.  
 
Nevertheless, compound 7 has a high MDR ratio of 83 compared to that of 
ispinesib, an Eg5 specific inhibitor in clinical trials; thus making it less than ideal 
for drug development in cancer therapy. It has long been known that tumours 
and tumour cell lines may develop drug resistance, de novo or acquired, against 
current microtubule-targeting drugs through a variety of putative mechanisms, 
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including the expression of point mutations in tubulins, overexpression of certain 
tubulin isoforms that are able to evade drug treatment, or multidrug 
resistance77-79. The best-known and probably the most important transporter for 
MDR is P-glycoprotein (Pgp, encoded by ABCB1), an efflux pump present in many 
tissues and tumours that has a very broad substrate specificity and is capable of 
eliminating xenobiotics, such as taxanes and vinca alkaloids from the cell177. To 
fight these liabilities associated with current treatments, efforts are underway 
to develop improved drugs with reduced susceptibility to MDR.  
 
As the results show, compound 9 has a low MDR ratio, which is comparable to 
ispinesib. The low MDR ratio is attributed to the loss of the carboxylate group 
from the cysteine moiety and is backed up by more unpublished cell-based assay 
results of STLC analogues without the carboxylate group. However, the loss of 
the carboxylic acid, as shown by the crystal structures of 8 and 9, results in the 
loss of a hydrogen bond with the Eg5 residue Arg221 and several hydrogen bonds 
with structural waters that act to stabilise and maintain rigidity of the amine 
tail. Due to the loss of the carboxylic acid, compound 8 though carrying a meta-
substituted acetate group is about 15 times less potent than 7. Nevertheless, the 
potency of compound 8 is comparable to STLC, thus demonstrating that the 
decrease in potency due to the loss of the carboxylate group may be 
compensated by the new hydrogen bond interaction between the acetate group 
and Arg221. 
 
Lastly, arriving at compound 9, we observe that meta-substitutions on two 
phenyl rings could greatly improve potency, while keeping the MDR ratio low by 
removing the carboxylate group. From the crystal structure, it can be seen that 
the lipophilic substituent (ethyl group) is positioned in the predicted P3 sub-
pocket. The unexpected finding is the position of the second meta-substituent 
(hydroxyl group). It sits in the P2 sub-pocket, which is in the core of the protein, 
instead of the P1 sub-pocket that is solvent exposed. However, by placing the 
crystal structure of Eg5-9 alongside Eg5-monastrol, one can see that the 3-
hydroxyphenyl group that is common to both inhibitors and to other monastrol 
analogues, sits in the same P2 sub-pocket (Figure 3-19). In this position, it forms 
a hydrogen bond with Ala133, stabilises the inhibitor in the allosteric site and 
increases the affinity of the ligand to the protein.  
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Figure 3-19. Comparison of Eg5-monastrol and Eg5-9 structures.  
Inhibitor-binding pocket of (A) Eg5-monastrol (PDB ID: 1X88)91 and (B) Eg5-9 complex. The 3-
hydroxyphenyl group, common to both inhibitors, sits in the P2 sub-pocket in the core of the 
protein.  
 
 
3.3.3 Pathway of structural change upon inhibitor binding 
Although several crystal structures of Eg5 in complex with inhibitors have been 
deposited in the Protein Data Bank, all of them exhibit the same conformation 
and structural changes representative of the final state of the inhibitor-bound 
Eg5. As the crystal structures are static images, it remains unclear how these 
structural changes come about and what the sequence of events leading to the 
final inhibitor-bound state may be. Kinetic studies by Maliga et al.92 propose a 
model in which, following monastrol binding to the Eg5 motor domain, the 
downward swing of loop L5 occurs first, followed by conformational changes in 
the switch II cluster, which allows the neck linker to dock.  
 
In this chapter, we report the crystal structure of an unprecedented 
intermediate state (molecule C) of the Eg5-STLC complex. By comparing the 
structure of native Eg5 with molecules C and B of the Eg5-STLC complex, we can 
dissect the pathway of structural changes that occur upon inhibitor binding. 
Hereafter, the structures of molecules A and B, which have similar 
conformations, will be referred to as the final inhibitor-bound state, while the 
structure of molecule C will be referred to as the intermediate state.  
 
 
 
A B 
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From the crystal structures, it can be seen that upon inhibitor binding, local 
changes in the inhibitor-binding pocket and at the switch I region have taken 
place in the intermediate and final states. However, in the intermediate state, 
the switch II region has not reached the conformation observed in the final 
state, and the neck linker remains undocked. The conformational changes 
observed in the intermediate state of the Eg5-STLC structure is consistent with 
that expected after initial inhibitor binding — significant local changes at the 
inhibitor-binding pocket — but before the docking of the neck linker.  
 
Significantly, the changes in the intermediate state are moving in the direction 
of the final state. Complete conversion only occurs in the final inhibitor-bound 
state, where the neck linker becomes docked. Therefore, we propose that the 
binding of STLC to Eg5 causes drug-induced structural transition in 3 steps: first, 
loop L5 swings downwards to close the inhibitor-binding pocket, which then 
translates to an upward shift of the switch II cluster toward the N-terminal of 
helix α4, and finally the neck linker docks onto the motor domain (Figure 3-20).  
 
 
 
 
 
 
Figure 3-20. Schematic diagram of the proposed pathway of structural changes upon 
inhibitor binding.  
From native to intermediate to final inhibitor-bound state. Green: Eg5, red: inhibitor, blue: loop L5, 
yellow: switch II cluster and magenta: neck linker. 
 
 
 
Native           Intermediate                      Final 
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3.3.4 Biophysical characterisation of Eg5-inhibitor complexes 
ITC binding study was performed to obtain a thermodynamic analysis of STLC 
binding to Eg5. A control experiment was also carried out for the binding of 
ispinesib to Eg5 at 25°C and the results obtained were compared to that of a 
similar study conducted by Sheth et al.172 at 20°C. The binding stoichiometry of 
ispinesib to Eg5 obtained from our study is 1.05 ± 0.002, which is in close 
agreement with the value obtained from their study (0.85 ± 0.2). Our study 
revealed a dissociation constant of 0.002 µM, which also agrees with their result 
of < 0.01 µM. As ispinesib is a very potent inhibitor, the association constant is 
large and only one data point is observed at the slope of the titration curve 
before the system becomes saturated. Hence, the Ka and Kd cannot be 
accurately determined, but are considered estimates. 
 
While our study showed an enthalpy change of -9.98 ± 0.05 kcal/mol, theirs 
showed an enthalpy change of -6.1 ± 0.2 kcal/mol. Lastly, our study revealed an 
entropy change of 1.79 ± 0.70 kcal/mol, while theirs revealed an entropy change 
of 5.2 kcal/mol. The slight difference in values obtained could be attributed to 
the fact that both experiments were conducted at difference temperatures. 
Nevertheless, both studies showed a negative enthalpy change and a positive 
entropy change; thus confirming that the binding event of ispinesib to Eg5 is 
enthalpically and entropically favourable.  
 
Having confirmed that the results obtained from our control experiment is 
reliable and in accordance with a similar study, I went on to analyse the binding 
event of STLC to Eg5. The calculated binding stoichiometry (1:1) is in full 
agreement with the crystal structure of the Eg5-STLC complex, which shows one 
inhibitor binding site per protein molecule. By fitting the data to a standard 
single-binding model, I obtained a dissociation constant of 0.096 µM, which is 
approximately 50 times larger than that for Eg5-ispinesib. This alludes to the 
fact that the binding of ispinesib to Eg5 is much tighter than that of Eg5-STLC. 
 
Under my supervision, Ms. Katarzyna Tkocz also solved the crystal structure of 
Eg5 in complex with ispinesib (unpublished data). The four aromatic rings of 
ispinesib are buried in the allosteric site and display several hydrophobic 
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interactions with residues of the inhibitor binding pocket (Figure 3-21). The 
coupled rings (quinazoline ring) of ispinesib are stabilised on one side by a salt 
bridge formed between side chains of Glu116 and Arg221 and on the other side 
by C—H---π interaction with Leu214. The phenyl ring that is linked to the 
quinazoline ring stacks on the Pro137 ring, and is also involved in edge-to-face 
(T-shape) interaction with the phenyl ring of Trp127. The isopropyl group of 
ispinesib forms C—H---π interaction with the phenyl ring of Tyr211. Hydrogen 
bonds are also observed between the nitrogen (NAD) of ispinesib and the side-
chain oxygen (OE1) of Glu116 and between the oxygen (DAE) of the inhibitor and 
a structural water molecule. 
 
Comparing the structures of Eg5-ispinesib and Eg5-STLC, we see many similar 
hydrophobic and hydrogen bond interactions between both ligands and the 
protein. The only outstanding interaction is the stacking of the quinazoline ring 
with the salt bridge in the Eg5-ispinesib complex, which is not present in the 
Eg5-STLC complex. This interaction could be one of the reasons for the strong 
binding affinity of ispinesib to Eg5. Though we did not quantify the affinity of 
the bonds between the ligands and protein, nor did we measure the 
contributions of individual interactions to the changes in enthalpy and entropy 
for both Eg5-ispinesib and Eg5-STLC complexes, the thermodynamic parameters 
obtained from ITC give us information, in addition to the crystal structure, for 
gaining a better understanding of the binding event of ligand to protein.  
 
Despite the big difference in binding affinities, the change in enthalpy for both 
binding events are negative, favourable and relatively similar. This shows that 
both reactions are exothermic and spontaneous. On the other hand, the entropy 
change for both events are opposite, with the change in entropy of Eg5-ispinesib 
being positive and favourable, while that of Eg5-STLC is negative and 
unfavourable. Nevetheless, the values are small with both being less than 2 
kcal/mol. In short, the binding of ispinesib to Eg5 is tighter, more favourable 
and more spontaneous than that of STLC to Eg5. Hence, this could explain why 
ispinesib is approximately 20 times more potent than STLC in cell-based assays 
performed in various cell lines (Table 3-9).  
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Figure 3-21. Stereoplot of ispinesib in the inhibitor-binding pocket.  
Hydrogen bonds between inhibitor (green) and Eg5 residues (beige) or structural water molecules 
(red spheres) are depicted by black broken lines. Blue broken lines depict the salt bridge formed 
between Glu116 and Arg221. 
 
 
Table 3-9. Growth inhibition assays of ispinesib and STLC conducted in different cell lines.  
 
EC50 [nM]
 a 
Compound HCT116 NCI-H1299 BxPC3 K562 
Ispinesib 25 ± 3 82 ± 10 80 ± 15 71 ± 8 
STLC 553 ± 57 1549 ± 111 1563 ± 155 1452 ± 76 
a Unpublished results from growth inhibition assays carried out by Oliver Rath, using human colon 
(HCT116), lung (NCI-H1299), pancreas (BxPC3) and leukemia (K562) tumour cell lines.  
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4 Mitotic kinesin Eg5 stalk364-520 domain facilitates 
dimerisation 
4.1 Aims and objectives 
Eg5 consists of a 457-residue stalk domain in the middle of the protein that 
connects the motor to the tail domain. Unlike the motor domain, there is little 
information about and no crystal structures available for the stalk domain. Using 
a coil prediction program and based on the heptad repeats in its sequence, the 
stalk domain is predicted to form an interrupted coiled-coil structure. This 
special quaternary structure could help to explain the stalk domains involvement 
in the function of Eg5. Firstly, it is believed to facilitate oligomerisation of the 
Eg5 molecule into a bipolar tetramer, so that it can bind anti-parallel 
microtubules and slide them apart. Secondly, it may be involved in coordinating 
the ‘hand-over-hand’ motility of the molecular motor along microtubule tracks.  
In this chapter, I will report the characterisation of the first 157 residues of the 
stalk domain, hereafter called the stalk364-520 domain. Using analytical 
ultracentrifugation, I will determine the oligomerisation state and sedimentation 
coefficient of this region of the stalk domain. Then, I will present results 
obtained from a circular dichroism facility that reveal the percentage of helical 
content in the stalk364-520 domain. Finally, I will describe the molecular envelope 
of the low resolution structure of stalk364-520, determined by small angle X-ray 
scattering. Taken together, these results provide us with a glimpse into the 
structural characteristics of the Eg5 stalk364-520 domain. 
 
 
4.2 Results 
4.2.1 Analytical Ultracentrifugation (AUC) 
To start with, sedimentation velocity (SV) experiment was carried out to 
investigate if there is concentration-dependent oligomerisation behaviour and to 
Chapter 4  101 
 
determine the sedimentation coefficient of the stalk364-520 domain. Seven 
different concentrations of the stalk364-520 domain were used for the experiment, 
which utilised both interference and absorbance optics. The resulting 
sedimentation profiles and data were fitted to a continuous c(s) distribution 
model using SEDFIT159. Individual size distribution c(s) profiles from the SV 
experiment using the interference optics are shown for all concentrations of 
samples in Figures 4-1a to g. Results from the SV experiment utilising the 
absorbance optics are not shown as the absorbance of the 20 mg/ml high 
concentration sample was beyond the linear range. 
 
 
 
 
 
A 
B 
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Figure 4-1. Individual size distribution c(s) profiles of samples analysed by SV experiment.  
Size distribution profiles of Eg5 stalk364-520 domain at concentrations of (A) 0.2, (B) 0.3, (C) 0.5, (D) 
1.0, (E) 2.0, (F) 10 and (G) 20 mg/ml from the SV experiment utilising the interference optics.   
 
 
From the size distribution profiles of the seven samples, one significant peak is 
observed for all concentrations. This peak corresponds to a sedimentation 
coefficient of about 1.2 S for samples with concentrations equal to or lower than 
2.0 mg/ml. It then gradually shifts to a sedimentation coefficient of slightly less 
than 1.0 S for samples with concentrations equal to or higher than 10 mg/ml. 
Comparison and overlaying of the size distribution c(s) profiles shown below 
illustrates the gradual shift of the peak from about 1.2 to below 1.0 S (Figure 4-
F 
G 
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2). In addition, a second smaller peak is observed for sample concentration of 
0.3 mg/ml. This peak has a sedimentation coefficient slightly above 1.5 S. There 
is also a buffer peak at about 0.0 S for several sample concentrations. 
 
From the c(s) profiles, the apparent sedimentation coefficient at 4°C in buffer 
(s4,b) of the single species at different concentrations were extracted and listed 
in Table 4-1. The corresponding true sedimentation coefficient at 20°C in water 
(s20,w) was calculated using equation 2 in section 2.2.3, to correct for the solvent 
viscosity and density. These values are also listed in Table 4-1. Subsequently, 
the s20,w values were plotted against the concentration of Eg5 stalk364-520 domain 
and a linear regression was fitted to the data points (Figure 4-3). The y-intercept 
provides the value for the true sedimentation coefficient that is independent of 
concentration (s°20,w). Based on the good fit of the linear regression to the data 
points, s°20,w of Eg5 stalk364-520 domain is 1.76 S.  
 
 
 
Figure 4-2. Normalised comparison of size distribution profiles.  
Overlay of the normalised size distribution c(s) profiles of the seven samples of different 
concentrations obtained from the SV experiment utilising the interference optics. Gradual shifting of 
the peak from a sedimentation coefficient of approximately 1.2 to less than 1.0 S is observed with 
increasing concentrations of Eg5 stalk364-520 domain.   
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Table 4-1. Apparent and true sedimentation coefficients for Eg5 stalk364-520 domain. 
 
Protein concentration (mg/ml) s4,b s20,w 
0.2 1.11 1.70 
0.3 1.17 1.79 
0.5 1.17 1.79 
1 1.13 1.72 
2 1.11 1.69 
10 0.87 1.33 
20 0.68 1.04 
 
 
 
Figure 4-3. Plot of true sedimentation coefficient against concentration of Eg5 stalk364-520 
domain.  
The calculated values of s20,w are plotted against the concentration of Eg5 stalk364-520 domain. The 
y-intercept of the curve gives the true sedimentation coefficient that is independent of 
concentration. R2 = goodness of fit, the closer the value is to 1, the better the linear regression fits 
the data. 
 
 
A sedimentation equilibrium (SE) experiment utilising the interference optics 
was carried out for the seven samples, at two rotor speeds (20000 and 30000 
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rpm), to determine the apparent weight average molecular weight (Mw,app) of 
the single species observed in the SV experiment. The data quality and results 
were analysed using SEDPHAT160. All the data sets were individually fitted with 
the species analysis model under the assumption that the protein is dimeric and 
has an approximate dimeric mass of 36325 Da. Overall, the fit of most data to 
the model were good, as evident from the almost perfect superimposition of the 
data and model, low r.m.s.d. values and small residuals that are well-dispersed 
(Figure 4-4).  
 
The Mw,app and r.m.s.d. value for each protein sample is presented in Table 4-2. 
Subsequently, the Mw,app values were plotted against the concentration of Eg5 
stalk364-520 domain (Figure 4-5). The distribution of points on the plot reveal a 
trend in which the Mw,app value decreases with increasing concentration, for both 
rotor speeds. Hence, the Mw,app is close to the molecular weight of dimeric Eg5 
stalk364-520 domain at low concentrations, near 0 mg/ml. Finally, the data sets 
for the SE experiment at each rotor speed were globally fitted to the above-
mentioned model to obtain the global Mw,app (Table 4-3). However, the global fit 
of the data to the model was not as good as the individual fits. Hence, data sets 
that have relatively higher r.m.s.d. values (10 and 20 mg/ml) were excluded 
from the subsequent global fit of the data sets at 30000 rpm. As a result, the 
overall Mw,app of the Eg5 stalk364-520 domain is 37826 Da. 
 
 
Figure 4-4. Representative SE profile fitted almost perfectly to the model.  
Good fit of the data to the model is evident from the almost perfect superimposition of the data and 
model, small residuals that are well-dispersed and a low r.m.s.d. value of 0.028. 
Residuals 
Fringes 
Radius (cm) 
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Table 4-2. Mw,app and r.m.s.d. of all samples determined by SE experiments at 20000 and 
30000 rpm. 
 
Rotor speed 
(rpm) 
Protein conc. 
(mg/ml) Mw,app (Da) 
r.m.s.d. 
(fringes) 
20000 0.2 37617 0.01 
 0.3 34679 0.11 
 0.5 35877 0.03 
 1 34292 0.20 
 2 31068 0.45 
 10 22366 0.74 
 20 23987 0.67 
30000 0.2 40744 0.04 
 0.3 39398 0.02 
 0.5 38679 0.03 
 1 38830 0.04 
 2 37116 0.09 
 10 27340 0.24 
 20 21349 0.40 
 
 
 
Figure 4-5. Plot of Mw,app against concentration of Eg5 stalk364-520 domain.  
Data sets from both the 20000 (diamond) and 30000 (triangle) rpm runs show the same trend of 
decreasing Mw,app with increasing concentrations of protein. 
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Table 4-3. Global Mw,app obtained from global fitting of data sets to model. 
 
Rotor speed (rpm) Global Mw,app (Da) 
20000 26295 
30000 28413 
30000 
(excluding 10 & 20 mg/ml data) 37826 
 
4.2.2 Circular Dichroism (CD) 
CD experiment was carried out to determine the secondary structure content of 
the Eg5 stalk364-520 domain in 20 mM potassium dihydrogen phosphate (buffered 
at pH 7.0). The CD spectra obtained in the far UV region (260 – 180 nm) relates 
to secondary structure elements present in the sample. A maximum is observed 
at about 190 nm and a double minimum is observed at 208 and 222 nm (Figure 4-
6). The ratio of molar ellipticity (Θ) at 222 to 208 nm is calculated to be 0.95. 
The data was then submitted to DichroWeb161, an online server, for secondary 
structure analysis using the CONTINLL algorithm162. The results, presented in 
Table 4-4, show that the Eg5 stalk364-520 domain contains approximately 52 % of 
helices and 5 % of strands.  
 
Figure 4-6. Far UV spectrum of Eg5 stalk364-520 domain.  
A maximum is observed at about 190 nm and a double minimum is observed at 208 and 222 nm. 
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Table 4-4. Estimates of secondary structure elements in Eg5 stalk364-520 domain. 
 
Protein Helix (%) Strand (%) Turns (%) Unordered (%) Total (%) 
Eg5 stalk364-520 
domain 52.2 5.2 15.3 27.3 100.0 
 
 
4.2.3 Small Angle X-ray Scattering (SAXS) 
In order to gain insight into the molecular shape of the Eg5 stalk364-520 domain, 
SAXS was carried out on six different concentrations of the protein (19.97, 9.86, 
2.14, 0.98, 0.49, 0.29 mg/ml), in 50 mM PIPES pH 6.8, 150 mM NaCl and 1 mM 
TCEP buffer. The data quality was examined using PRIMUS163 and the data sets 
from samples with concentrations of 0.49 and 0.29 mg/ml were excluded due to 
aggregation and poor signal-to-noise ratio respectively. A representative 
scattering curve of one of the samples is shown in Figure 4-7. Based on the 
Guinier plot, the values of Rg and I(0) were extracted and listed in Table 4-5. 
These values are relatively close for all four samples of different concentrations, 
with the average Rg and I(0) being 4.95 and 42.49 respectively. The errors are 
generally small, but increases with decreasing concentration of sample.  
 
 
 
Figure 4-7. Representative scattering profile of Eg5 stalk364-520 domain obtained from SAXS.  
Scattering curve (intensity versus scattering angle) of 19.97 mg/ml of Eg5 stalk364-520 domain 
reveals no aggregation and good signal-to-noise ratio. 
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Table 4-5. Rg and I(0) obtained from the Guinier and p(r) plots, and Dmax for four 
concentrations of Eg5 stalk364-520 domain. 
 
Guinier plot p(r) plot Conc. 
(mg/ml) Rg (nm) I(0)  Rg (nm) I(0) 
Dmax (nm) 
19.97 5.31 ± 0.03 48.03 ± 0.19 5.64 49.05 19 
9.86 5.13 ± 0.03 44.34 ± 0.23 5.74 46.69 20.5 
2.14 4.67 ± 0.07 42.13 ± 0.50 5.31 44.72 19 
0.98 4.67 ± 0.20 35.45 ± 1.17 5.32 37.04 18.5 
Average 4.95 42.49 5.50 44.38 19.3 
 
 
Next, the p(r) plots were generated using GNOM165 and the Dmax values of the 
protein samples were determined (Table 4-5). A representative p(r) plot is 
shown in Figure 4-8. The peak position is located at approximately 2.5 nm for all 
samples and the shape of the p(r) plot, which shows a roughly linear decrease 
with increasing r, is indicative of an elongated rod-shaped protein178. The Dmax 
values generally agree for all four concentrations and the average is 19.3 nm. 
From the p(r) analysis, the Rg and I(0) values obtained were similar for all 
concentrations and the average Rg and I(0) are 5.50 and 44.38 respectively. The 
Rg and I(0) values obtained from the Guinier plot are consistently smaller than 
those from the p(r) function, but the differences are relatively small.  
 
The molecular envelope of Eg5 stalk364-520 domain was then generated by ab 
initio modelling from the scattering profile using GASBOR166 in reciprocal space 
and incorporating P2 symmetry, as the protein has been shown to exist 
predominantly as a single dimeric species by AUC. Twenty independent 
simulations of each protein sample produced molecular envelopes of largely 
reproducible shape. Thus, DAMAVER167 was utilised to obtain an average and 
filtered model. The results revealed an elongated rod-shaped molecular 
envelope that is approximately 165 Å long and 18 Å wide (Figure 4-9). However, 
it is not a straight rod-shaped molecular envelope, but one that has several kinks 
along its length. 
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Figure 4-8. Representative p(r) plot of Eg5 stalk364-520 domain (9.86 mg/ml).  
The peak location is ~2.5 nm and the shape of the curve is indicative of a rod-shaped molecule. 
 
 
 
 
Figure 4-9. Elongated rod-shaped molecular envelope of Eg5 stalk364-520 domain.  
An averaged and filtered model of the Eg5 stalk364-520 domain reveals a molecular envelope that is 
approximately 165 Å long and 18 Å wide, with several kinks along its length. 
 
4.3 Discussion 
4.3.1 Sedimentation coefficient of Eg5 stalk364-520 domain 
The SV experiments were performed for seven different concentrations of Eg5 
stalk364-520 domain, using both the interference and absorbance optics. The 
165 Å 
18 Å 
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individual data sets were fitted to the continuous c(s) distribution model. Going 
through all the size distribution c(s) profiles individually, several conclusions 
that are consistent for all concentrations and optical systems can be made. 
Firstly, only one significant peak is observed; thus, revealing that Eg5 stalk364-520 
domain exists predominantly as one species, instead of an equilibrium of several 
species, at all concentrations. Although the c(s) profile of the 0.3 mg/ml sample 
revealed a second smaller peak, the anomaly could be attributed to a 
contaminant or lysed sample. Based on this first conclusion, we can also confirm 
that there is no concentration-dependent oligomerisation effect, as the protein 
exists as one species at both low and high concentrations. 
 
Secondly, the position of the single significant peak is fairly consistent and shifts 
gradually, from 1.2 S at low concentrations to less than 1.0 S at high 
concentrations. The gradual migration of the peak, which is illustrated in Figure 
4-2, is most likely due to the effects of non-ideal behaviour of the protein. This 
occurs when the overcrowding of protein molecules at higher concentrations 
prevents proper packing of the molecules at the base of the cell. The proposed 
rod-shaped structure of the protein could further exacerbate the effects of non-
ideal behaviour of the protein, which may not be as obvious in globular 
structures. Finally, by plotting the true sedimentation coefficient against the 
concentration of the protein and fitting a linear regression through the data, the 
s°20,w of Eg5 stalk364-520 domain is revealed to be 1.76 S. Since the goodness of fit 
is 0.98, this value is highly reliable. 
 
4.3.2 Oligomerisation state of Eg5 stalk364-520 domain 
As the stalk364-520 domain is expected to be an elongated coiled-coil structure, 
the use of analytical gel filtration would not be ideal for determining the 
molecular mass and oligomerisation state of the non-globular polypeptide. 
Hence, SE experiment was carried out on seven different concentrations of Eg5 
stalk364-520 domain, at two rotor speeds (20000 and 30000 rpm) using the 
interference optics. Based on the results obtained from the SV experiments, I 
tried to fit the SE data sets individually to the species analysis model, with the 
assumption that the Eg5 stalk364-520 domain exists as a single dimeric species with 
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a calculated molecular mass of 36325 Da. Going through all the individually 
fitted data sets, a good fit of the data to the model is observed for the majority 
of data sets.  
 
The resulting Mw,app for each sample of different concentration consistently 
follows a trend: the mass decreases with increasing concentration of protein. 
This is most likely a consequence of concentration- and shape-dependent non-
ideal behaviour of the protein, as seen in the SV experiments. The failure of the 
protein molecules to pack properly prevents the formation of steep 
concentration gradients in the cell. In addition, the Mw,app values obtained from 
the SE experiment conducted at 20000 rpm is generally lower than that of the 
30000 rpm run. This could be because the protein molecules have not reached a 
full equilibrium, that is the formation of a steep concentration gradient in the 
cell, at the lower speed of 20000 rpm.  
 
Nevertheless, all Mw,app values obtained are above the monomeric molecular 
mass of 18163 Da; thus, indicating that the protein does not exist as a single 
monomeric species. Further fitting of the data sets to the monomer-dimer, 
monomer-trimer and monomer-tetramer self-association models revealed poor 
fits, high r.m.s.d. values, and large residuals (results not shown). Together with 
the SV results that showed a single significant peak, we can confirm that Eg5 
stalk364-520 domain does not exist as an equilibrium of different oligomeric states. 
Finally, by performing a global fit of the model with data sets obtained at each 
rotor speed, a Mw,app value of approximately 27 kDa was obtained. This is roughly 
25 % less than the expected molecular weight of the dimeric species.  
 
Given that some data sets do not fit very well with the model, as evident by 
their relatively higher r.m.s.d. values, they were excluded from the subsequent 
global fitting of data to the model. Consequently, the Mw,app of Eg5 stalk364-520 
domain is approximately 37 kDa. This value is very close to the expected dimeric 
molecular mass of 36 kDa. The data sets that were excluded from this global 
fitting are mainly from samples of high protein concentrations, which are more 
prone to non-ideal behaviour. Hence, the low Mw,app value obtained from the 
global fitting of all data sets may be accounted for by the non-ideal behaviour of 
the protein. In short, the SE experiment reveals that the Eg5 stalk364-520 domain 
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most likely exists as a single dimeric species at both low and high 
concentrations. 
 
4.3.3 Secondary structure elements in Eg5 stalk364-520 domain 
Prior to CD analysis, the Eg5 stalk364-520 domain protein sample had to be dialysed 
in 20 mM potassium dihydrogen phosphate (pH 7.0). This is because both the 
buffers used in gel filtration and AUC contain chloride ions that absorb strongly 
in the far UV region, below 205 nm. The peak produced from the absorption of 
the buffer could overlap with the peak that relates to the secondary structure 
elements present; thus, interfering with analysis of the secondary structure 
composition of the Eg5 stalk364-520 domain.  The CD spectrum reveals a maximum 
at about 190 nm and a double minimum at 208 and 222 nm. In general, the 
shape of the CD spectrum is characteristic of α-helices.  
 
The ratio of Θ222/Θ208 is telling of the presence of coiled-coil helices in the 
protein sample. For non-coiled helices, the typical ratio is around 0.83 and this 
increases to about 1.03 for coiled-coils179. As the Θ222/Θ208 ratio calculated from 
the CD spectra is 0.95, the Eg5 stalk364-520 domain is neither fully coiled-coil nor 
entirely made up of non-coiled helices. While it tends to be closer to a coiled-
coil structure, it may still contain some non-coiled regions. This finding is 
supported by the estimated percentage of helices (52 %) and turns and 
unordered regions (total of 43 %) in the protein sample. This is in contrast to the 
human kinesin-1 construct (residues 771-963), which revealed a higher α-helical 
content (~70 %) in CD analysis180. Thus, the results from the CD analysis point 
towards an interrupted coiled-coil Eg5 stalk364-520 domain. 
 
4.3.4 Low resolution structure of Eg5 stalk364-520 domain in 
solution 
As attempts to crystallise the Eg5 stalk364-520 domain were unsuccessful, we 
turned to SAX to gain insights into the molecular shape of the protein in solution. 
The scattering profiles of the four samples of protein with different 
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concentrations (ranging from 1 to 20 mg/ml) are similar, which concurs with the 
conclusion from AUC that there is no concentration-dependent oligomerisation 
behaviour. The shape of the scattering curve hints at a rod-shaped molecule. 
Dmax value for all four concentrations is very close and is approximately 19.3 nm. 
The values of Rg and I(0) obtained through the Guinier and p(r) analyses, for all 
four concentrations, are also highly consistent, although the values obtained 
from the Guinier analysis are generally lower than that of the p(r) plot.  
 
For a protein that is predicted to be a coiled-coil structure, the values obtained 
using the p(r) plot is deemed more accurate than that obtained from the Guinier 
analysis181. This is because for an elongated rod-shaped protein, only a small 
angle region is applicable for the Guinier approximation; thus, resulting in less 
reliable values of Rg and I(0). On the other hand, the p(r) function, which is 
calculated from the overall scattering profile, is more tolerant to the limited 
small angle region; hence, the values obtained are deemed as reliable estimates 
of Rg and I(0). In short, the mean Rg and I(0) values for the Eg5 stalk364-520 
domain, obtained from the p(r) function, are 5.5 nm and 44.4 respectively. 
 
Individual ab initio modelling of the molecular envelope of Eg5 stalk364-520 
domain from the scattering profiles reveal a reproducible rod-like molecular 
envelope that is approximately 165 Å long and 18 Å wide. To validate this 
structure, we compare it with the Drosophila melanogaster homologue that has 
10 residues more than human Eg5. Electron micrographs of the rotary-shadowed 
fruit fly homologue revealed a bipolar kinesin that is ~956 Å in length57. The rod-
shaped structure connecting the motor domain to tail domain has a length of 
~613 Å. If the 157-residue Eg5 stalk364-520 domain is ~165 Å in length as shown by 
SAXS, the entire 457-residue stalk domain would be approximately 484 Å long. 
This value is less than the length of the stalk domain observed in the electron 
micrographs of the rotary-shadowed D. melanogaster homologue.  
 
However, it is important to note that the platinum coating of the rotary-
shadowed protein is generally 25 Å thick; thus, making it appear larger than it 
actually is. Hence, the length of the molecular envelope of the Eg5 stalk364-520 
domain determined by SAXS is probably not far from its actual length. The 
molecular envelope also appears to contain several kinks along its length. This 
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could indicate an interrupted coiled-coil structure, as supported by the Θ222/Θ208 
ratio and α-helical content from CD analysis. In short, we propose that the Eg5 
stalk364-520 domain facilitates dimerisation of the protein by forming an elongated 
coiled-coil structure that may be interrupted by kinks along its length (Figure 4-
10).  
 
 
Figure 4-10. Proposed model of dimeric Eg5 motor domains linked by the stalk domains.  
Two motor domains (cyan, PDB ID: 1X8891), spanning approximately 200 Å, are brought together 
by the dimerisation of the Eg5 stalk364-520 domains (green, bead model), which is ~165 Å in length. 
The rest of the stalk domain has been drawn with black lines to show the length of the entire stalk 
domain (~ 484 Å). The Eg5 tail domain, whose structure is not known, is not shown in the diagram. 
 
 
200 Å 
165 Å 
484 Å 
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5 Autoinhibitory mechanism of kinesin-1 
The results in this chapter have been published in a peer-reviewed journal: 
 
Kaan, H.Y., Hackney, D.D. & Kozielski, F. The structure of the kinesin-1 motor-
tail complex reveals the mechanism of autoinhibition. Science 333, 883-5 
(2011). (Appendix 4) 
 
5.1 Aims and objectives 
Kinesin-1 is a processive, plus-end directed motor that uses energy from ATP 
hydrolysis to carry out various functions, including cargo transport along axons, 
and transport of organelles along microtubules. It is widely accepted that 
dimeric kinesin-1 moves along microtubules in a ‘hand-over-hand’ manner. 
However, the exact details of its motility remain unclear. On the other hand, 
when kinesin-1 is not transporting cargo along the microtubule track, it has to be 
regulated to prevent squandering of ATP and overcrowding of the microtubule 
highway. The tail domain has been implicated in an autoinhibitory mechanism 
that keeps the kinesin in a compact, folded and inactive conformation in the 
absence of cargo. Several models of autoinhibition have been proposed, 
including steric and allosteric inhibition; however, there are no high resolution 
structures available to validate the proposed models. 
 
In this chapter, I will report the crystal structures of kinesin-1 motor domain 
dimer alone and in complex with the tail domain, to 2.7 Å and 2.2 Å 
respectively. The structure of the motor domain dimer serves as additional 
structural information for docking onto cryo-EM maps of microtubules decorated 
with kinesins and for modelling of kinesin-1 motility. It will also serve as a 
comparison for the dimer-tail structure, in order to tease out the conformational 
changes that occur when kinesin-1 is autoinhibited. The dimer-tail structure will 
be complemented with a peptide array assay to reveal important residues 
involved in the binding of the tail to the motor domain. Lastly, together with 
results from single turnover experiments conducted by our collaborator, we will 
propose a novel model for the autoinhibition mechanism of kinesin-1. 
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5.2 Results 
5.2.1 Structure of the kinesin-1 motor domain dimer 
The crystal structure of D. melanogaster kinesin-1 motor domain dimer was 
solved at a resolution of 2.7 Å. Data collection and refinement statistics are 
shown in Table 5-1. The final model comprises of residues Glu10 to Lys356 
(excluding residues 246 to 258) and Glu10 to Lys354 (excluding residues 244 to 
259) for molecules A and B respectively. The excluded region is loop L11, which 
is disordered and not modelled.  The asymmetric unit consists of a dimer, where 
the monomers are not related by crystallographic symmetry. Each monomer has 
one molecule of Mg2+ADP bound in the nucleotide-binding site.  
 
The motor domains of the dimer have the same fold as other kinesin-1 
homologues: eight major β-strands in the core, surrounded by three major α-
helices on each side. Overall, the two monomers are related by a non-
crystallographic two-fold symmetry (180°) and interact mainly at the coiled-coil 
domain via the neck linker (Figure 5-1). Four residues in the catalytic core are 
shown to contribute to the interfacial surface with the coiled-coil domain: 
Asn167 and Arg168 of molecule B and Lys166 of both molecules A and B. The two 
monomers of the kinesin-1 dimer overlay very well in the catalytic core up to 
the neck linker, but differ slightly in the position of the α-helix forming the 
coiled-coil domain (r.m.s.d. = 0.84).  
 
 
 
Figure 5-1. Crystal structure of kinesin-1 motor domain dimer. 
D. melanogaster kinesin motor domain dimer with Mg2+ADP (red, sticks) bound in the nucleotide-
binding pocket. Ser181 (yellow, spheres), will be modified to cysteine for cross-linking experiments, 
and catalytic core residues (green, spheres) interacting with the coiled-coil domain are shown. 
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Table 5-1. Data collection and refinement statistics for kinesin-1 motor domain dimer and 
dimer-tail complex. 
 
 Dimer Dimer-tail 
 
Unit cell dimensions 
a, b, c, β (Å, °) 
 
 
76.9, 89.2, 
138.4, 90.0 
 
113.8, 190.7, 
146.0, 90.0 
Space group 
 
P212121 C2221 
Beamline / Detector 
 
ID23-2 / Q315R PXI / Pilatus 6M 
Molecules per 
asymmetric unit 
 
2 4 
Resolution range (Å) 
 
30.0 - 2.7 30.0 - 2.2 
No. of unique reflections 
 
35890 80517 
Completeness (%) 
 
99.9 (100.0) b 99.9 (99.6) 
Multiplicity 
 
4.1 (4.1) 8.8 (8.3) 
Rsym (%) 
 
8.3 (39.5) 5.7 (36.6) 
I/σ(I) 
 
12.0 (3.6) 21.7 (5.5) 
Wilson B (Å2) 
 
55.87 
 
41.38 
 
Refinement statistics 
 
  
Rwork / Rfree (%) 
 
21.0 / 28.9 19.5 / 25.2 
Average B Factors   
     Protein 
 
41.3 43.1 
     Ligand and ions / 
     Water 
 
30.0 / 35.5 28.9 / 43.0 
No. of Mg2+ADP / Water 
 
2 / 181 4 / 656 
r.m.s.d. c in bond length 
(Å) 
 
0.012 0.012 
r.m.s.d. in bond 
angle (°) 
1.82 1.79 
a Values in parentheses pertain to the highest resolution shell.  
b r.m.s.d. is the root-mean-square deviation from ideal geometry. 
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5.2.2 Structure of the kinesin-1 motor domain dimer-tail complex 
We have solved the first crystal structure of a kinesin motor domain dimer in 
complex with the tail domain at a resolution of 2.2 Å (Figure 5-2a). Data 
collection and refinement statistics are shown in Table 5-1. The asymmetric unit 
comprises of four molecules of the kinesin-1 motor domain, with two molecules 
(chains C and D) forming a dimer via interactions of the coiled-coil domains and 
the other two molecules (chains A and B) forming dimers with their symmetry-
related molecules (A’ and B’ respectively). Each monomer has one molecule of 
Mg2+ADP bound in the nucleotide-binding site. The motor domains in the dimer-
tail complex share many similarities with that of the kinesin-1 dimer structure 
described above. First, they exhibit the same fold. Second, the catalytic core of 
the motor domains in the free dimer and dimer-tail complex overlay very well, 
only differing in the positions of the neck linker and α-helix forming the coiled-
coil domain (mean r.m.s.d. = 0.765) (Figure 5-2b). Third, the motor domain 
dimer of both structures exhibit a two-fold symmetry. 
 
The major difference between the dimer-tail complex and the dimer structure is 
the global conformation of the two monomers forming the dimer, due to the 
binding of the tail domain. Each motor domain dimer is complexed with a 
monomeric tail domain and the final model of the tail domain comprises of 
residues Gln939 to Ser948, with the rest of the tail domain being disordered and 
not modelled. The 10-residue tail peptide has an extended and linear 
conformation, which resembles a β-strand. Owing to its amino acid sequence, 
the peptide is almost symmetrical, in terms of side chain properties, about the 
Lys944 residue. This distinctive feature of the tail peptide allows it to bind in 
two directions between the motor domain dimer, which also exhibits a two-fold 
symmetry (Figure 5-2c and d). As such, we observe pseudosymmetry in the 
crystal structure and the tail domains binding to the AA’ and BB’ dimers lie on 
the two-fold symmetry axis. The tail peptide binds simultaneously to β4 of both 
motor domains in the dimer and the total buried surface area between the dimer 
and the tail domain is approximately 1000 Å2.  
 
The crystal structure of the motor domain dimer-tail complex has given us an 
insight into the dimer-tail interface. Taking a closer look at the dimer-tail 
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interface, hydrogen bond interactions between the main chain carbonyl and 
amino groups of the tail domain and the N-terminal of the β4 strand of each 
motor domain are observed (Figure 5-3). Consequently, the 10-residue tail 
peptide, with its extended and linear conformation, may be seen as an extension 
of the eight-stranded β-sheet of the monomeric motor domain. Besides the 
hydrogen bond interactions that are characteristic of a β-sheet, hydrophobic 
interactions between Ile942, Ile946 of the tail domain and Phe123, Ile126, and 
Phe135 of each motor domain are observed. In addition, a C—H--π interaction 
between the pyrrolidine ring of Pro945 and Phe179 is observed. Finally, the 
His136 side chains of each motor domain are in close proximity in the interface 
(~2.9 Å) (Figure 5-4). 
 
 
 
 
 
 
Figure 5-2. Overall structure of kinesin-1 motor domain dimer-tail complex.  
(A) D. melanogaster kinesin-1 motor domain dimer complexed with tail domain (yellow). Cyan 
sticks: Mg2+ADP; green spheres: Ser 181. (B) Overlay of a monomer of the dimer structure (blue) 
with that of the dimer-tail complex (magenta), revealing differing positions of the α-helix forming the 
coiled-coil domain. (C) Dimer-tail interface showing residues of motor domain (chain A: grey, B: 
beige), tail domain (yellow) and omit map (Fo-Fc) (contoured at σ=3.00). The tail domain binds in 
one direction with residue Gln939 on the left and Ser948 on the right, and fits well into the electron 
density. (D) The tail domain is seen binding in the opposite direction with Ser948 on the left and 
Gln939 on the right, but it still fits well into the electron density map. 
A B 
C D 
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Figure 5-3. Motor domain dimer-tail interface. 
The tail domain and its interactions with the motor domain shown as an enlarged inset. The motor 
domain dimer (grey, left) is viewed from the top of Figure 5-2a and downwards onto the start of the 
α-helix forming the coiled-coil domain. The hydrogen bond interactions (dotted lines, right), 
between the tail domain (green) and the N-terminal of the β4 strand of each motor domain, are 
characteristic of a β-sheet.     
 
 
 
 
 
Figure 5-4. Residues involved in the binding of the tail to the motor domains. 
Stereoplot showing C—H---π and hydrogen bond interactions (dotted lines) between the tail 
(green) and motor domains (chain A: grey, chain B: beige). His136 side chains of each motor 
domain are in close proximity in the interface (~2.9 Å). 
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5.2.3 Peptide array 
To determine which residues in the tail peptide are crucial for binding to the 
motor domain, I did a single alanine-scan peptide array study, where each 
residue of the tail peptide is mutated to an alanine in turn. The results revealed 
that when Lys944 and Arg947 are mutated to alanine, the binding of the tail to 
motor domains is abolished (Figure 5-5). Double and triple alanine-scan peptide 
array, where two and three residues of the tail peptide are mutated to alanines 
in turn respectively, were also used to confirm the results. All experiments 
performed in duplicates revealed the same result, which confirms undoubtedly 
that Lys944 and Arg947 are the two crucial residues that allow the tail to bind to 
the motor domains.  
 
 
 
Figure 5-5. Single, double and triple alanine-scan peptide arrays reveal crucial residues 
involved in dimer-tail binding.  
Single (left), double (middle) and triple (right) alanine-scan peptide arrays, with the native peptide 
sequence in black and mutated residues in red. 
 
5.3 Discussion 
5.3.1 Docking of kinesin-1 motor domain dimer on microtubules 
In order to study how kinesins move along microtubule tracks, several groups 
have produced cryo-EM maps and three-dimensional image reconstructions of 
microtubules decorated with kinesin monomers or dimers, with different 
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nucleotides bound, to create static images of kinesins frozen in each step of the 
processive motion127,128,182-184. Here, I overlay the monomers of the kinesin-1 
dimer structure with the human monomeric kinesin-1 structure docked into the 
highest resolution cryo-EM map obtained thus far (9 Å, PDB ID: 2P4N)184. The 
least squares fit (LSQ) superpose method was used to overlay helix α4 of each 
monomer of the dimer structure with that of the human monomeric kinesin-1 
structure, because this motif is conserved and forms the main interactions with 
the tubulin heterodimer185. For both overlays, the second unattached motor 
domain points toward the direction of movement (plus end); however, helix α2 
of the second motor domain inadvertently clashes with α-tubulin (Figure 5-6), 
indicating that the dimer structure is not compatible with its binding to 
microtubules in this conformation.  
 
Nevertheless, the unsuccessful docking of the kinesin-1 dimer structure onto 
microtubules should not come as a surprise. This is because the cryo-EM map 
shows microtubules decorated with kinesin monomers; thus it may not reflect 
the exact conformation of the kinesin dimer bound to microtubules. Moreover, if 
the asymmetric ‘hand-over-hand’ model holds true for kinesin motility, the 
conformation of each motor at the end of a step would be different from the 
conformation at the beginning of the step. Since the cryo-EM map only shows 
one conformation of the bound kinesin monomer, we are missing crucial details 
of the other conformation, which may be applicable for the docking of the 
kinesin-1 dimer structure onto the cryo-EM map.  
 
Lastly, the crystal structure with Mg2+ADP bound in both motor domains does not 
reflect the alternating head catalysis model of microtubule-stimulated ATP 
hydrolysis186, whereby each motor domain of the dimer undergoes ATP hydrolysis 
in turn, while the other retains a tightly-bound ADP during processive 
movement. According to the model, Mg2+ADP bound kinesin represents either a 
detached or a weakly-bound state of kinesin187. By trying to dock the dimer 
structure onto the map, we are assuming that the attached monomer is either in 
the ‘initial’ weakly-bound state after binding to a new tubulin site, or in the 
‘final’ weakly-bound state just before detachment. Consequently, the crystal 
structure of the kinesin-1 dimer provides a new conformation for modelling the 
mechanism of motility, but does not provide sufficient information to explain it. 
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Figure 5-6. Docking of kinesin-1 dimer structure onto cryo-EM map.  
Kinesin-1 dimer structure docked onto cryo-EM map of kinesin-tubulin complex (PDB ID: 2P4N)184, 
by overlaying helix α4 (red) of (A) chain A and (B) chain B of the dimer with that of human 
monomeric kinesin, reveals clash of helix α2 with α-tubulin. 
   
 
5.3.2 Covalent mimic of tail-inhibited kinesin-1  
Comparison of the dimer and dimer-tail structures reveals a global 
conformational change of the dimer. Binding of the tail domain to the motor 
domains bring the latter closer together, such that the motor domain dimer no 
longer forms a T-shape, but resembles an inverted umbrella (Figure 5-7). The 
distance between the Cα atoms of Phe179 of both motor domains was 
approximately 48 Å in the dimer structure, but decreased to 10 Å upon binding 
of the tail domain. Similarly, the angle between β7 of both motor domains was 
about 180° in the dimer structure, but decreased to about 100° upon binding of 
the tail domain.  
 
To mimic inhibition of kinesin-1 by the tail domain, our collaborator (Prof. David 
Hackney, Carnegie Mellon University) introduced a covalent cross-link between 
the motor domains at the tail interface. Ser181 residues in the two motor 
domains (Figure 5-1) were substituted with cysteine in a background with the 
other reactive cyteines removed. A covalent cross-link between them could be 
readily formed by oxidation to a disulfide and reversed by reduction with DTT 
(Figure 5-8a). In this preparation, about 10 % of the motor domain monomers 
were refractory to cross-linking, as determined by densitometry of stained SDS 
gel samples. Microtubule-stimulated ATPase activity was lost and regained in 
parallel with the extent of cross-linking, indicating that cross-linking strongly 
inhibits hydrolysis (Figure 5-8b).  
A B 
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Figure 5-7. Global conformational change of kinesin-1 dimer upon tail-binding.  
Binding of tail domain (magenta) brings motor domains (green) closer together, such that the motor 
domain dimer no longer forms a T-shape, but resembles an inverted umbrella. The distance 
between Cα of Phe179 decreases from 48.5 to 10.2 Å and the angle between β7 of motor domains 
decreases from 180° to about 100° upon tail binding. ADP in the nucleotide pockets are 
represented by blue ball-and-stick models. 
 
 
 
 
 
Figure 5-8. Influence of cross-linking on microtubule-stimulated ATPase activity.  
(A) The amount of cross-linked dimer and uncross-linked monomer, remaining in the oxidised and 
DTT-treated samples, were visualised and determined by densitometry of stained SDS gel samples 
(reducing agents were not used in the running of the gel). (B) The concentration of monomer in 
each preparation is indicated as a value relative to that of the unmodified sample (100 %). 
Microtubule-stimulated ATPase assay was performed as previously described133 at 25°C, and in 
duplicate or greater with the standard deviation indicated. The activity of each preparation is 
indicated as a value relative to that of the unmodified sample (100 %). 
 
 
 
A 
B 
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Single turnover experiments were then carried out by Prof. Hackney to allow 
direct evaluation of the high extent of inhibition of the cross-linked fraction 
(Figure 5-9a). In this experiment, a dimer with S181C substitutions was 
equilibrated with the fluorescent ADP analogue mant-ADP before oxidation. 
Mant-ADP is released from kinesin with kinetics similar to those of unmodified 
ADP and gives a fluorescence decrease188. In the absence of microtubules, ADP 
release from the uncross-linked dimer is slow (red trace) and is further 
decreased when the dimer is cross-linked (blue trace). Microtubules greatly 
accelerate the rate of mant-ADP release from uncross-linked dimers (black 
trace), but produces a biphasic transient with cross-linked dimers (green trace).  
 
In the biphasic curve, the amplitude of the fast phase is small and similar to the 
active fraction that is refractory to cross-linking in this preparation (Figure 5-
9b). However, the majority of the cross-linked preparation exhibits no 
stimulation of mant-ADP release by microtubules, as can be seen by the slow 
phase of the green trace, which is approximately parallel to the blue trace (very 
slow ADP release from cross-linked dimer in the absence of microtubules). 
Partial reversal of cross-linking by DTT (orange trace) restores the amplitude of 
the fast phase in parallel to regain of uncross-linked protein (Figure 5-9b). In 
short, the covalent cross-link, which mimics the tail-inhibited kinesin-1 dimer, 
prevents ADP release from the motor domains. 
 
Figure 5-9. Covalent mimic in single turnover mant-ADP experiment.  
(A) Release of mant-ADP from unmodified (SH), oxidised (SS) and DTT treated (SS + DTT) 
species after mixing with a chase of excess unlabeled ATP, with and without microtubules (MTs). 
(B) Samples were analyzed by denaturing SDS-PAGE in the absence of reducing agents. 
A B 
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5.3.3 Proposed autoinhibition mechanism of kinesin-1 
Several models for the mechanism of inhibition by the tail domain are 
eliminated by the structure of the dimer-tail complex. Firstly, the tail domain 
does not bind to the microtubule-binding site (helix α4-loop L12-helix α5) of the 
motor domain and the microtubule-binding sites on the motor domains of the 
complex are fully exposed (Figure 5-10). Hence, the tail domain cannot cause 
steric interference with microtubule binding. Next, it does not bind to the neck 
linker or coiled-coil domain, so it cannot prevent the ‘power stroke’ or interfere 
with coordination of the coiled-coil domain to inhibit movement. Thirdly, the 
binding site for the tail domain is on the opposite side of the motor domain from 
the nucleotide-binding site; thus, ruling out models in which the tail sterically 
blocks the release of ADP or interacts with switch I or switch II137 that play 
critical roles in coupling conformational changes to nucleotide binding189.  
 
Finally, binding of the tail to the motor domains also does not cause 
conformational changes in the catalytic core of the motor domain. The 
structural similarity between the catalytic core of the free motor domain dimer 
and the dimer-tail complex (Figure 5-2b) argues against an allosteric model 
proposed by Dietrich et al.137. They published an 8 Å cryo-EM map of the kinesin-
1 monomer-tail-microtubule complex, which shows the tail domain binding 
simultaneously to the microtubule and to switch I of the motor domain137. 
Accordingly, they deduced that the binding of the tail to the motor domain 
induces a conformational change that prevents the release of ADP; hence, the 
motor domain is halted in an ADP state on the microtubule track.  
 
However, the lack of agreement between their results and ours can be 
attributed to the fact that they photochemically cross-linked the tail to the 
motor domain by modifying and derivatising cysteine residues in the motor 
domain with benzophenone. They did not test any residues in the motor-tail 
interface as revealed by the crystal structure and the observed cross-linking of 
modified cysteines to the motor domain could be due to flexibility. Therefore, 
the high resolution crystal structure of the motor domain dimer in complex with 
the tail refutes the allosteric model of autoinhibition, while providing us with 
structural evidence for a novel mechanism of autoinhibition. 
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From the crystal structures of the dimer and dimer-tail complex, we identified 
one significant difference between the free dimer and the tail-inhibited dimer: 
the relative movement of the two motor domains is highly restricted in the 
latter because the motor domains are cross-linked at two positions: coiled-coil 
and tail interface. In the absence of tail binding, the motor domains likely have 
considerable freedom of movement, as evident from the different orientation of 
the Rattus norvegicus dimer structure115 (Figure 1-21, PDB ID: 3KIN) as compared 
to our dimer structure. In the dimer-tail complex, however, the ‘double 
lockdown’ at both the neck coil and the tail interface freezes out major relative 
movements of the motor domains. This could prevent the undocking of the neck 
linker and the overlying N-terminal strand190. 
 
The undocking of the neck linker has been hypothesised and shown to be linked 
to hydrolysis and release of ADP18,191. Coupling of neck linker undocking and ADP 
release is also supported by a study, which showed that the introduction of a 
cross-link between the neck linker and core motor domain inhibits ADP 
release192. Conequently, the dimer-tail crystal structure and the covalent mimic 
of tail-inhibited dimer suggests that the observed inhibition of ADP release could 
be due to blocking of neck linker undocking through a double lockdown 
mechanism. In short, we propose a double lockdown autoinhibition mechanism, 
whereby cross-linking at both the coiled-coil and tail interface prevents the 
movement of the motor domains that is needed to undock the neck linker and 
release ADP (Figure 5-11). This opens up the possibility that other kinesins may 
be regulated by a common autoinhibitory mechanism. 
 
 
Figure 5-10. Docking of the kinesin-1 dimer-tail structure onto cryo-EM map.  
The tail domain does not cause steric hindrance at the microtubule-binding site of the motor 
domains (helix α4 colored in red). (PDB ID: 2P4N)184. 
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Our proposed model sufficiently explains and confirms the half-site inhibition 
stoichiometry (one monomeric tail binds to one motor domain dimer) and that 
dimerisation of the motor domains is required for tight binding of the tail 
domain133. Nevertheless, it is inadequate in explaining the role of the other tail 
domain. We speculate that when one monomeric tail domain binds to the 
dimeric motor domains in an inhibitory manner, the other tail domain could 
interact with the microtubule and immobilise the kinesin on the track while 
waiting for cargo to arrive. Alternatively, the second tail domain could interact 
with a kinesin-associated protein, such as UNC-76, which could further regulate 
cargo-binding and transport abilities of kinesin-128. 
 
 
 
Figure 5-11. Proposed model for double lockdown mechanism of autoinhibition.  
In the absence of tail (green, sticks) binding, the motor domains (yellow, cartoon) have 
considerable freedom of movement for neck linker (red) undocking and ADP (red, spheres) 
release. Cyan oval represents nucleotide-free motor domain with neck-linker undocked. However, 
when the tail binds, the motor domains are also cross-linked at the tail interface. This double 
lockdown mechanism prevents the separation of the motor domains, which is required for neck 
linker undocking and ADP release. Ser181 residues (green) are far apart in the free dimer but close 
together in the dimer-tail complex, and are on opposite sides of the tail interface. 
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5.3.4 Important residues involved in motor-tail interaction 
The crystal structure of the motor domain dimer-tail complex not only provides 
us with a new model for the autoinhibitory mechanism of kinesin-1, it also 
reveals the important residues involved in motor-tail binding. In support of the 
crystal structure, the alanine-scan peptide array confirms that Lys944 and 
Arg947 of the tail domain are two crucial residues involved in the binding of the 
tail to the motor domains. Additional support for the structure in the form of 
mutagenesis studies was provided by Prof. Hackney. Analysis of the motor-tail 
interface reveals that Asp185 of the motor domain directly interacts with Lys944 
of the tail region and the His136 side chains of each motor domain are in close 
proximity in the interface (~2.9 Å) (Figure 5-4). Hence, mutations of the Asp185 
and His136 residues of the motor domain should abolish binding.  
 
These positions are far removed from the nucleotide-binding pocket and the 
microtubule-binding surface. Microtubule-stimulated single turnover assay was 
carried out to show that the D185R and H136E substitutions do not affect the 
normal ATPase function of the motor domain (Table 5-1). However, upon 
interaction with the tail domain, both D185R and H136E mutated motor domain 
dimers were not significantly inhibited by the tail domain, instead the basal 
ATPase activity was preserved (Figure 5-12). In conclusion, structural and 
biochemical evidences reveal that Lys944 and Arg947 of the tail and Asp185 and 
His136 of the motor are essential residues involved in the binding of the tail to 
the motor domain dimer, in order to keep the latter in an inactive conformation. 
 
Table 5-1. Microtubule-stimulated mant-ADP release rates of wild-type and mutant motor 
domains. 
 
Construct 
 
Rate  (µM-1s-1) 
Wild-type 
 
11.6  ± 0.9 
H136E 
 
11.8  ± 0.5 
a CLM-S156C  
 
10.4  ± 0.7 
CLM-S156C-D185R 
 
11.6  ± 0.9 
a CLM is 'Cys-lite mutant' 
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Figure 5-12. Influence of the tail domain on basal ATPase activity of wild-type and mutant 
motor domains.  
Blue profile: wild-type; diamonds: CLM-S156C; triangles: H136E; squares: CLM-S156C-D185R. 
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6 Summary and future directions 
6.1 Summary 
6.1.1 Mitotic kinesin Eg5 and its inhibitors 
The structures of Eg5 in complex with enastron, dimethylenastron, fluorastrol, 
STLC, compounds 6, 7, 8 and 9 have been solved separately. They provide 
information for structure-activity relationship (SAR) studies and future structure-
guided drug design. The crystal structures of Eg5 in complex with enastron, 
dimethylenastron and fluorastrol reveal the main reasons for increased potency 
of these inhibitors as compared to monastrol: namely the better fit of the ligand 
to the allosteric binding site for enastron and dimethylenastron and the addition 
of two fluorine atoms for fluorastrol. The structures also show that monastrol, 
enastron and dimethylenastron belong to class I DHPM inhibitors that bind in the 
S configuration, whereas fluorastrol is a class II DHPM inhibitor that binds 
preferentially in the R configuration. 
 
In the Eg5-STLC structure, the three phenyl rings are buried in the allosteric site 
and form hydrophobic interactions with the residues in the inhibitor-binding 
pocket. On the other hand, the cysteine moiety is exposed to the solvent and 
forms hydrogen bond interactions with Eg5 residues. This binding conformation is 
observed in and further confirmed by the structures of Eg5 in complex with STLC 
analogues 6 to 9. In the structure of Eg5 in complex with 6, which has one of the 
phenyl rings substituted by an alkyl chain, the substituent points towards the 
solvent-exposed region of the protein. The reason for the slight decrease in 
potency of compound 6 as compared to STLC is attributed to the loss of a π-π 
interaction, due to the substitution of the phenyl ring by an alkyl chain.  
 
Compound 7, which has a meta-substituted methyl group on one of its phenyl 
rings, is 15 times more potent than STLC. The crystal structure of the complex 
reveals that the small lipophilic substituent sits in a complementary hydrophobic 
sub-pocket and improves the potency of the inhibitor. The structure of Eg5 with 
compound 8, which has a meta-substituted acetate group on one of its phenyl 
rings, also shows that the substituent sits in the same hydrophobic sub-pocket. 
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However, as it lacks the carboxylic acid group in its amine tail, it is about 15 
times less potent than 7, due to the loss of hydrogen bonds and lack of rigidity.  
 
Finally, compound 9 also lacks the carboxylic acid in its amine tail, but it has 
meta-substitutions on two phenyl rings that greatly improve its potency. From 
the crystal structure, it can be seen that the lipophilic substituent (ethyl group) 
is positioned in the same hydrophobic sub-pocket as that of 7 and 8, while the 
second meta-substituent (hydroxyl group) sits in a different sub-pocket in the 
core of the protein, similar to the position of the hydroxylphenyl group in 
monastrol and its analogues. In short, the crystal structures of Eg5-inhibitor 
complexes reveal important interactions between the ligands and protein, the 
preferential binding conformations of the ligands and the positions of 
substituents in the inhibitor-binding pocket. 
 
The structure of Eg5-STLC revealed an intermediate state, which by comparison 
with the native and final inhibitor-bound structures, allows one to dissect the 
pathway of structural changes that occur upon inhibitor binding. Based on the 
crystal structures and in agreement with spectroscopic data92, we propose that 
the binding of STLC to Eg5 causes drug-induced structural changes in 3 steps: 
first, loop L5 swings downwards to close the inhibitor-binding pocket, which then 
translates to an upward shift of the switch II cluster toward the N-terminal of 
helix α4, and finally the neck linker docks onto the motor domain. Therefore, 
the Eg5-STLC structure provides structural evidence for the molecular 
mechanism of inhibition of Eg5.  
 
Finally, ITC experiment was carried out to obtain thermodynamic parameters of 
the binding event of STLC to Eg5. A 1:1 binding stoichiometry was determined, 
which concurs with the crystal structure of the Eg5-STLC complex. The 
dissociation constant is 0.096 µM, which is 50 times larger than that for Eg5-
ispinesib. This alludes to the fact that the binding of ispinesib to Eg5 is tighter 
than that of Eg5-STLC. The enthalpy change is negative and favourable, while 
the entropy change is negative and unfavourable for the binding of STLC to Eg5. 
Taken together, the structural information and thermodynamic parameters 
obtained help us to gain a better understanding of the binding event of Eg5 and 
its inhibitor.  
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6.1.2 Mitotic kinesin Eg5 stalk364-520 domain 
Characterisation of the Eg5 stalk364-520 domain by analytical ultracentrifugation 
(AUC) provides insights into the oligomerisation state of the protein. From the 
sedimentation velocity (SV) experiment, only one significant peak is observed; 
thus, indicating that Eg5 stalk364-520 domain exists predominantly as one species 
at both low and high concentrations. This also suggests that there is no 
concentration-dependent oligomerisation effect. The true sedimentation 
coefficient at 20°C and in water, at zero concentration (s°20,w) of the Eg5 
stalk364-520 domain was calculated to be 1.76 S. This value is highly reliable as the 
fitting of a linear regression through the data produced a goodness of fit that is 
approximately 1.  
 
From the sedimentation equilibrium (SE) experiment and the global fitting of the 
data to the species analysis model, the apparent weight averaged molecule 
weight (Mw,app) was found to be approximately 27 kDa. This is larger than the 
expected monomeric molecular weight of the protein, but less than the 
expected dimeric molecular weight. Hence, by exclusion of data with high 
r.m.s.d. values and subsequent global fitting, the Mw,app of Eg5 stalk364-520 domain 
was found to be approximately 37 kDa. This value is very close to the expected 
dimeric molecular mass of 36 kDa. In short, the SE experiment reveals that the 
Eg5 stalk364-520 domain most likely exists as a single dimeric species at both low 
and high concentrations. 
 
Next, a circular dichroism (CD) analysis was carried out for the Eg5 stalk364-520 
domain. The CD spectrum revealed a maximum at about 190 nm and a double 
minimum at 208 and 222 nm. In general, the shape of the CD spectrum is 
characteristic of α-helices. The Θ222/Θ208 ratio was calculated to be 0.95, which 
suggests that the Eg5 stalk364-520 domain is neither fully coiled-coil nor entirely 
made up of non-coiled helices. The estimated percentage of helices is 52 %, 
while that of the turns and unordered regions is a total of 43 %. These results 
from the CD analysis suggest that the Eg5 stalk364-520 domain may form an 
interrupted coiled-coil structure. 
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Lastly, small angle X-ray scattering (SAXS) experiment was carried out to 
determine the low resolution molecular envelope of the Eg5 stalk364-520 domain. 
The scattering profiles of four samples of protein with different concentrations 
(ranging from 1 to 20 mg/ml) are similar; thus agreeing with the AUC data that 
there is no concentration-dependent oligomerisation behaviour. The 
reproducible shape of the scattering curve hints at a rod-shaped molecule. The 
mean maximum dimension (Dmax) is 19.3 nm, while the mean radius of gyration 
(Rg) and extrapolated intensity at zero scattering angle for the Eg5 stalk364-520 
domain, obtained from the pair-distance distribution function plot, are 5.5 nm 
and 44.4 respectively. 
 
Ab initio modelling of the molecular envelope of Eg5 stalk364-520 domain from the 
scattering profiles reveal a reproducible rod-like molecular envelope that is 
approximately 165 Å long and 18 Å wide. The molecular envelope appears to 
contain kinks along its length, which could indicate an interrupted coiled-coil 
structure, as supported by the CD results. In short, the AUC, CD and SAXS results 
suggest that the Eg5 stalk364-520 domain facilitates dimerisation of the protein by 
forming an elongated coiled-coil structure that may be interrupted by kinks 
along its length.  
 
6.1.3 Autoinhibition mechanism of kinesin-1 
The structure of the kinesin-1 motor domain dimer was solved to provide 
additional structural information for the modelling of kinesin-1 motility. 
Unfortunately, the docking of the kinesin-1 dimer structure onto microtubules 
was unsuccessful, revealing clashes between helix α2 of the unattached motor 
domain and α-tubulin. This is probably because both motor domains of the dimer 
structure are in the ADP-bound state. Nevertheless, the crystal structure reveals 
an alternate global conformation of the dimer, which provides a new 
conformation for modelling the mechanism of motility. The dimer structure also 
serves as a comparison for the structure of the kinesin-1 motor domain dimer-
tail complex that was solved. 
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Differences between the free dimer structure and the dimer-tail complex 
provide insights into the autoinhibition mechanism of kinesin-1. In the absence 
of the tail domain, the motor domain dimer is likely to have considerable 
freedom of movement. However, when the monomeric tail domain binds to the 
dimeric motor domain, the latter becomes highly restricted due to cross-linking 
at two positions: coiled-coil and tail interface. As a result, major relative 
movements, such as the undocking of the neck linker, may be prevented. Results 
from our collaborator have shown that by engineering a covalent cross-link in 
the dimer at the tail interface, tail-mediated autoinhibition of kinesin-1 can be 
mimicked.  
 
This covalent mimic was then shown to release ADP very slowly in the presence 
and absence of microtubules, as compared to the wild-type dimer. The release 
of ADP has been hypothesised and shown to be linked to undocking of the neck 
linker. Hence, based on the structural information and biochemical data, we 
propose a double lockdown autoinhibition mechanism, whereby cross-linking at 
both the coiled-coil and tail interface prevents the movement of the motor 
domains that is needed to undock the neck linker and release ADP. This opens up 
the possibility that other kinesins may be regulated by a common autoinhibitory 
mechanism. 
 
Finally, the crystal structure of the dimer-tail complex reveals several important 
residues in the motor-tail interface that may be responsible for the binding of 
the tail to the motor domains. Alanine-scan peptide array confirms that Lys944 
and Arg947 of the tail domain are crucial residues that would abolish motor-tail 
interaction when mutated. In addition, microtubule-stimulated single turnover 
assays carried out by our collaborator showed that Asp185 and His136 of the 
motor domain are important residues involved in the binding of the tail. In short, 
the crystal structures and biochemical data provide us with a better 
understanding of the mechanism of autoinhibition of kinesin-1. 
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6.2 Future directions 
6.2.1 Continued development of mitotic kinesin Eg5 inhibitors 
Based on the SAR studies and the crystal structures of Eg5-inhibitor complexes, 
we propose several steps for the future development of Eg5 inhibitors. As we 
have shown that some inhibitors have preferential binding conformations, we 
suggest separating the racemic mixtures of potential compounds into their 
enantiomers to identify the more active biological agent. For S-trityl-L-cysteine 
(STLC) analogues, the addition of a small lipophilic substituent on the meta- or 
para- positions of the phenyl ring has been shown to greatly improve potency. 
Substitution of the sulphur in STLC with a carbon atom did not decrease the 
potency of the small molecule. Hence, it might be a good idea to adopt the 
carbon scaffold in future development, as it is more stable and less likely to be 
hydrolysed or oxidized in the human gut.  
 
To develop STLC analogues that are weak substrates or less susceptible to the P-
glycoprotein (Pgp) efflux pump, the carboxylic acid group should be removed 
from the amine tail. However, the resultant flexibility of the small molecule and 
the loss of several hydrogen bonds may result in a decrease in potency. In 
addition, an analogue of compound 7 lacking the carboxylic acid group revealed 
hERG liability, high microsomal clearance in mice, low bioavailability, and is a 
moderate substrate for several cytochrome P450 isoforms, as compared to 7 
which has the carboxylic acid group (unpublished data). These liabilities would 
have to be overcome by a different subgroup or more substituents on the phenyl 
rings to increase stability and potency. Next, by comparing the crystal structures 
of Eg5 in complex with monastrol, monastrol analogues and compound 9, we 
realised that the common 3-hydroxyphenyl group forms important hydrogen 
bond interactions with the residues in the pocket. Hence, it may be useful to 
keep this subgroup while modifying the rest of the small molecule.   
 
Taking into account all the observations from the various crystal structures and 
the SAR studies, we now have a basis for structure-guided optimisation that will 
hopefully lead to compounds with improved potency. Eg5 inhibitors that prove to 
be highly potent should then be tested in cell-based assays for their 
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susceptibility to the Pgp efflux pump. Cox et al. consider compounds with 
multidrug resistance (MDR) ratios of less than 10 as having the potential to 
overcome MDR193,194. Subsequently, absorption, distribution, metabolism and 
excretion (ADME) profiling and in vivo xenograft studies should be conducted on 
inhibitors that are weak substrates of Pgp, in order to shortlist potential 
candidates with optimal drug-like properties for clinical trials.  
 
6.2.2 Characterisation of mitotic kinesin Eg5 stalk domain 
Characterisation of the Eg5 stalk domain will aid us in understanding its 
purported functions: formation of a tetramer and coordination of Eg5 motility. 
However, attempts to express the full length Eg5 stalk domain in the bacterial 
Escherichia coli system have not been successful; therefore, little is known 
about the structure or biophysical properties of the stalk domain. In order to 
investigate the role of the stalk domain in the normal functioning of Eg5, we 
need to first express and purify the protein. To this end, using a different 
expression system, such as the yeast Pichia pastoris system, may result in higher 
protein expression and yield. In addition, P. pastoris is capable of producing 
certain post-translational modifications, such as glycosylation, which could allow 
proper folding of the protein.  
 
Once the protein has been expressed and purified to a high yield and purity, 
crystallisation trials can be carried out. With a high resolution crystal structure 
of the Eg5 stalk domain, the structural characteristics of the molecule will 
become apparent and we will be able to confirm if it is a full or interrupted 
coiled-coil domain. Based on the structure, we can then try to understand how 
the stalk domain facilitates the formation of a bipolar tetrameric kinesin and 
coordinates the ‘hand-over-hand’ motility of Eg5. AUC experiment can also be 
used to determine whether there is a concentration-dependent oligomerisation 
behaviour. Nonetheless, if crystallisation is unsuccessful, CD and SAXS could be 
used to determine the secondary structure elements and the shape of the 
molecular envelope respectively.  
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6.2.3 Autoinihibition mechanism of kinesins 
The proposed double lockdown mechanism of kinesin-1 autoinhibition opens up 
possibilities that other kinesins may be regulated by a common mechanism. 
Although the autoinhibition mechanism has been best studied in kinesin-1, other 
members, such as the kinesin-2, kinesin-3 and kinesin-7 families, are also 
regulated by autoinhibition when they are not performing their functions. 
Similar to kinesin-1, these kinesin members adopt a folded conformation when 
inactive195-198. Hence, it is possible that the folded conformation allows the tail 
to interact with the motor domains in the same way as the double lockdown 
mechanism does in kinesin-1. Future work should therefore be focused on 
dissecting the autoinhibition mechanism of these kinesins and identifying the 
region of the tail domain that is involved in the regulation of the molecular 
motor.  
 
Based on the crystal structure of the kinesin-1 motor-tail complex, only one tail 
is shown to bind to the dimeric motor domains to prevent them from undergoing 
relative movements to undock the neck linker and release ADP. However, the 
function and position of the other tail domain of the kinesin dimer remain 
unclear. We speculate that the second tail domain could interact with 
microtubules and immobilise the kinesin on the track, while waiting for cargo to 
arrive. Alternatively, it could interact with kinesin-associated proteins, which 
could further regulate cargo-binding and transport abilities of kinesin28. Further 
experiments would have to be conducted to confirm or disprove these 
hypotheses.  
 
The dimer-tail structure, the peptide array and the biochemical data have 
revealed several residues that are implicated in the autoinhibition of kinesin-1. 
When these residues are mutated, binding of the tail to the motor domains is 
abolished and autoinhibition is relieved. In a recent paper by Moua et al., 
randomly generated lethal mutations in the Drosophila melanogaster kinesin 
heavy chain led to the identification of two mutations in the IAK region of the 
tail domain that may be crucial for development, namely P945S and S948F199. 
However, the results of the study showed that these mutants do not relieve 
autoinhibition but inhibit kinesin-1 functions instead. As these mutations are 
Chapter 6  141 
 
different from those identified in our studies, we propose revisiting the 
experiments using mutants of residues identified in our studies to gain insight 
into the true functions of the tail-mediated autoinhibition mechanism in vivo. 
 
Kinesin-1 has been linked to several diseases in humans, such as Alzheimer’s 
disease, neurofibromatosis (cancer of nerve tissues) and vaccinia and herpes 
viral infections119-122. It has been found to bind to amyloid precursor protein, 
form a complex with neurofibromatosis tumour suppressors and transport the 
vaccinia and herpes viruses. With insight into how kinesin-1 is autoinhibited, we 
open new avenues for understanding how kinesin-1 may play a role in the above 
diseases and for the possible development of therapeutics. In short, the basic 
knowledge of the autoinhibition mechanism of kinesin-1 may lead to and be 
translated into clinically-relevant findings for the treatment of diseases.  
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